# Patent

## Title
Methods and compositions for treating flaviviruses and pestiviruses

## Abstract

A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

## Background
FIELD OF THE INVENTION
This invention is in the area of pharmaceutical chemistry, and in particular, is a compound, method and composition for the treatment of flaviviruses and pestiviruses. This applicatidn is a divisional of U.S. application Ser. No. 09/863,816, filed on May 23, 2001, now U.S. Pat. No. 6,812,219, which claims priority to U.S. provisional application No. 60/207,674, filed on May 26, 2000 and U.S. provisional application No. 60/283,276, filed on Apr. 11, 2001, the disclosures of which are incorporated herein by reference.


BACKGROUND OF THE INVENTION
Pestiviruses and flaviviruses belong to the Flaviviridae family of viruses along with hepatitis C virus. The pestivirus genus includes bovine viral diarrhea virus (BVDV), classical swine fever virus (CSFV, also called hog cholera virus) and border disease virus (BDV) of sheep (Moennig, V. et al. Adv. Vir. Res. 1992, 41, 53–98). Pestivirus infections of domesticated livestock (cattle, pigs and sheep) cause significant economic losses worldwide. BVDV causes mucosal disease in cattle and is of significant economic importance to the livestock industry (Meyers, G. and Thiel, H.-J., Advances in Virus Research, 1996, 47, 53–118; Moennig V., et al., Adv. Vir. Res. 1992, 41, 53–98).
Human pestiviruses have not been as extensively characterized as the animal pestiviruses. However, serological surveys indicate considerable pestivirus exposure in humans. Pestivirus infections in man have been implicated in several diseases including congenital brain injury, infantile gastroenteritis and chronic diarrhea in human immunodeficiency virus (HIV) positive patients. M. Giangaspero et al., Arch. Virol. Suppl., 1993, 7, 53–62; M. Giangaspero et al., Int. J. Std. Aids, 1993, 4 (5): 300–302.
The flavivirus genus includes more than 68 members separated into groups on the basis of serological relatedness (Calisher et al., J. Gen. Virol, 1993, 70, 37–43). Clinical symptoms vary and include fever, encephalitis and hemorrhagic fever. Fields Virology, Editors: Fields, B. N., Knipe, D. M., and Howley, P. M., Lippincott-Raven Publishers, Philadelphia, Pa., 1996, Chapter 31, 931–959. Flaviviruses of global concern that are associated with human disease include the dengue hemorrhagic fever viruses (DHF), yellow fever virus, shock syndrome and Japanese encephalitis virus. Halstead, S. B., Rev. Infect. Dis., 1984, 6, 251–264; Halstead, S. B., Science, 239:476–481, 1988; Monath, T. P., New Eng. J. Med., 1988, 319, 641–643.
Examples of antiviral agents that have been identified as active against the flavivirus or pestiviruses include:

    
    
        (1) interferon and ribavirin (Battaglia, A. M. et al., Ann. Pharmacother, 2000,. 34, 487–494); Berenguer, M. et al. Antivir. Ther., 1998, 3 (Suppl. 3), 125–136);
        (2) Substrate-based NS3 protease inhibitors (Attwood et al., Antiviral peptide derivatives, PCT WO 98/22496, 1998; Attwood et al., Antiviral Chemistry and Chemotherapy 1999, 10, 259–273; Attwood et al., Preparation and use of amino acid derivatives as anti-viral agents, German Patent Pub. DE 19914474; Tung et al. Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease, PCT WO 98/17679), including alphaketoamides and hydrazinoureas, and inhibitors that terminate in an electrophile such as a boronic acid or phosphonate (Llinas-Brunet et al., Hepatitis C inhibitor peptide analogues, PCT WO 99/07734).
        (3) Non-substrate-based inhibitors such as 2,4,6-trihydroxy-3-nitro-benzamide derivatives (Sudo K. et al., Biochemical and Biophysical Research Communications, 1997, 238, 643–647; Sudo K. et al. Antiviral Chemistry and Chemotherapy, 1998, 9, 186), including RD3-4082 and RD3-4078, the former substituted on the amide with a 14 carbon chain and the latter processing apara-phenoxyphenyl group;
        (4) Thiazolidine derivatives which show relevant inhibition in a reverse-phase HPLC assay with an NS3/4A fusion protein and NS5A/5B substrate (Sudo K. et al., Antiviral Research, 1996, 32, 9–18), especially compound RD-1-6250, possessing a fused cinnamoyl moiety substituted with a long alkyl chain, RD4 6205 and RD4 6193;
        (5) Thiazolidines and benzanilides identified in Kakiuchi N. et al. J. EBS Letters 421, 217–220; Takeshita N. et al. Analytical Biochemistry, 1997, 247, 242–246;
        (6) A phenan-threnequinone possessing activity against protease in a SDS-PAGE and autoradiography assay isolated from the fermentation culture broth of Streptomyces sp., Sch 68631 (Chu M. et al., Tetrahedron Letters, 1996, 37, 7229–7232), and Sch 351633, isolated from the fungus Penicillium griscofuluum, which demonstrates activity in a scintillation proximity assay (Chu M. et al., Bioorganic and Medicinal Chemistry Letters 9, 1949–1952);
        (7) Selective NS3 inhibitors based on the macromolecule elgin c, isolated from leech (Qasim M. A. et al., Biochemistry, 1997, 36, 1598–1607);
        (8) Helicase inhibitors (Diana G. D. et al., Compounds, compositions and methods for treatment of hepatitis C, U.S. Pat. No. 5,633,358; Diana G. D. et al., Piperidine derivatives, pharmaceutical compositions thereof and their use in the treatment of hepatitis C, PCT WO 97/36554);
        (9) Polymerase inhibitors such as nucleotide analogues, gliotoxin (Ferrari R. et al. Journal of Virology, 1999, 73, 1649–1654), and the natural product cerulenin (Lohmann V. et al., Virology, 1998, 249, 108–118);
        (10) Antisense phosphorothioate oligodeoxynucleotides (S-ODN) complementary to sequence stretches in the 5′ non-coding region (NCR) of the virus (Alt M. et al., Hepatology, 1995, 22, 707–717), or nucleotides 326–348 comprising the 3′ end of the NCR and nucleotides 371–388 located in the core coding region of the IICV RNA (Alt M. et al., Archives of Virology, 1997, 142, 589–599; Galderisi U. et al., Journal of Cellular Physiology, 1999, 181, 251–257);
        (11) Inhibitors of IRES-dependent translation (Ikeda N et al., Agent for the prevention and treatment of hepatitis C, Japanese Patent Pub. JP-08268890; Kai Y. et al. Prevention and treatment of viral diseases, Japanese Patent Pub. JP-10101591);
        (12) Nuclease-resistant ribozymes (Maccjak, D. J. et al., Hepatology 1999, 30, abstract 995); and
        (13) Other miscellaneous compounds including 1-amino-alkylcyclohexanes (U.S. Pat. No. 6,034,134 to Gold et al.), alkyl lipids (U.S. Pat. No. 5,922,757 to Chojkier et al.), vitamin E and other antioxidants (U.S. Pat. No. 5,922,757 to Chojkier et al.), squalene, amantadine, bile acids (U.S. Pat. No. 5,846,964 to Ozeki et al.), N-(phosphonoacetyl)-L-aspartic acid, (U.S. Pat. No. 5,830,905 to Diana et al.), benzenedicarboxamides (U.S. Pat. No. 5,633,388 to Diana et al.), polyadenylic acid derivatives (U.S. Pat. No. 5,496,546 to Wang et al.), 2′,3′-dideoxyinosine (U.S. Pat. No. 5,026,687 to Yarchoan et al.), and benzimidazoles (U.S. Pat. No. 5,891,874 to Colacino et al.).
    
    


In view of the severity of diseases associated with pestiviruses and flaviviruses, and their pervasiveness in animal and man, it is an object of the present invention to provide a compound, method and composition for the treatment of a host infected with flavivirus or pestivirus.
SUMMARY OF THE INVENTION
Compounds, methods and compositions for the treatment of a host infected with a flavivirus or pestivirus infection are described that includes an effective treatment amount of a β-D- or β-L-nucleoside of the Formulas (I)–(XVIII), or a pharmaceutically acceptable salt or prodrug thereof.
In a first principal embodiment, a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    R1, R2 and R3 are independently H, phosphate (including mono-, di- or triphosphate and a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
    Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
    X1 and X2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
    R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).


In a second principal embodiment, a compound of Formula II, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
    Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
    X1 and X2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
    R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).


In a third principal embodiment, a compound of Formula III, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
    Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
    X1 and X2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
    R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).


In a fourth principal embodiment, a compound of Formula W, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    R1, R2 and R3 are independently H, phosphate (including mono-, di- or triphosphate and a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
    Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
    X1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
    R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).


In a fifth principal embodiment, a compound of Formula V, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
    Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
    X1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
    R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).


In a sixth principal embodiment, a compound of Formula VI, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
    Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
    X1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
    R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).


In a seventh principal embodiment, a compound selected from Formulas VII, VIII and IX, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
    R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, 2-Br-ethyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), CF3, chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2; and
    X is O, S, SO2 or CH2.


In a eighth principal embodiment, a compound of Formulas X, XI and XII, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
    R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
    R7 is hydrogen, OR3, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2; and
    X is O, S, SO2 or CH2.


In a ninth principal embodiment a compound selected from Formulas XIII, XIV and XV, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
    R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2; and
    X is O, S, SO2, or CH2.


In a tenth principal embodiment the invention provides a compound of Formula XVI, or a pharmaceutically acceptable salt or prodrug thereof:




wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1 and R2 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 or R2 is independently H or phosphate;
    R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
    R7 and R9 are independently hydrogen, OR2, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
    R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine or iodine;
    alternatively, R7 and R9, R7 and R10, R8 and R9, or R8 and R10 can come together to form a pi bond; and
    X is O, S, SO2 or CH2.


In a eleventh principal embodiment the invention provides a compound of Formula XVII, or a pharmaceutically acceptable salt or prodrug thereof:




wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1 and R2 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 or R2 is independently H or phosphate;
    R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
    R7 and R9 are independently hydrogen, OR2, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
    R10 is H, alkyl (including lower alkyl), chlorine, bromine or iodine;
    alternatively, R7 and R9, or R7 and R10 can come together to form a pi bond; and
    X is O, S, SO2 or CH2.


In an twelfth principal embodiment, the invention provides a compound of Formula XVIII, or a pharmaceutically acceptable salt or prodrug thereof:




wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1 and R2 independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 or R2 is independently H or phosphate;
    R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
    R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino or di(lower-alkyl)amino;
    R8 is H, alkyl (including lower alkyl), chlorine, bromine or iodine;
    alternatively, R7 and R9, or R8 and R9 can come together to form a pi bond;
    X is O, S, SO2 or CH2.


The β-D- and β-L-nucleosides of this invention may inhibit flavivirus or pestivirus polymerase activity. These nucleosides can be assessed for their ability to inhibit flavivirus or pestivirus polymerase activity in vitro according to standard screening methods.
In one embodiment the efficacy of the anti-flavivirus or pestivirus compound is measured according to the concentration of compound necessary to reduce the plaque number of the virus in vitro, according to methods set forth more, particularly herein, by 50% (i.e. the compound's EC50). In preferred embodiments the compound exhibits an EC50 of less than 15 or preferably, less than 10 micromolar in vitro.
In another embodiment, the active compound can be administered in combination or alternation with another anti-flavivirus or pestivirus agent. In combination therapy, effective dosages of two or more agents are administered together, whereas during alternation therapy an effective dosage of each agent is administered serially. The dosages will depend on absorption, inactivation and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens and schedules should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.
HCV is a member of the Flaviviridae family; however, now, HCV has been placed in a new monotypic genus, hepacivirus. Therefore, in one embodiment, the flavivirus or pestivirus is not HCV.
Nonlimiting examples of antiviral agents that can be used in combination with the compounds disclosed herein include:
(1) an interferon and/or ribavirin (Battaglia, A. M. et al., Ann. Pharmacother. 34:487–494, 2000); Berenguer, M. et al. Antivir. Ther. 3(Suppl. 3):125–136, 1998);
(2) Substrate-based NS3 protease inhibitors (Attwood et al., Antiviral peptide derivatives, PCT WO 98/22496, 1998; Attwood et al., Antiviral Chemistry and Chemotherapy 10.259–273, 1999; Attwood et al., Preparation and use of amino acid derivatives as anti-viral agents, German Patent Publication DE 19914474; Tung et al. Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease, PCT WO 98/17679), including alphaketoamides and hydrazinoureas, and inhibitors that terminate in an electrophile such as a boronic acid or phosphonate. Llinas-Brunet et al., Hepatitis C inhibitor peptide analogues, PCT WO 99/07734.
(3) Non-substrate-based inhibitors such as 2,4,6-trihydroxy-3-nitro-benzamide derivatives(Sudo K. et al., Biochemical and Biophysical Research Communications, 238:643–647, 1997; Sudo K. et al. Antiviral Chemistry and Chemotherapy 9:186, 1998), including RD3-4082 and RD3-4078, the former substituted on the amide with a 14 carbon chain and the latter processing apara-phenoxyphenyl group;
(4) Thiazolidine derivatives which show relevant inhibition in a reverse-phase HPLC assay with an NS3/4A fusion protein and NS5A/5B substrate (Sudo K. et al., Antiviral Research 32:9–18, 1996), especially compound RD-1-6250, possessing a fused cinnamoyl moiety substituted with a long alkyl chain, RD4 6205 and RD4 6193;
(5) Thiazolidinesf and benzanilides identified in Kakiuchi N. et al. J. EBS Letters 421:217–220; Takeshita N. et al. Analytical Biochemistry 247:242–246, 1997;
(6) A phenan-threnequinone possessing activity against protease in a SDS-PAGE and autoradiography assay isolated from the fermentation culture broth of Streptomyces sp., Sch 68631 (Chu M. et al., Tetrahedron Letters 37:7229–7232, 1996), and Sch 351633, isolated from the fungus Penicillium griscofuluum, which demonstrates activity in a scintillation proximity assay (Chu M. et al., Bioorganic and Medicinal Chemistry Letters 9: 1949–1952);
(7) Selective NS3 inhibitors based on the macromolecule elgin c, isolated from leech (Qasim M. A. et al., Biochemistry 36:1598–1607, 1997);,
(8) Helicase inhibitors (Diana G. D. et al., Compounds, compositions and methods for treatment of hepatitis C, U.S. Pat. No. 5,633,358; Diana G. D. et al., Piperidine derivatives, pharmaceutical compositions thereof and their use in the treatment of hepatitis C, PCT WO 97/36554);
(9) Polymerase inhibitors such as nucleotide analogues, gliotoxin (Ferrari R. et al. Journal of Virology 73:1649–1654, 1999), and the natural product cerulenin (Lohmann V. et al, Virology 249:108–118, 1998);
(10) Antisense phosphorothioate oligodeoxynucleotides (S-ODN) complementary to sequence stretches in the 5′ non-coding region (NCR) of the virus (Alt M. et al., Hepatology 22:707–717, 1995), or nucleotides 326–348 comprising the 3′ end of the NCR and nucleotides 371–388 located in the core coding region of the IICV RNA (Alt M. et al., Archives of Virology 142:589–599, 1997; Galderisi U. et al., Journal of Cellular Physiology 181:251–257, 1999);
(11) Inhibitors of IRES-dependent translation (Ikeda N et al., Agent for the prevention and treatment of hepatitis C, Japanese Patent Publication JP-08268890; Kai Y. et al. Prevention and treatment of viral diseases, Japanese Patent Publication JP-10101591);
(12) Nuclease-resistant ribozymes. (Maccjak D. J. et al., Hepatology 30 abstract 995, 1999); and
(13) Other miscellaneous compounds including 1-amino-alkylcyclohexanes (U.S. Pat. No. 6,034,134 to Gold et al.), alkyl lipids (U.S. Pat. No. 5,922,757 to Chojkier et al.), vitamin E and other antioxidants (U.S. Pat. No. 5,922,757 to Chojkier et al.), squalene, amantadine, bile acids. (U.S. Pat. No. 5,846,964 to Ozeki et al.), N-(phosphonoacetyl)-L-aspartic acid, (U.S. Pat. No. 5,830,905 to Diana et al.), benzenedicarboxamides (U.S. Pat. No. 5,633,388 to Diana et al.), polyadenylic acid derivatives (U.S. Pat. No. 5,496,546 to Wang et al.), 2′,3′-dideoxyinosine (U.S. Pat. No. 5,026,687 to Yarchoan et al.), and benzimidazoles (U.S. Pat. No. 5,891,874 to Colacino et al.).



BRIEF DESCRIPTION OF THE FIGURES
FIG. 1 provides the structure of various non-limiting examples of nucleosides of the present invention, as well as other known nucleosides, FIAU and Ribavirin, which are used as comparative examples in the text.
FIG. 2 is a line graph of the pharmacokinetics (plasma concentrations) of β-D-2′-CH3-riboG administered to Cynomolgus Monkeys over time after administration.
FIGS. 3a and 3b are line graphs of the pharmacokinetics (plasma concentrations) of β-D-2′-CH3-riboG administered to Cynomolgus Monkeys either intravenously (3a) or orally (3b) over time after administration.
FIG. 4 depicts line graphs of the results of the cell protection assay of β-D-2′-CH3-riboG against BVDV.
FIG. 5 depicts line graphs of the results of the cell protection assay of ribavirin against BVDV.
FIG. 6 are line graphs of the cell protection assay of β-D-2′-CH3-riboG, β-D-2′-CH3-riboC, β-D-2′-CH3-riboU, β-D-2′-CH3-riboA and ribavirin.
FIG. 7 are line graphs of the results of the plaque reduction assay for β-D-2′-CH3-riboU, β-D-2′-CH3-riboC and β-D-2′-CH3-riboG.
FIG. 8 is an illustration, of plaque reduction based on increasing concentrations of β-D-2′-CH3-riboU.
FIG. 9 is a line graph of the results of the yield reduction assay for β-D-2′-CH3-riboG, depicting a 4 log reduction at 9 μM.
FIG. 10 is an illustration of the yield reduction based on increasing concentrations of β-D-2′-CH3-riboC.



DETAILED DESCRIPTION OF THE INVENTION
The invention as disclosed herein is a compound, method and composition for the treatment of pestiviruses and flaviviruses in humans and other host animals, that includes the administration of an effective flavivirus or pestivirus treatment amount of an β-D- or β-L-nucleoside as described herein. or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier. The compounds of this invention either, possess antiviral (i.e., anti-flavivirus or pestivirus) activity, or are metabolized to a compound that exhibits such activity.
In summary, the present invention includes the following features:

    
    
        (a) β-D- and β-L-nucleosides, as described herein, and pharmaceutically acceptable salts and prodrugs thereof;
        (b) β-D- and β-L-nucleosides as described herein, and pharmaceutically acceptable salts and prodrugs thereof for use in the treatment or prophylaxis of a flavivirus or pestivirus infection, especially in individuals diagnosed as having a flavivirus or pestivirus infection or being at risk for becoming infected by flavivirus or pestivirus;
        (c) use of these β-D- and β-L-nucleosides, and pharmaceutically acceptable salts and prodrugs thereof in the manufacture of a medicament for treatment of a flavivirus or pestivirus infection;
        (d) pharmaceutical formulations comprising the β-D- and β-L-nucleosides or pharmaceutically acceptable salts or prodrugs thereof together with a pharmaceutically acceptable carrier or diluent;
        (e) β-D- and β-L-nucleosides as described herein substantially in the absence of enantiomers of the described nucleoside, or substantially isolated from other chemical entities;
        (f) processes for the preparation of β-D- and β-L-nucleosides, as described in more detail below; and
        (g) processes for the preparation of β-D- and β-L-nucleosides substantially in the absence of enantiomers of the described nucleoside, or substantially isolated from other chemical entities.
    
    


Flaviviruses included within the scope of this invention are discussed generally in Fields Virology, Editors: Fields, B. N., Knipe, D. M., and Howley, P. M., Lippincott-Raven Publishers, Philadelphia, Pa., Chapter 31, 1996. Specific flaviviruses include, without limitation: Absettarov, Alfuy, Apoi, Aroa, Bagaza, Banzi, Bouboui, Bussuquara, Cacipacore, Carey Island, Dakar bat, Dengue 1, Dengue 2, Dengue 3, Dengue 4, Edge Hill, Entebbe bat, Gadgets Gully, Hanzalova, Hypr, Ilheus, Israel turkey meningoencephalitis, Japanese encephalitis, Jugra, Jutiapa, Kadam, Karshi, Kedougou, Kokobera, Koutango, Kumlinge, Kunjin, Kyasanur Forest disease, Langat, Louping ill, Meaban, Modoc, Montana myotis leukoencephalitis, Murray valley encephalitis, Naranjal, Negishi, Ntaya, Omsk hemorrhagic fever, Phnom-Penh bat, Powassan, Rio Bravo, Rocio, Royal Farm, Russian spring-summer encephalitis, Saboya, St. Louis encephalitis, Sal Vieja, San Perlita, Saumarez Reef, Sepik, Sokuluk, Spondweni, Stratford, Tembusu, Tyuleniy, Uganda S, Usutu, Wesselsbron, West Nile, Yaounde, Yellow fever, and Zika.
Pestiviruses included within the scope of this invention are discussed generally in Fields Virology, Editors: Fields, B. N., Knipe, D. M., and Howley, P. M., Lippincott-Raven Publishers, Philadelphia, Pa., Chapter 33, 1996. Specific pestiviruses include, without limitation: bovine viral diarrhea virus (“BVDV”), classical swine fever virus (“CSFV,” also called hog cholera virus), and border disease virus (“BDV”).
I. Active Compound, and Physiologically Acceptable Salts and Prodrugs Thereof
In a first principal embodiment, a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    R1, R2 and R3 are independently H, phosphate (including mono-, di- or triphosphate and a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
    Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
    X1 and X2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
    R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).


In a preferred subembodiment, a compound of Formula I, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:

    R1, R2 and R3 are independently H or phosphate (preferably H);
    X1 is H;
    X2 is H or NH2; and
    Y is hydrogen, bromo, chloro, fluoro, iodo, NH2 or OH.


In a second principal embodiment, a compound of Formula II, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
    Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
    X1 and X2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
    R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).


In a preferred subembodiment, a compound of Formula II, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:

    R1, R2 and R3 are independently H or phosphate (preferably H);
    X1 is H;
    X2 is H or NH2; and
    Y is hydrogen, bromo, chloro, fluoro, jodo, NH2 or OH.


In a third principal embodiment, a compound of Formula III, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
    Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
    X1 and X2 are independently selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
    R4 and R5: are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).


In a preferred subembodiment, a compound of Formula III, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:

    R1, R2 and R3 are independently H or phosphate (preferably H);
    X1 is H;
    X2is H or NH2; and
    Y is hydrogen, bromo, chloro, fluoro, iodo, NH2 or OH.


In a fourth principal embodiment, a compound of Formula IV, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    R1, R2 and R3 are independently H, phosphate (including mono-, di- or triphosphate and a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
    Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
    X1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
    R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).


In a preferred subembodiment, a compound of Formula IV, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:

    R1, R2 and R3 are independently H or phosphate (preferably H);
    X1 is H or CH3; and
    Y is hydrogen, bromo, chloro, fluoro, iodo, NH2 or OH.


In a fifth principal embodiment, a compound of Formula V, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
    Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R5 or SR4;
    X1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
    R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).


In a preferred subembodiment, a compound of Formula V, or a pharmnaceutically acceptable salt or prodrug thereof, is provided wherein:

    R1, R2 and R3 are independently H or phosphate (preferably H);
    X1 is H or CH3; and
    Y is hydrogen, bromo, chloro, fluoro, iodo, NH2 or OH.


In a sixth principal embodiment, a compound of Formula VI, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate; and
    Y is hydrogen, bromo, chloro, fluoro, iodo, OR4, NR4R or SR4;
    X1 is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, chloro, bromo, fluoro, iodo, OR4, NR4NR5 or SR5; and
    R4 and R5 are independently hydrogen, acyl (including lower acyl), or alkyl (including but not limited to methyl, ethyl, propyl and cyclopropyl).


In a preferred subembodiment, a compound of Formula VI, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:

    R1, R2 and R3 are independently H or phosphate (preferably H);
    X1 is H or CH3; and
    Y is hydrogen, bromo, chloro, fluoro, iodo, NH2 or OH.


In a seventh principal embodiment, a compound selected from Formulas VII, VIII and IX, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
    R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, 2-Br-ethyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), CF3, chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2; and
    X is O, S, SO2, or CH2.


In a first preferred subembodiment, a compound of Formula VII, VIII or IX, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1, R2 and R3 are independently hydrogen or phosphate;
    R6 is alkyl; and
    X is O, S, SO2 or CH2.


In a second preferred subembodiment, a compound of Formula VII, VIII or IX, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1, R2 and R3 are hydrogens;
    R6 is alkyl; and
    X is O, S, SO2 or CH2.


In a third preferred subembodiment, a compound of Formula VII, VIII or IX, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1, R2 and R3 are independently hydrogen or phosphate;
    R6 is alkyl; and
    X is O.


In a eighth principal embodiment, a compound of Formula X, XI or XII, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
    R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
    R7 is hydrogen, OR3, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(loweralkyl)2, —N(acyl)2; and
    X is O, S, SO2 or CH2.


In a first preferred subembodiment, a compound of Formula X, XI or XII, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1, R2 and R3 are independently hydrogen or phosphate;
    R6 is alkyl; and
    X is O, S, SO2 or CH2.


In a second preferred subembodiment, a compound of Formula X, XI or XII, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1, R2 and R3 are hydrogens;
    R6 is alkyl; and
    X is O, S, SO2 or CH2.


In a third preferred subembodiment, a compound of Formula X, XI or XII, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1, R2 and R3 are independently H or phosphate;
    R6 is alkyl; and
    X is O.


In even more preferred subembodiments, a compound of Formula XI, or its pharmaceutically acceptable salt or prodrug, is provided:




wherein:

    Base is a purine or pyrimidine base as defined herein; optionally substituted with an amine or cyclopropyl (e.g., 2-amino, 2,6-diamino or cyclopropyl guanosine); and
    R1 and R2 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 or R2 is independently H or phosphate.


In a ninth principal embodiment a compound selected from Formula XIII, XIV or XV, or a pharmaceutically acceptable salt or prodrug thereof, is provided:




wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1, R2 and R3 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1, R2 or R3 is independently H or phosphate;
    R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2; and
    X is O, S, SO2 or CH2.


In a first preferred subembodiment, a compound of Formula XIII, XIV or XV, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1, R2 and R3 are independently hydrogen or phosphate;
    R6 is alkyl; and
    X is O, S, SO2 or CH2.


In a second preferred subembodiment, a compound of Formula XIII, XIV or XV, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1, R2 and R3 are hydrogens;
    R6 is alkyl; and
    X is O, S, SO2 or CH2.


In a third preferred subembodiment, a compound of Formula XIII, XIV or XV, or a pharmaceutically acceptable salt or prodrug thereof, is provided wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1, R2 and R3 are independently hydrogen or phosphate;
    R6 is alkyl; and
    X is O.


In a tenth principal embodiment the invention provides a compound of Formula XVI, or a pharmaceutically acceptable salt or prodrug thereof:




wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1 and R2 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the. definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 and R2 are independently H or phosphate;
    R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower akyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
    R7 and R9 are independently hydrogen, OR2, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
    R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine or iodine;
    alternatively, R7 and R9, R7 and R10, R8 and R9, or R8 and R10 can come together to form a pi bond; and
    X is O, S, SO2 or CH2.


In a first preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2, alkyl, alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino or di(loweralkyl)amino; (5) R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O, S, SO2 or CH2.
In a second preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl; alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (4) R7 and R9 are independently OR2; (5) R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O, S, SO2 or CH2.
In a third preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl, alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino or di(loweralkyl)amino; (4) R7 and R9 are independently OR2, alkyl, alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, loweralkylamino or di(loweralkyl)amino; (5) R8 and R10 are H; and (6) X is O, S, SO2 or CH2.
In a fourth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl, alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (4) R7 and R9 are independently OR2, alkyl, alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (5) R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O.
In a fifth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR1; (5) R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine or iodine; and (6) X is O, S, SO2 or CH2.
In a sixth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (5) R8 and R10 are H; and (6) X is O, S, SO2, or CH2.
In a seventh preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2, alky (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, loweralkylamino or di(loweralkyl)amino; (5) R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine or iodine; and (6) X is O.
In a eighth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino or di(loweralkyl)amino; (4) R7 and R9 are independently OR2; (5) R8 and R10 are hydrogen; and (6) X is O, S, SO2 or CH2.
In a ninth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino or di(loweralkyl)amino; (4) R7 and R9 are independently OR2; (5) R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine or iodine; and (6) X is O.
In a tenth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino or di(loweralkyl)amino; (4) R7 and R9 are independently OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (5) R8 and R10 are hydrogen; and (6) X is O.
In an eleventh preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino or di(loweralkyl)amino; (4) R7 and R9 are independently OR2; (5) R8 and R10 are hydrogen; and (6) X is O, S, SO2 or CH2.
In a twelfth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl; (4)

    R7 and R9 are independently OR2; (5) R8 and R10 are hydrogen; and (6) X is O, S, SO2, or CH2.


In a thirteenth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2; (5) R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O.
In a fourteenth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, loweralkylamino or di(loweralkyl)amino; (5) R8 and R10 are hydrogen; and (6) X is O.
In even more preferred subembodiments, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which:
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is guanine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is cytosine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is thymine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is uracil; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is phosphate; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is ethyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is propyl; (4) R7and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is butyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 is hydrogen and R9 is hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is S;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is SO2;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 and R10 are hydrogen; and (6) X is CH2;
In a eleventh principal embodiment the invention provides a compound of Formula XVII, or a pharmaceutically acceptable salt or prodrug thereof:




wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1 is H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate;
    R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
    R7 and R9 are independently hydrogen, OR2, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
    R10 is H, alkyl (including lower alkyl), chlorine, bromine, or iodine;
    alternatively, R7 and R9, or R7 and R10 can come together to form a pi bond; and
    X is OS, SO2 or CH2.


In a first preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R 6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (4) R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, loweralkylamino or di(loweralkyl)-amino; (5) R10 is H; and (6) X is O, S, SO2, or CH2.
In a second preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino or di(loweralkyl)amino; (4) R7 and R9 are independently OR2; (5) R10 is H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O, S, SO2 or CH2.
In a third preferred subembodinient, a. compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (4) R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, loweralkylamino or di(loweralkyl)-amino; (5) R10 is H, alkyl (including lower alkyl), chlorine, bromine or iodine; and (6) X is O.
In a fourth preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino or di(loweralkyl)amnino; (4) R7 and R9 are independently OR2; (5) R10 is H; and (6) X is O, S, SO2 or CH2.
In a fifth preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino or di(loweralkyl)amino; (4) R7 and R9 are independently OR2; (5) R10 is H, alkyl (including lower alkyl), chlorine, bromine or iodine; and (6) X is O.
In a sixth preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (4) R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (5) R10 is H; and (6) X is O.
In a seventh preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (4) R7 and R9 are independently OR2; (5) R10 is H; and (6) X is O.
In an eighth preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, loweralkylamino or di(loweralkyl)-amino; (5) R10 is H, alkyl (including lower alkyl), chlorine, bromine or iodine; and (6) X is O, S, SO2, or CH2.
In a ninth preferred subembodiment, a compound of Formula XVI, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (4) R7 and R9 are independently OR2; (5) R10 is H; and (6) X is O, S, SO2, or CH2.
In a tenth preferred subembodiment, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2; (5) R10 is H; and (6) X is O, S, SO2, or CH2.
In even more preferred subembodiments, a compound of Formula XVII, or its pharmaceutically acceptable salt or prodrug, is provided in which:
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is guanine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is cytosine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is thymine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is uracil; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is phosphate; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is ethyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is propyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is butyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is O;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is S;
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is SO2; or
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R10 is hydrogen; and (6) X is CH2.
In an twelfth principal embodiment the invention provides a compound of Formula XVIII, or a pharmaceutically acceptable salt or prodrug thereof:




wherein:

    Base is a purine or pyrimidine base as defined herein;
    R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate;
    R6 is hydrogen, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
    R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, lower alkylamino, or di(loweralkyl)amino;
    R8 is H, alkyl (including lower alkyl), chlorine, bromine or iodine;
    alternatively, R7 and R9, or R8 and R9 can come together to form a pi bond;


X is O, S, SO2 or CH2.
In a first preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, loweralkylamino or di(loweralkyl)amino; (5) R8 is H, alkyl (including lower alkyl), chlorine, bromine or iodine; and (6) X is O, S, SO2 or CH2.
In a second preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of acyl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino or di-(loweralkyl)amino; (4) R7 and R9 are independently OR2; (5) R8 is H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O, S, SO2 or CH2.
In a third preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable, leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino, or di(lower-alkyl)amino; (4) R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (5) R8 is H; and (6) X is O, S, SO2 or CH2.
In a fourth preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower. acyl); alkyl (including. lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (4) R7 and R9 are independently hydrogen, OR2; alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (5) R8 is H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O.
In a fifth preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (4) R7 and R9 are independently OR2; (5) R8 is H; and (6) X is O, S, SO2, or CH2.
In a sixth preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including allyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (4) R7 and R9 are independently OR2; (5) R8 is H, alkyl (including lower alkyl), chlorine, bromine, or iodine; and (6) X is O.
In a seventh preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H; phosphate (including, monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (4) R7 and R9 are independently hydrogen, OR2, alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, amino, loweralkylamino, or di(loweralkyl)amino; (5) R8 is H; and (6) X is O.
In an eighth preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl (including lower alkyl), alkenyl, alkynyl, Br-vinyl, hydroxy, O-alkyl, O-alkenyl, chloro, bromo, fluoro, iodo, NO2, amino, loweralkylamino or di(loweralkyl)amino; (4) R7 and R9 are independently OR2; (5) R8 is H; and (6) X is O, S, SO2 or CH2.
In a ninth preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2; (5) R8 is H; and (6) X is O, S, SO2, or CH2.
In a tenth preferred subembodiment, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which: (1) Base is a purine or pyrimidine base as defined herein; (2) R1 is independently H or phosphate; (3) R6 is alkyl; (4) R7 and R9 are independently OR2; (5) R8 is H; and (6) X is O.
In even more preferred subembodiments, a compound of Formula XVIII, or its pharmaceutically acceptable salt or prodrug, is provided in which:
(1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is O;
(1) Base is guanine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is O;

    (1) Base is cytosine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is O;
    (1) Base is thymine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is O;
    (1) Base is uracil; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is O;
    (1) Base is adenine; (2) R1 is phosphate; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R1 is hydrogen; and (6) X is O;
    (1) Base is adenine; (2) R1 is hydrogen; (3) R6 is ethyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is O;
    (1) Base is adenine; (2) R1 is hydrogen; (3) R6 is propyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is O;
    (1) Base is adenine; (2) R1 is hydrogen; (3) R6 is butyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is O;
    (1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R1 is hydrogen; and (6) X is S;
    (1) Base is adenine; (2) R1 is hydrogen; (3) R6 is methyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is SO2; or
    (1) Base is adenine; (2) R1 is hydrogen; (3) R is methyl; (4) R7 and R9 are hydroxyl; (5) R8 is hydrogen; and (6) X is CH2.


The β-D- and β-L-nucleosides of this invention belong to a class of anti-flavivirus or pestivirus agents that may inhibit flavivirus or pestivirus polymerase activity. Nucleosides can be screened for their ability to inhibit flavivirus or pestivirus polymerase activity in vitro according to screening methods set forth more particularly herein. One can readily determine the spectrum of activity by evaluating the compound in the assays described herein or with another confirmatory assay.
In one embodiment the efficacy of the anti-flavivirus or pestivirus compound is measured according to the concentration of compound necessary to reduce the plaque-number of the virus in vitro, according to methods set forth more particularly herein, by 50% (i.e. the compound's EC50). In preferred embodiments the compound exhibits an EC50 of less than 15 or 10 micromolar.
HCV is a member of the Flaviviridae family; however, now, HCV has been placed in a new monotypic genus, hepacivirus. Therefore, in one embodiment, the flavivirus or pestivirus is not HCV.
The active compound can be administered as any salt or prodrug that upon administration to the recipient is capable of providing directly or indirectly the parent compound, or that exhibits activity itself. Nonlimiting examples are the pharmaceutically acceptable salts (alternatively referred to as “physiologically acceptable salts”), and a compound, which has been alkylated or acylated at the 5′-position, or on the purine or pyrimidine base (a type of “pharmaceutically acceptable prodrug”). Further, the modifications can affect the biological activity of the compound, in some cases increasing the activity over the parent compound. This can easily be assessed by preparing the salt or prodrug and testing its antiviral activity according to the methods described herein, or other methods known to those skilled in the art.
II. Definitions
The term alkyl, as used herein, unless otherwise specified, refers to a saturated straight, branched, or cyclic, primary, secondary, or tertiary hydrocarbon of typically C1 to C10, and specifically includes methyl, trifluoromethyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, neopentyl, hexyl, isohexyl, cyclohexyl, cyclohexylmethyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl. The term includes both substituted and unsubstituted alkyl groups. Moieties with which the alkyl group can be substituted are selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, hereby incorporated by reference.
The term lower alkyl, as used herein, and unless otherwise specified, refers to a C1 to C4 saturated straight, branched, or if appropriate, a cyclic (for example, cyclopropyl) alkyl group, including both substituted and unsubstituted forms. Unless otherwise specifically stated in this application, when alkyl is a suitable moiety, lower alkyl is preferred. Similarly, when alkyl or lower alkyl is a suitable moiety, unsubstituted alkyl or lower alkyl is preferred.
The term alkylamino or arylamino refers to an amino group that has one or two alkyl or aryl substituents, respectively.
The term “protected” as used herein and unless otherwise defined refers to a group that is added to an oxygen, nitrogen, or phosphorus atom to prevent its further reaction or for other purposes. A wide variety of oxygen and nitrogen protecting groups are known to those skilled in the art of organic synthesis.
The term aryl, as used herein, and unless otherwise specified, refers to phenyl, biphenyl, or naphthyl, and preferably phenyl. The term includes both substituted and unsubstituted moieties. The aryl group can be substituted with one or more moieties selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate, either unprotected, or protected as necessary, as known to those skilled in the art, for example, as taught in Greene, et al., Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
The term alkaryl or alkylaryl refers to an alkyl group with an aryl substituent. The term aralkyl or arylalkyl refers to an aryl group with an alkyl substituent.
The term halo, as used herein, includes chloro, bromo, iodo, and fluoro.
The term purine or pyrimidine base includes, but is not limited to, adenine, N6-alkylpurines, N6-acylpurines (wherein acyl is C(O)(alkyl, aryl, alkylaryl, or arylalkyl), N6-benzylpurine, N6-halopurine, N6-vinylpurine, N6-acetylenic purine, N6-acyl purine, N6-hydroxyalkyl purine, N6-thioalkyl purine, N2-alkylpurines, N2-alkyl-6-thiopurines, thymine, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-azapyrimidine, including 6-azacytosine, 2- and/or 4-mercaptopyrmidine, uracil, 5-halouracil, including 5-fluorouracil, C5-alkylpyrimidines, C5-benzylpyrimidines, C5-halopyrimidines, C5-vinylpyrimidine, C5-acetylenic pyrimidine, C5-acyl pyrimidine, C5-hydroxyalkyl purine, C5-amidopyrimidine, C5-cyanopyrimidine, C5-nitropyrimidine, C5-aminopyrimidine, N2-alkylpurines, N2-alkyl-6-thiopurines, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, and pyrazolo-pyrimidinyl. Purine bases include, but are not limited to, guanine, adenine, hypoxanthine, 2,6-diaminopurine, and 6-chloropurine. Functional oxygen and nitrogen groups on the base can be protected as necessary or desired. Suitable protecting groups are well known to those skilled in the art, and include trimethylsilyl, dimethylhexylsilyl, t-butyldimethylsilyl and t-butyldiphenylsilyl, trityl, alkyl groups, and acyl groups such as acetyl and propionyl, methanesulfonyl, and p-toluenesulfonyl. Alternatively, the purine or pyrimidine base can optionally substituted such that it forms a viable prodrug, which can be cleaved in vivo. Examples of appropriate substituents include acyl moiety, an amine or cyclopropyl (e.g., 2-amino, 2,6-diamino or cyclopropyl guanosine).
The term acyl refers to a carboxylic acid ester in which the non-carbonyl moiety of the ester group is selected from straight, branched, or cyclic alkyl or lower alkyl, alkoxyalkyl including methoxyrnethyl, aralkyl including benzyl, aryloxyalkyl such as phenoxymethyl, aryl including phenyl optionally substituted with halogen, C1 to C4 alkyl or C1 to C4 alkoxy, sulfonate esters such as alkyl or aralkyl sulphonyl including methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl (e.g. dimethyl-t-butylsilyl) or diphenylmethylsilyl. Aryl groups in the esters optimally comprise a phenyl group. The term “lower acyl” refers to an acyl group in which the non-carbonyl moiety is lower alkyl.
As used herein, the term “substantially free of” or “substantially in the absence of” refers to a nucleoside composition that includes at least 85 or 90% by weight, preferably 95% to 98% by weight, and even more preferably 99% to 100% by weight, of the designated enantiomer of that nucleoside. In a preferred embodiment, in the methods and compounds of this invention, the compounds are substantially free of enantiomers.
Similarly, the term “isolated” refers to a nucleoside composition that includes at least 85 or 90% by weight, preferably 95% to 98% by weight, and even more preferably 99% to 100% by weight, of the nucleoside, the remainder comprising other chemical species or enantiomers.
The term “independently” is used herein to indicate that the variable, which is independently applied, varies independently from application to application. Thus, in a compound such as R′′XYR′′, wherein R′′ is “independently carbon or nitrogen,” both R′′ can be carbon, both R′′ can be nitrogen, or one R′′ can be carbon and the other R′′ nitrogen.
The term host, as used herein, refers to an unicellular or multicellular organism in which the virus can replicate, including cell lines and animals, and preferably a human. Alternatively, the host can be carrying a part of the flavivirus or pestivirus genome, whose replication or function can be altered by the compounds of the present invention. The term host specifically refers to infected cells, cells transfected with all or part of the flavivirus or pestivirus genome and animals, in particular, primates (including chimpanzees) and humans. In most animal applications of the present invention, the host is a human patient. Veterinary applications, in certain indications, however, are clearly anticipated by the present invention (such as chimpanzees).
The term “pharmaceutically acceptable salt or prodrug” is used throughout the specification to describe any pharmaceutically acceptable form (such as an ester, phosphate ester, salt of an ester or a related group) of a nucleoside compound which, upon administration to a patient, provides the nucleoside compound. Pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium and magnesium, among numerous other acids well known in the pharmaceutical art. Pharmaceutically acceptable prodrugs refer to a compound that is metabolized, for example hydrolyzed or oxidized, in the host to form the compound of the present invention. Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound. Prodrugs include compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, dephosphorylated to produce the active compound. The compounds of this invention possess antiviral activity against flavivirus or pestivirus, or are metabolized to a compound that exhibits such activity.
III. Nucleotide Salt or Prodrug Formulations
In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compound as a pharmaceutically acceptable salt may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids, which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α-ketoglutarate, and α-glycerophosphate. Suitable inorganic salts may also be formed, including, sulfate, nitrate, bicarbonate, and carbonate salts.
Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made.
Any of the nucleosides described herein can be administered as a nucleotide prodrug to increase the activity, bioavailability, stability or otherwise alter the properties of the nucleoside. A number of nucleotide prodrug ligands are known. In general, alkylation, acylation or other lipophilic modification of the mono, di or triphosphate of the nucleoside will increase the stability of the nucleotide. Examples of substituent groups that can replace one or more hydrogens on the phosphate moiety are alkyl, aryl, steroids, carbohydrates, including sugars, 1,2-diacylglycerol and alcohols. Many are described in R. Jones and N. Bischofberger, Antiviral Research, 27 (1995) 1–17. Any of these can be used in combination with the disclosed nucleosides to achieve a desired effect.
The active nucleoside can also be provided as a 5′-phosphoether lipid or a 5′-ether lipid, as disclosed in the following references, which are incorporated by reference herein: Kucera, L. S., N. lyer, E. Leake, A. Raben, Modest E. K., D. L. W., and C. Piantadosi, “Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation,” AIDS Res. Hum. Reno Viruses, 1990, 6, 491–501; Piantadosi, C., J. Marasco C. J., S. L. Morris-Natschke, K. L. Meyer, F. Gumus, J. R. Surles, K. S. Ishaq, L. S. Kucera, N. Iyer, C. A. Wallen, S. Piantadosi, and E. J. Modest, “Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV activity,” J. Med. Chem., 1991, 34, 1408–1414; Hosteller, K. Y., D. D. Richman, D. A. Carson, L. M. Stuhmiller, G. M. T. van Wijk, and H. van den Bosch, “Greatly enhanced inhibition of human immunodeficiency virus type 1 replication in CEM and HT4-6C cells by 3′-deoxythymidine diphosphate dimyristoylglycerol, a lipid prodrug of 3,-deoxythymidine,” Antimicrob. Agents Chemother., 1992, 36, 2025–2029; Hosetler, K. Y., L. M. Stuhmiller, H. B. Lenting, H. van den Bosch, and D. D. Richman, “Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides.” J. Biol. Chem., 1990, 265, 61127.
Nonlimiting examples of U.S. patents that disclose suitable lipophilic substituents that can be covalently incorporated into the nucleoside, preferably at the 5′-OH position of the nucleoside or lipophilic preparations, include U.S. Pat. No. 5,149,794 (Sep. 22, 1992, Yatvin et al.); U.S. Pat. No. 5,194,654 (Mar. 16, 1993, Hostetler et al., U.S. Pat. No. 5,223,263 (Jun. 29, 1993, Hostetler et al.); U.S. Pat. No. 5,256,641 (Oct. 26, 1993, Yatvin et al.); U.S. Pat. No. 5,411,947 (May 2, 1995, Hostetler et al.); U.S. Pat. No. 5,463,092 (Oct. 31, 1995, Hostetler et al.); U.S. Pat. No. 5,543,389 (Aug. 6, 1996, Yatvin et al.); U.S. Pat. No. 5,543,390 (Aug. 6, 1996, Yatvin et al.); U.S. Pat. No. 5,543,391 (Aug. 6, 1996, Yatvin et al.); and U.S. Pat. No. 5,554,728 (Sep. 10, 1996; Basava et al.), all of which are incorporated herein by reference. Foreign patent applications that disclose lipophilic substituents that can be attached to the nucleosides of the present invention, or lipophilic preparations, include WO 89/02733, WO 90/00555, WO 91/16920, WO 91/18914, WO 93/00910, WO 94/26273, WO 96/15132, EP 0 350 287, EP 93917054.4, and WO 91/19721.
IV. Combination and Alternation Therapy
It has been recognized that drug-resistant variants of viruses can emerge after prolonged treatment with an antiviral agent. Drug resistance most typically occurs by mutation of a gene that encodes for an enzyme used in viral replication. The efficacy of a drug against flavivirus or pestivirus infection can be prolonged, augmented, or restored by administering the compound in combination or alternation with a second, and perhaps third, antiviral compound that induces a different mutation from that caused by the principle drug. Alternatively, the pharmacokineties, biodistribution or other parameter of the drug can be altered by such combination or alternation therapy. In general, combination therapy is typically preferred over alternation therapy because it induces multiple simultaneous stresses on the virus.
Nonlimiting examples of antiviral agents that can be used in combination or alternation with the compounds disclosed herein include:
(1) an interferon and/or ribavirin (Battaglia, A. M. et al., Ann. Pharmacother. 34:487–494, 2000); Berenguer, M. et al. Antivir. Ther. 3(Suppl. 3):125–136, 1998);
(2) Substrate-based NS3 protease inhibitors (Attwood et al., Antiviral peptide derivatives, PCT WO 98/22496, 1998; Attwood et al., Antiviral Chemistry and Chemotherapy 10.259–273, 1999; Attwood et al., Preparation and use of amino acid derivatives as anti-viral agents, German Patent Publication DE 19914474; Tung et al. Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease, PCT WO 98/17679), including alphaketoamides and hydrazinoureas, and inhibitors that terminate in an electrophile such as a boronic acid or phosphonate. Llinas-Brunet et al., Hepatitis C inhibitor peptide analogues, PCT WO 99/07734.
(3) Non-substrate-based inhibitors such as 2,4,6-trihydroxy-3-nitro-benzamide derivatives(Sudo K. et al., Biochemical and Biophysical Research Communications, 238:643–647, 1997; Sudo K. et al. Antiviral Chemistry and Chemotherapy 9:186, 1998), including RD3-4082 and RD3-4078, the former substituted on the amide with a 14 carbon chain and the latter processing a para-phenoxyphenyl group;
(4) Thiazolidine derivatives which show relevant inhibition in a reverse-phase HPLC assay with an NS3/4A fusion protein and NS5A/5B substrate (Sudo K. et al., Antiviral Research 32:9–18, 1996), especially compound RD-1-6250, possessing a fused cinnamoyl moiety substituted with a long alkyl chain, RD4 6205 and RD4 6193;
(5) Thiazolidines and benzanilides identified in Kakiuchi N. et al. J. EBS Letters 421:217–220; Takeshita N. et al. Analytical Biochemistry 247:242–246, 1997;
(6) A phenan-threnequinone possessing activity against protease in a SDS-PAGE and autoradiography assay isolated from the fermentation culture broth of Streptomyces sp., Sch 68631 (Chu M. et al., Tetrahedron Letters 37:7229–7232, 1996), and Sch 351633, isolated from the fungus Penicillium griscofuluum, which demonstrates activity in a scintillation proximity assay (Chu M. et al., Bioorganic and Medicinal Chemistry Letters 9:1949–1952);
(7) Selective NS3 inhibitors based on the macromolecule elgin c, isolated from leech (Qasim M. A. et al., Biochemistry 36:1598–1607, 1997);
(8) Helicase inhibitors (Diana G. D. et al., Compounds, compositions and methods for treatment of hepatitis C, U.S. Pat. No. 5,633,358; Diana G. D. et al., Piperidine derivatives, pharmaceutical compositions thereof and their use in the treatment of hepatitis C, PCT WO 97/36554);
(9) Polymerase inhibitors such as nucleotide analogues, gliotoxin (Ferrari R. et al. Journal of Virology 73:1649–1654, 1999), and the natural product cerulenin (Lohmann V. et al., Virology 249:108–118, 1998);
(10) Antisense phosphorothioate oligodeoxynucleotides (S-ODN) complementary to sequence stretches in the 5′ non-coding region (NCR) of the virus (Alt M. et al., Hepatology 22:707–717, 1995), or nucleotides 326–348 comprising the 3′ end of the NCR and nucleotides 371–388 located in the core coding region of the IICV RNA (Alt M. et al., Archives of Virology 142:589–599, 1997; Galderisi U. et al., Journal of Cellular Physiology 181:251–257, 1999);
(11) Inhibitors of IRES-dependent translation (Ikeda N et al., Agent for the prevention and treatment of hepatitis C, Japanese Patent Publication JP-08268890; Kai Y. et al. Prevention and treatment of viral diseases, Japanese Patent Publication JP-10101591);
(12) Nuclease-resistant ribozymes. (Maccjak D. J. et al., Hepatology 30 abstract 995, 1999); and
(13) Other miscellaneous compounds including 1-amino-alkylcyclohexanes (U.S. Pat. No. 6,034,134 to Gold et al.), alkyl lipids (U.S. Pat. No. 5,922,757 to Chojkier et al.), vitamin E and other antioxidants (U.S. Pat. No. 5,922,757 to Chojkier et al.), squalene, amantadine, bile acids (U.S. Pat. No. 5,846,964 to Ozeki et al.), N-(phosphonoacetyl)-L-aspartic acid, (U.S. Pat. No. 5,830,905 to Diana et al.), benzenedicarboxamides (U.S. Pat. No. 5,633,388 to Diana et al.), polyadenylic acid derivatives (U.S. Pat. No. 5,496,546 to Wang et al.), 2′,3′-dideoxyinosine (U.S. Pat. No. 5,026,687 to Yarchoan et al.), and benzimidazoles (U.S. Pat. No. 5,891,874 to Colacino et al.).
V. Pharmaceutical Compositions
Host, including humans, infected with flavivirus or pestivirus, or a gene fragment thereof can be treated by administering to the patient an effective amount of the active compound or a pharmaceutically acceptable prodrug or salt thereof in the presence of a pharmaceutically acceptable carrier or diluent. The active materials can be administered by any appropriate route, for example, orally, parenterally, intravenously, intradermally, subcutaneously, or topically, in liquid or solid form.
A preferred dose of the compound for flavivirus or pestivirus infection will be in the range from about 1 to 50 mg/kg, preferably 1 to 20 mg/kg, of body weight per day, more generally 0.1 to about 100 mg per kilogram body weight of the recipient per day. The effective dosage range of the pharmaceutically acceptable salts and prodrugs can be calculated based on the weight of the parent nucleoside to be delivered. If the salt or prodrug exhibits activity in itself, the effective dosage can be estimated as above using the weight of the salt or prodrug, or by other means known to those skilled in the art.
The compound is conveniently administered in unit any suitable dosage form, including but not limited to one containing 7 to 3000 mg, preferably 70 to 1400 mg of active ingredient per unit dosage form. A oral dosage of 50–1000 mg is usually convenient.
Ideally the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.2 to 70 μM, preferably about 1.0 to 10 μM. This may be achieved, for example, by the intravenous injection of a 0.1 to 5% solution of the active ingredient, optionally in saline, or administered as a bolus of the active ingredient.
The concentration of active compound in the drug composition will depend on absorption, inactivation, and excretion rates of the drug as well as other factors known to those of skill in the art. It is to be noted that dosage values will also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition. The active ingredient may be administered at once, or may be divided into a number of smaller doses to be administered at varying intervals of time.
A preferred mode of administration of the active compound is oral. Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid earner such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.
The compound can be administered as a component of an elixir, suspension, syrup, wafer, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.
The compound or a pharmaceutically acceptable prodrug or salts thereof can also be mixed with other active materials that do not impair the desired action, or with materials that supplement the desired action, such as antibiotics, antifungals, anti-inflammatories, or other antivirals, including other nucleoside compounds. Solutions or suspensions used for parenteral, intradermal, subcutaneous, or topical application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parental preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
If administered intravenously, preferred carriers are physiological saline or phosphate buffered saline (PBS).
In a preferred embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation.
Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) are also preferred as pharmaceutically acceptable carriers. These may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811 (which is incorporated herein by reference in its entirety). For example, lipdsome formulations may be prepared by dissolving appropriate lipid(s) (such as stearoyl phosphatidyl ethanolamine, stearoyl phosphatidyl choline, arachadoyl phosphatidyl choline, and cholesterol) in an inorganic solvent that is then evaporated, leaving behind a thin film of dried lipid on the surface of the container. An aqueous solution of the active compound or its monophosphate, diphosphate, and/or triphosphate derivatives is then introduced into the container. The container is then swirled by hand to free lipid material from the sides of the container and to disperse lipid aggregates, thereby forming the liposomal suspension.
VI. Processes for the Preparation of Active Compounds
The nucleosides of the present invention can be synthesized by any means known in the art. In particular, the synthesis of the present nucleosides can be achieved by either alkylating the appropriately modified sugar, followed by glycosylation or glycosylation followed by alkylation of the nucleoside. The following non-limiting embodiments illustrate some general methodology to obtain the nucleosides of the present invention.
A. General Synthesis of 1′-C-Branched Nucleosides
1′-C-Branched ribonucleosides of the following structure:




    wherein BASE is a purine or pyrimidine base as defined herein;
    R7 and R9 are independently hydrogen, OR2, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
    R8 and R10 are independently H, alkyl (including lower alkyl), chlorine, bromine or iodine; alternatively, R7 and R9, R7 and R10, R8 and R9, or R8 and R10 can come together to form a pi bond;
    R1 and R2 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate;
    R6 is an alkyl, halogeno-alkyl (i.e. CF3), alkenyl, or alkynyl (i.e. allyl); and
    X is O, S, SO2 or CH2 

can be prepared by one of the following general methods.

1) Modification from the Lactone



The key starting material for this process is an appropriately substituted lactone. The lactone can be purchased or can be prepared by any known means including standard epimerization, substitution and cyclization techniques. The lactone can be optionally protected with a suitable protecting group, preferably with an acyl or silyl group, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991. The protected lactone can then be coupled with a suitable coupling agent, such as anorganometallic carbon nucleophile, such as a Grignard reagent, an organolithium, lithium dialkylcopper or R6-SiMe3 in TBAF with the appropriate non-protic solvent at a suitable temperature, to give the 1′-alkylated sugar.
The optionally activated sugar can then be coupled to the BASE by methods well known to those skilled in the art, as taught by Townsend Chemistry of Nucleosides and Nucleotides, Plenum Press, 1994. For example, an acylated sugar can be coupled to a silylated base with a lewis acid, such as tin tetrachloride, titanium tetrachloride or trimethylsilyltriflate in the appropriate solvent at a suitable temperature.
Subsequently, the nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
In a particular embodiment, the 1′-C-branched ribonucleoside is desired. The synthesis of a ribonucleoside is shown in Scheme 1. Alternatively, deoxyribo-nucleoside is desired. To obtain these nucleosides, the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent. Optionally, the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.




2. Alternative Method for the Preparation of 1′-C-Branched Nucleosides

The key starting material for this process is an appropriately substituted hexose. The hexose can be purchased or can be prepared by any known means including standard epimerization (e.g. via alkaline treatment), substitution and coupling techniques. The hexose can be selectively protected to give the appropriate hexa-faranose, as taught by Townsend Chemistry of Nucleosides and Nucleotides, Plenum Press, 1994.
The 1′-hydroxyl can be optionally activated to a suitable leaving group such as an acyl group or a halogen via acylation or halogenation, respectively. The optionally activated sugar can then be coupled to the BASE by methods well known to those skilled in the art, as taught by Townsend Chemistry of Nucleosides and Nucleotides, Plenum Press, 1994. For example, an acylated sugar can be coupled to a silylated base with a lewis acid, such as tin tetrachloride, titanium tetrachloride or trimethylsilyltriflate in the appropriate solvent at a suitable temperature.
Alternatively, a halo-sugar can be coupled to a silylated base with the presence of trimethylsilyltriflate.
The 1′-CH2—OH, if protected, can be selectively deprotected by methods well known in the art. The resultant primary hydroxyl can be functionalized to yield various C-branched nucleosides. For example, the primary hydroxyl can be reduced to give the methyl, using a suitable reducing agent. Alternatively, the hydroxyl can be activated prior to reduction to facilitate the reaction; i.e. via the Barton reduction. In an alternate embodiment, the primary hydroxyl can be oxidized to the aldehyde, then coupled with a carbon nucleophile, such as a Grignard reagent, an organolithium, lithium dialkylcopper or R6—SiMe3 in TBAF with the appropriate non-protic solvent at a suitable temperature.
In a particular embodiment, the 1′-C-branched ribonucleoside is desired. The synthesis of a ribonucleoside is shown in Scheme 2. Alternatively, deoxyribo-nucleoside is desired. To obtain these nucleosides, the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent. Optionally, the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.




In addition, the L-enantiomers corresponding to the compounds of the invention can be prepared following the same general methods (1 or 2), beginning with the corresponding L-sugar or nucleoside L-enantiomer as starting material.
B. General Synthesis of 2′-C-Branched Nucleosides
2′-C-Branched ribonucleosides of the following structure:




    wherein BASE is a purine or pyrimidine base as defined herein;
    R7 and R9 are independently hydrogen, OR2, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorines bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
    R10 is H, alkyl (including lower alkyl), chlorine, bromine or iodine;
    alternatively, R7 and R9, or R7 and R10 can come together to form a pi bond;
    R1 and R2 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate;
    R6 is an alkyl, halogeno-alkyl (i.e. CF3), alkenyl, or alkynyl (i.e. allyl); and
    X is O, S SO2 or CH2 

can be prepared by one of the following general methods.

1. Glycosylation of the Nucleobase with an Appropriately Modified Sugar



The key starting material for this process is an appropriately substituted sugar with a 2′-OH and 2′-H, with the appropriate leaving group (LG), for example an acyl group or a halogen. The sugar can be purchased or can be prepared by any known means including standard epimerization, substitution, oxidation and reduction techniques. The substituted sugar can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 2′-modified sugar. Possible oxidizing agents are Jones reagent (a mixture of chromic acid and sulfuric acid), Collins's reagent (dipyridine Cr(VI) oxide, Corey's reagent (pyridinium chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate, MnO2, ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, Cl2-pyridine, H2O2-ammonium molybdate, NaBrO2-CAN, NaOCl in HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-Pondorf-Verley reagent (aluminum t-butoxide with another ketone) and N-bromosuccinimide.
Then coupling of an organometallic carbon nucleophile, such as a Grignard reagent, an organolithium, lithium dialkylcopper or R6—SiMe3 in TBAF with the ketone with the appropriate non-protic solvent at a suitable temperature, yields the 2′-alkylated sugar. The alkylated sugar can be optionally protected with a suitable protecting group, preferably with an acyl or silyl group, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
The optionally protected sugar can then be coupled to the BASE by methods well known to those skilled in the art, as taught by Townsend Chemistry of Nucleosides and Nucleotides, Plenum Press, 1994. For example, an acylated sugar can be coupled to a silylated base with a lewis acid, such as tin tetrachloride, titanium tetrachloride or trimethylsilyltriflate in the appropriate solvent at a suitable temperature. Alternatively, a halo-sugar can be coupled to a silylated base with the presence of trimethylsilyltriflate.
Subsequently, the nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
In a particular embodiment, the 2′-C-branched ribonucleoside is desired. The synthesis of a ribonucleoside is shown in Scheme 3. Alternatively, deoxyribo-nucleoside is desired. To obtain these nucleosides, the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent. Optionally, the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.




2. Modification of a Pre-Formed Nucleoside

The key starting material for this process is an appropriately substituted nucleoside with a 2′-OH and 2′-H. The nucleoside can be purchased or can be prepared by any known means including standard coupling techniques. The nucleoside can be optionally protected with suitable protecting groups, preferably with acyl or silyl groups, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
The appropriately protected nucleoside can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 2′-modified sugar. Possible oxidizing agents are Jones reagent (a mixture of chromic acid and sulfuric acid), Collins's reagent (dipyridine Cr(VI) oxide, Corey's reagent (pyridinium chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate, MnO2, ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, Cl2-pyridine, H2O2-ammonium molybdate, NaBrO2-CAN, NaOCl in HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-Pondorf-Verley reagent (aluminum t-butoxide with another ketone) and N-bromosuccinimide.
Subsequently, the nucleoside can be deprotected by methods well known to those skilled in the art, as taught by GreeneGreene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
In a particular embodiment, the 2′-C-branched ribonucleoside is desired. The synthesis of a ribonucleoside is shown in Scheme 4. Alternatively, deoxyribo-nucleoside is desired. To obtain these nucleosides, the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent. Optionally, the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.




In another embodiment of the invention, the L-enantiomers are desired. Therefore, the L-enantiomers can be corresponding to the compounds of the invention can be prepared following the same foregoing general methods, beginning with the corresponding L-sugar or nucleoside L-enantiomer as starting material.
C. General Synthesis of 3′-C-Branched Nucleosides
3′-C-Branched ribonucleosides of the following structure:




    wherein BASE is a purine or pyrimidine base as defined herein;
    R7 and R9 are independently hydrogen, OR2, hydroxy, alkyl (including lower alkyl), azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —C(O)O(lower alkyl), —O(acyl), —O(lower acyl), —O(alkyl), —O(lower alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, —N(acyl)2;
    R8 is H, alkyl (including lower alkyl), chlorine, bromine or iodine;
    alternatively, R7 and R9, or R8 and R9 can come together to form a pi bond;
    R1 and R2 are independently H; phosphate (including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug); acyl (including lower acyl); alkyl (including lower alkyl); sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl and benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given herein; a lipid, including a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol, or other pharmaceutically acceptable leaving group which when administered in vivo is capable of providing a compound wherein R1 is independently H or phosphate;
    R6 is an alkyl, halogeno-alkyl (i.e. CF3), alkenyl, or alkynyl (i.e. allyl); and
    X is O, S, SO2 or CH2 

can be prepared by one of the following general methods.

1 Glycosylation of the Nucleobase with an Appropriately Modified Sugar



The key starting material for this process is an appropriately substituted sugar with a 3′-OH and 3′-H, with the appropriate leaving group (LG), for example an acyl group or a halogen. The sugar can be purchased or can be prepared by any known means including standard epimerization, substitution, oxidation and reduction techniques. The substituted sugar can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 3′-modified sugar. Possible oxidizing agents are Jones reagent (a mixture of chromic acid and sulfuric acid), Collins's reagent (dipyridine Cr(VI) oxide, Corey's reagent (pyridinium chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate, MnO2, ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, Cl2-pyridine, H2O2-ammonium molybdate, NaBrO2-CAN, NaOCl in HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-Pondorf-Verley reagent (aluminum t-butoxide with another ketone) and N-bromosuccinimide.
Then coupling of an organometallic carbon nucleophile, such as a Grignard reagent, an organolithium, lithium dialkylcopper or R6—SiMe3 in TBAF with the ketone with the appropriate non-protic solvent at a suitable temperature, yields the 3′-C-branched sugar. The 3′-C-branched sugar can be optionally protected with a suitable protecting group, preferably with an acyl or silyl group, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
The optionally protected sugar can then be coupled to the BASE by methods well known to those skilled in the art, as taught by Townsend Chemistry of Nucleosides and Nucleotides, Plenum Press, 1994. For example, an acylated sugar can be coupled to a silylated base with a lewis acid, such as tin tetrachloride, titanium tetrachloride or trimethylsilyltriflate in the appropriate solvent at a suitable temperature. Alternatively, a halo-sugar can be coupled to a silylated base with the presence of trimethylsilyltriflate.
Subsequently, the nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
In a particular embodiment, the 3′-C-branched ribonucleoside is desired. The synthesis of a ribonucleoside is shown in Scheme 5. Alternatively, deoxyribo-nucleoside is desired. To obtain these nucleosides, the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent. Optionally, the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.




2. Modification of a Pre-Formed Nucleoside

The key starting material for this process is an appropriately substituted nucleoside with a 3′-OH and 3′-H. The nucleoside can be purchased or can be prepared by any known means including standard coupling techniques. The nucleoside can be optionally protected with suitable protecting groups, preferably with acyl or silyl groups, by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
The appropriately protected nucleoside can then be oxidized with the appropriate oxidizing agent in a compatible solvent at a suitable temperature to yield the 2′-modified sugar. Possible oxidizing agents are Jones reagent (a mixture of chromic acid and sulfuric acid), Collins's reagent (dipyridine Cr(VI) oxide, Corey's reagent (pyridinium chlorochromate), pyridinium dichromate, acid dichromate, potassium permanganate, MnO2, ruthenium tetroxide, phase transfer catalysts such as chromic acid or permanganate supported on a polymer, Cl2-pyridine, H2O2-ammonium molybdate, NaBrO2-CAN, NaOCl in HOAc, copper chromite, copper oxide, Raney nickel, palladium acetate, Meerwin-Pondorf-Verley reagent (aluminum t-butoxide with another ketone) and N-bromosuccinimide.
Subsequently, the nucleoside can be deprotected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991.
In a particular embodiment, the 3′-C-branched ribonucleoside is desired. The synthesis of a ribonucleoside is shown in Scheme 6. Alternatively, deoxyribo-nucleoside is desired. To obtain these nucleosides, the formed ribonucleoside can optionally be protected by methods well known to those skilled in the art, as taught by Greene et al. Protective Groups in Organic Synthesis, John Wiley and Sons, Second Edition, 1991, and then the 2′-OH can be reduced with a suitable reducing agent. Optionally, the 2′-hydroxyl can be activated to facilitate reduction; i.e. via the Barton reduction.




In another embodiment of the invention, the L-enantiomers are desired. Therefore, the L-enantiomers can be corresponding to the compounds of the invention can be prepared following the same foregoing general methods, beginning with the corresponding L-sugar or nucleoside L-enantiomer as starting material.
EXAMPLES
Example 1
Preparation of 1′-C-methylriboadenine via 6-amino-9-(1-deoxy-β-D-psicofuranosyl)purine
The title compound could also be prepared according to a published procedure (J. Farkas, and F. Sorm, “Nucleic acid components and their analogues. XCIV. Synthesis of 6-amino-9-(1-deoxy-β-D-psicofuranosyl)purine” Collect. Czech. Chem. Commun. 1967, 32, 2663–2667; J. Farkas”, Collect. Czech. Chem. Commun. 1966, 31, 1535) (Scheme 7).




In a similar manner, but using the appropriate sugar and pyrimidine or purine bases, the following nucleosides of Formula I are prepared.












(I)








 







wherein:












R1
R2
R3
X1
X2
Y





H
H
H
H
H
H


H
H
H
H
H
NH2


H
H
H
H
H
NH-cyclopropyl


H
H
H
H
H
NH-methyl


H
H
H
H
H
NH-ethyl


H
H
H
H
H
NH-acetyl


H
H
H
H
H
OH


H
H
H
H
H
OMe


H
H
H
H
H
OEt


H
H
H
H
H
O-cyclopropyl


H
H
H
H
H
O-acetyl


H
H
H
H
H
SH


H
H
H
H
H
SMe


H
H
H
H
H
SEt


H
H
H
H
H
5-cyclopropyl


H
H
H
H
H
F


H
H
H
H
H
Cl


H
H
H
H
H
Br


H
H
H
H
H
I


monophosphate
H
H
H
H
NH2


monophosphate
H
H
H
H
NH-acetyl


monophosphate
H
H
H
H
NH-cyclopropyl


monophosphate
H
H
H
H
NH-methyl


monophosphate
H
H
H
H
NH-ethyl


monophosphate
H
H
H
H
OH


monophosphate
H
H
H
H
O-acetyl


monophosphate
H
H
H
H
OMe


monophosphate
H
H
H
H
OEt


monophosphate
H
H
H
H
O-cyclopropyl


monophosphate
H
H
H
H
SH


monophosphate
H
H
H
H
SMe


monophosphate
H
H
H
H
SEt


monophosphate
H
H
H
H
5-cyclopropyl


monophosphate
H
H
H
H
F


monophosphate
H
H
H
H
Cl


monophosphate
H
H
H
H
Br


monophosphate
H
H
H
H
I


diphosphate
H
H
H
H
NH2


diphosphate
H
H
H
H
NH-acetyl


diphosphate
H
H
H
H
NH-cyclopropyl


diphosphate
H
H
H
H
NH-methyl


diphosphate
H
H
H
H
NH-ethyl


diphosphate
H
H
H
H
OH


diphosphate
H
H
H
H
O-acetyl


diphosphate
H
H
H
H
OMe


diphosphate
H
H
H
H
OEt


diphosphate
H
H
H
H
O-cyclopropyl


diphosphate
H
H
H
H
SH


diphosphate
H
H
H
H
SMe


diphosphate
H
H
H
H
SEt


diphosphate
H
H
H
H
5-cyclopropyl


diphosphate
H
H
H
H
F


diphosphate
H
H
H
H
Cl


diphosphate
H
H
H
H
Br


diphosphate
H
H
H
H
I


triphosphate
H
H
H
H
NH2


triphosphate
H
H
H
H
NH-acetyl


triphosphate
H
H
H
H
NH-cyclopropyl


triphosphate
H
H
H
H
NH-methyl


triphosphate
H
H
H
H
NH-ethyl


triphosphate
H
H
H
H
OH


triphosphate
H
H
H
H
OMe


triphosphate
H
H
H
H
OEt


triphosphate
H
H
H
H
O-cyclopropyl


triphosphate
H
H
H
H
O-acetyl


triphosphate
H
H
H
H
SH


triphosphate
H
H
H
H
SMe


triphosphate
H
H
H
H
SEt


triphosphate
H
H
H
H
5-cyclopropyl


triphosphate
H
H
H
H
F


triphosphate
H
H
H
H
Cl


triphosphate
H
H
H
H
Br


triphosphate
H
H
H
H
I


monophosphate
monophosphate
monophosphate
H
H
NH2


monophosphate
monophosphate
monophosphate
H
H
NH-cyclopropyl


monophosphate
monophosphate
monophosphate
H
H
OH


monophosphate
monophosphate
monophosphate
H
H
F


monophosphate
monophosphate
monophosphate
H
H
Cl


diphosphate
diphosphate
diphosphate
H
H
NH2


diphosphate
diphosphate
diphosphate
H
H
NH-cyclopropyl


diphosphate
diphosphate
diphosphate
H
H
OH


diphosphate
diphosphate
diphosphate
H
H
F


diphosphate
diphosphate
diphosphate
H
H
Cl


triphosphate
triphosphate
triphosphate
H
H
NH2


triphosphate
triphosphate
triphosphate
H
H
NH-cyclopropyl


triphosphate
triphosphate
triphosphate
H
H
OH


triphosphate
triphosphate
triphosphate
H
H
F


triphosphate
triphosphate
triphosphate
H
H
Cl


H
H
H
F
H
NH2


H
H
H
F
H
NH-cyclopropyl


H
H
H
F
H
OH


H
H
H
F
H
F


H
H
H
F
H
Cl


H
H
H
Cl
H
NH2


H
H
H
Cl
H
NH-cyclopropyl


H
H
H
Cl
H
OH


H
H
H
Cl
H
F


H
H
H
Cl
H
Cl


H
H
H
Br
H
NH2


H
H
H
Br
H
NH-cyclopropyl


H
H
H
Br
H
OH


H
H
H
Br
H
F


H
H
H
Br
H
Cl


H
H
H
NH2
H
NH2


H
H
H
NH2
H
NH-cyclopropyl


H
H
H
NH2
H
OH


H
H
H
NH2
H
F


H
H
H
NH2
H
Cl


H
H
H
SH
H
NH2


H
H
H
SH
H
NH-cyclopropyl


H
H
H
SH
H
OH


H
H
H
SH
H
F


H
H
H
SH
H
Cl


acetyl
H
H
H
H
NH2


acetyl
H
H
H
H
NH-cyclopropyl


acetyl
H
H
H
H
OH


acetyl
H
H
H
H
F


acetyl
H
H
H
H
Cl


acetyl
H
H
F
H
NH2


aceiyl
H
H
F
H
NH-cyclopropyl


acetyl
H
H
F
H
OH


acetyl
H
H
F
H
F


acetyl
H
H
F
H
Cl


H
acetyl
acetyl
H
H
NH2


H
acetyl
acetyl.
H
H
NH-cyclopropyl


H
acetyl
acetyl
H
H
OH


H
acetyl
acetyl
H
H
F


H
acetyl
acetyl
H
H
Cl


acetyl
acetyl
acetyl
H
H
NH2


acetyl
acetyl
acetyl
H
H
NH-cyclopropyl


acetyl
acetyl
acetyl
H
H
OH


acetyl
acetyl
acetyl
H
H
F


acetyl
acetyl
acetyl
H
H
Cl


monophosphate
acetyl
acetyl
H
H
NH2


monophosphate
acetyl
acetyl
H
H
NH-cyclopropyl


monophosphate
acetyl
acetyl
H
H
OH


monophosphate
acetyl
acetyl
H
H
F


monophosphate
acetyl
acetyl
H
H
Cl


diphosphate
acetyl
acetyl
H
H
NH2


diphosphate
acetyl
acetyl
H
H
NH-cyclopropyl


diphosphate
acetyl
acetyl
H
H
OH


diphosphate
acetyl
acetyl
H
H
F


diphosphate
acetyl
acetyl
H
H
Cl


triphosphate
acetyl
acetyl
H
H
NH2


triphosphate
acetyl
acetyl
H
H
NH-cyclopropyl


triphosphate
acetyl
acetyl
H
H
OH


triphosphate
acetyl
acetyl
H
H
F


triphosphate
acetyl
acetyl
H
H
Cl


H
H
H
H
NH2
H


H
H
H
H
NH2
NH2


H
H
H
H
NH2
NH-cyclopropyl


H
H
H
H
NH2
NH-methyl


H
H
H
H
NH2
NH-ethyl


H
H
H
H
NH2
NH-acetyl


H
H
H
H
NH2
OH


H
H
H
H
NH2
OMe


H
H
H
H
NH2
OEt


H
H
H
H
NH2
O-cyclopropyl


H
H
H
H
NH2
O-acetyl


H
H
H
H
NH2
SH


H
H
H
H
NH2
SMe


H
H
H
H
NH2
SEt


H
H
H
H
NH2
5-cyclopropyl


H
H
H
H
NH2
F


H
H
H
H
NH2
Cl


H
H
H
H
NH2
Br


H
H
H
H
NH2
I


monophosphate
H
H
H
NH2
NH2


monophosphate
H
H
H
NH2
NH-acetyl


monophosphate
H
H
H
NH2
NH-cyclopropyl


monophosphate
H
H
H
NH2
NH-methyl


monophosphate
H
H
H
NH2
NH-ethyl


monophosphate
H
H
H
NH2
OH


monophosphate
H
H
H
NH2
O-acetyl


monophosphate
H
H
H
NH2
OMe


monophosphate
H
H
H
NH2
OEt


monophosphate
H
H
H
NH2
O-cyclopropyl


monophosphate
H
H
H
NH2
SH


monophosphate
H
H
H
NH2
SMe


monophosphate
H
H
H
NH2
SEt


monophosphate
H
H
H
NH2
5-cyclopropyl


monophosphate
H
H
H
NH2
F


monophosphate
H
H
H
NH2
Cl


monophosphate
H
H
H
NH2
Br


monophosphate
H
H
H
NH2
I


diphosphate
H
H
H
NH2
NH2


diphosphate
H
H
H
NH2
NH-acetyl


diphosphate
H
H
H
NH2
NH-cyclopropyl


diphosphate
H
H
H
NH2
NH-methyl


diphosphate
H
H
H
NH2
NH-ethyl


diphosphate
H
H
H
NH2
OH


diphosphate
H
H
H
NH2
O-acetyl


diphosphate
H
H
H
NH2
OMe


diphosphate
H
H
H
NH2
OEt


diphosphate
H
H
H
NH2
O-cyclopropyl


diphosphate
H
H
H
NH2
SH


diphosphate
H
H
H
NH2
SMe


diphosphate
H
H
H
NH2
SEt


diphosphate
H
H
H
NH2
S-cyclopropyl


diphosphate
H
H
H
NH2
F


diphosphate
H
H
H
NH2
Cl


diphosphate
H
H
H
NH2
Br


diphosphate
H
H
H
NH2
I


triphosphate
H
H
H
NH2
NH2


triphosphate
H
H
H
NH2
NH-acetyl


triphosphate
H
H
H
NH2
NH-cyclopropyl


triphosphate
H
H
H
NH2
NH-methyl


triphosphate
H
H
H
NH2
NH-ethyl


triphosphate
H
H
H
NH2
OH


triphosphate
H
H
H
NH2
OMe


triphosphate
H
H
H
NH2
OEt


triphosphate
H
H
H
NH2
O-cyclopropyl


triphosphate
H
H
H
NH2
O-acetyl


triphosphate
H
H
H
NH2
SH


triphosphate
H
H
H
NH2
SMe


triphosphate
H
H
H
NH2
SEt


triphosphate
H
H
H
NH2
5-cyclopropyl


triphosphate
H
H
H
NH2
F


triphosphate
H
H
H
NH2
Cl


triphosphate
H
H
H
NH2
Br


triphosphate
H
H
H
NH2
I


monophosphate
monophosphate
monophosphate
H
NH2
NH2


monophosphate
monophosphate
monophosphate
H
NH2
NH-cyclopropyl


monophosphate
monophosphate
monophosphate
H
NH2
OH


monophosphate
monophosphate
monophosphate
H
NH2
F


monophosphate
monophosphate
monophosphate
H
NH2
Cl


diphosphate
diphosphate
diphosphate
H
NH2
NH2


diphosphate
diphosphate
diphosphate
H
NH2
NH-cyclopropyl


diphosphate
diphosphate
diphosphate
H
NH2
OH


diphosphate
diphosphate
diphosphate
H
NH2
F


diphosphate
diphosphate
diphosphate
H
NH2
Cl


triphosphate
triphosphate
triphosphate
H
NH2
NH2


triphosphate
triphosphate
triphosphate
H
NH2
NH-cyclopropyl


triphosphate
triphosphate
triphosphate
H
NH2
OH


triphosphate
triphosphate
triphosphate
H
NH2
F


triphosphate
triphosphate
triphosphate
H
NH2
Cl


H
H
H
F
NH2
NH2


H
H
H
F
NH2
NH-cyclopropyl


H
H
H
F
NH2
OH


H
H
H
F
NH2
F


H
H
H
F
NH2
Cl


H
H
H
Cl
NH2
NH2


H
H
H
Cl
NH2
NH-cyclopropyl


H
H
H
Cl
NH2
OH


H
H
H
Cl
NH2
F


H
H
H
Cl
NH2
Cl


H
H
H
Br
NH2
NH2


H
H
H
Br
NH2
NH-cyclopropyl


H
H
H
Br
NH2
OH


H
H
H
Br
NH2
F


H
H
H
Br
NH2
Cl


H
H
H
NH2
NH2
NH2


H
H
H
NH2
NH2
NH-cyclopropyl


H
H
H
NH2
NH2
OH


H
H
H
NH2
NH2
F


H
H
H
NH2
NH2
Cl


H
H
H
SH
NH2
NH2


H
H
H
SH
NH2
NH-cyclopropyl


H
H
H
SH
NH2
OH


H
H
H
SH
NH2
F


H
H
H
SH
NH2
Cl


acetyl
H
H
H
NH2
NH2


acetyl
H
H
H
NH2
NH-cyclopropyl


acetyl
H
H
H
NH2
OH


acetyl
H
H
H
NH2
F


acetyl
H
H
H
NH2
Cl


acetyl
H
H
F
NH2
NH2


acetyl
H
H
F
NH2
NH-cyclopropyl


acetyl
H
H
F
NH2
OH


acetyl
H
H
F
NH2
F


acetyl
H
H
F
NH2
Cl


H
acetyl
acetyl
H
NH2
NH2


H
acetyl
acetyl
H
NH2
NH-cyclopropyl


H
acetyl
acetyl
H
NH2
OH


H
acetyl
acetyl
H
NH2
F


H
acetyl
acetyl
H
NH2
Cl


acetyl
acetyl
acetyl
H
NH2
NH2


acetyl
acetyl
acetyl
H
NH2
NH-cyclopropyl


acetyl
acetyl
acetyl
H
NH2
OH


acetyl
acetyl
acetyl
H
NH2
F


acetyl
acetyl
acetyl
H
NH2
Cl


monophosphate
acetyl
acetyl
H
NH2
NH2


monophosphate
acetyl
acetyl
H
NH2
NH-cyclopropyl


monophosphate
acetyl
acetyl
H
NH2
OH


monophosphate
acetyl
acetyl
H
NH2
F


monophosphate
acetyl
acetyl
H
NH2
Cl


diphosphate
acetyl
acetyl
H
NH2
NH2


diphosphate
acetyl
acetyl
H
NH2
NH-cyclopropyl


diphosphate
acetyl
acetyl
H
NH2
OH


diphosphate
acetyl
acetyl
H
NH2
F


diphosphate
acetyl
acetyl
H
NH2
Cl


triphosphate
acetyl
acetyl
H
NH2
NH2


triphosphate
acetyl
acetyl
H
NH2
NH-cyclopropyl


triphosphate
acetyl
acetyl
H
NH2
OH


triphosphate
acetyl
acetyl
H
NH2
F


triphosphate
acetyl
acetyl
H
NH2
Cl


H
H
H
H
Cl
H


H
H
H
H
Cl
H


H
H
H
H
Cl
NH2


H
H
H
H
Cl
NH-cyclopropyl


H
H
H
H
Cl
NH-methyl


H
H
H
H
Cl
NH-ethyl


H
H
H
H
Cl
NH-acetyl


H
H
H
H
Cl
OH


H
H
H
H
Cl
OMe


H
H
H
H
Cl
OEt


H
H
H
H
Cl
O-cyclopropyl


H
H
H
H
Cl
O-acetyl


H
H
H
H
Cl
SH


H
H
H
H
Cl
SMe


H
H
H
H
Cl
SEt


H
H
H
H
Cl
S-cyclopropyl


monophosphate
H
H
H
Cl
NH2


monophosphate
H
H
H
Cl
NH-acetyl


monophosphate
H
H
H
Cl
NH-cyclopropyl


monophosphate
H
H
H
Cl
NH-methyl


monophosphate
H
H
H
Cl
NH-ethyl


monophosphate
H
H
H
Cl
OH


monophosphate
H
H
H
Cl
O-acetyl


monophosphate
H
H
H
Cl
OMe


monophosphate
H
H
H
Cl
GEt


monophosphate
H
H
H
Cl
O-cyclopropyl


monophosphate
H
H
H
Cl
SH


monophosphate
H
H
H
Cl
SMe


monophosphate
H
H
H
Cl
SEt


monophosphate
H
H
H
Cl
5-cyclopropyl


diphosphate
H
H
H
Cl
NH2


diphosphate
H
H
H
Cl
NH-acetyl


diphosphate
H
H
H
Cl
NH-cyclopropyl


diphosphate
H
H
H
Cl
NH-methyl


diphosphate
H
H
H
Cl
NH-ethyl


diphosphate
H
H
H
Cl
OH


diphosphate
H
H
H
Cl
O-acetyl


diphosphate
H
H
H
Cl
OMe


diphosphate
H
H
H
Cl
OEt


diphosphate
H
H
H
Cl
O-cyclopropyl


diphosphate
H
H
H
Cl
SH


diphosphate
H
H
H
Cl
SMe


diphosphate
H
H
H
Cl
SEt


diphosphate
H
H
H
Cl
S-cyclopropyl


triphosphate
H
H
H
Cl
NH2


triphosphate
H
H
H
Cl
NH-acetyl


triphosphate
H
H
H
Cl
NH-cyclopropyl


triphosphate
H
H
H
Cl
NH-methyl


triphosphate
H
H
H
Cl
NH-ethyl


triphosphate
H
H
H
Cl
OH


triphosphate
H
H
H
Cl
OMe


triphosphate
H
H
H
Cl
OEt


triphosphate
H
H
H
Cl
O-cyclopropyl


triphosphate
H
H
H
Cl
O-acetyl


triphosphate
H
H
H
Cl
SH


triphosphate
H
H
H
Cl
SMe


triphosphate
H
H
H
Cl
SEt


triphosphate
H
H
H
Cl
S-cyclopropyl


monophosphate
monophosphate
monophosphate
H
Cl
NH2


monophosphate
monophosphate
monophosphate
H
Cl
NH-cyclopropyl


monophosphate
monophosphate
monophosphate
H
Cl
OH


diphosphate
diphosphate
diphosphate
H
Cl
NH2


diphosphate
diphosphate
diphosphate
H
Cl
NH-cyclopropyl


diphosphate
diphosphate
diphosphate
H
Cl
OH


triphosphate
triphosphate
triphosphate
H
Cl
NH2


triphosphate
triphosphate
triphosphate
H
Cl
NH-cyclopropyl


triphosphate
triphosphate
triphosphate
H
Cl
OH


H
H
H
F
Cl
NH2


H
H
H
F
Cl
NH-cyclopropyl


H
H
H
F
Cl
OH


H
H
H
Cl
Cl
NH2


H
H
H
Cl
Cl
NH-cyclopropyl


H
H
H
Cl
Cl
OH


H
H
H
Br
Cl
NH2


H
H
H
Br
Cl
NH-cyclopropyl


H
H
H
Br
Cl
OH


H
H
H
NH2
Cl
NH2


H
H
H
NH2
Cl
NH-cyclopropyl


H
H
H
NH2
Cl
OH


H
H
H
SH
Cl
NH2


H
H
H
SH
Cl
NH-cyclopropyl


H
H
H
SH
Cl
OH


acetyl
H
H
H
Cl
NH2


acetyl
H
H
H
Cl
NH-cyclopropyl


acetyl
H
H
H
Cl
OH


acetyl
H
H
F
Cl
NH2


acetyl
H
H
F
Cl
NH-cyclopropyl


acetyl
H
H
F
Cl
OH


H
acetyl
acetyl
H
Cl
NH2


H
acetyl
acetyl
H
Cl
NH-cyclopropyl


H
acetyl
acetyl
H
Cl
OH


acetyl
acetyl
acetyl
H
Cl
NH2


acetyl
acetyl
acetyl
H
Cl
NH-cyclopropyl


acetyl
acetyl
acetyl
H
Cl
OH


monophosphate
acetyl
acetyl
H
Cl
NH2


monophosphate
acetyl
acetyl
H
Cl
NH-cyclopropyl


monophosphate
acetyl
acetyl
H
Cl
OH


diphosphate
acetyl
acetyl
H
Cl
NH2


diphosphate
acetyl
acetyl
H
Cl
NH-cyclopropyl


diphosphate
acetyl
acetyl
H
Cl
OH


triphosphate
acetyl
acetyl
H
Cl
NH2


triphosphate
acetyl
acetyl
ii
Cl
NU-cyclopropyl


triphosphate
acetyl
acetyl
H
Cl
OH


H
H
H
H
Cl
NH2


H
H
H
H
Cl
NH-cyclopropyl


H
H
H
H
Cl
OH


H
H
H
H
Br
NH2


H
H
H
H
Br
NH-cyclopropyl


H
H
H
H
Br
OH









Alternatively, the following nucleosides of Formula IV are prepared, using the appropriate sugar and pyrimidine or purine bases.












(IV)








 







wherein:











R1
R2
R3
X1
Y





H
H
H
H
H


H
H
H
H
NH2


H
H
H
H
NH-






cyclopropyl


H
H
H
H
NH-methyl


H
H
H
H
NH-ethyl


H
H
H
H
NH-acetyl


H
H
H
H
OH


H
H
H
H
OMe


H
H
H
H
OEt


H
H
H
H
O-






cyclopropyl


H
H
H
H
O-acetyl


H
H
H
H
SH


H
H
H
H
SMe


H
H
H
H
SEt


H
H
H
H
5-






cyclopropyl


monophosphate
H
H
H
NH2


monophosphate
H
H
H
NH-acetyl


monophosphate
H
H
H
NH-






cyclopropyl


monophosphate
H
H
H
NB-methyl


monophosphate
H
H
H
NB-ethyl


monophosphate
H
H
H
OH


monophosphate
H
H
H
O-acetyl


monophosphate
H
H
H
OMe


monophosphate
H
H
H
OEt


monophosphate
H
H
H
O-






cyclopropyl


monophosphate
H
H
H
SH


monophosphate
H
H
H
SMe


monophosphate
H
H
H
SEt


monophosphate
H
H
H
5-






cyclopropyl


diphosphate
H
H
H
NH2


diphosphate
H
H
H
NH-acetyl


diphosphate
H
H
H
NH-






cyclopropyl


diphosphate
H
H
H
NH-methyl


diphosphate
H
H
H
NH-ethyl


diphosphate
H
H
H
OH


diphosphate
H
H
H
O-acetyl


diphosphate
H
H
H
OMe


diphosphate
H
H
H
OEt


diphosphate
H
H
H
O-






cyclopropyl


diphosphate
H
H
H
SH


diphosphate
H
H
H
SMe


diphosphate
H
H
H
SEt


diphosphate
H
H
H
S-






cyclopropyl


triphosphate
H
H
H
NH2


triphosphate
H
H
H
NH-acetyl


triphosphate
H
H
H
NH-






cyclopropyl


triphosphate
H
H
H
NH-methyl


triphosphate
H
H
H
NH-ethyl


triphosphate
H
H
H
OH


triphosphate
H
H
H
OMe


triphosphate
H
H
H
OEt


triphosphate
H
H
H
O-






cyclopropyl


triphosphate
H
H
H
O-acetyl


triphosphate
H
H
H
SH


triphosphate
H
H
H
SMe


triphosphate
H
H
H
SEt


triphosphate
H
H
H
S-






cyclopropyl


monophosphate
monophosphate
monophosphate
H
NH2


monophosphate
monophosphate
monophosphate
H
NH-






cyclopropyl


monophosphate
monophosphate
monophosphate
H
OH


diphosphate
diphosphate
diphosphate
H
NH2


diphosphate
diphosphate
diphosphate
H
NH-






cyclopropyl


diphosphate
diphosphate
diphosphate
H
OH


triphosphate
triphosphate
triphosphate
H
NH2


triphosphate
triphosphate
triphosphate
H
NH-






cyclopropyl


triphosphate
triphosphate
triphosphate
H
OH


H
H
H
F
NH2


H
H
H
F
NH-






cyclopropyl


H
H
H
F
OH


H
H
H
Cl
NH2


H
H
H
Cl
NH-






cyclopropyl


H
H
H
Cl
OH


H
H
H
Br
NH2


H
H
H
Br
NH-






cyclopropyl


H
H
H
Br
OH


H
H
H
NH2
NH2


H
H
H
NH2
NH-






cyclopropyl


H
H
H
NH2
OH


H
H
H
SH
NH2


H
H
H
SH
NH-






cyclopropyl


H
H
H
SH
OH


acetyl
H
H
H
NH2


acetyl
H
H
H
NH-






cyclopropyl


acetyl
H
H
H
OH


acetyl
H
H
F
NH2


acetyl
H
H
F
NH-






cyclopropyl


acetyl
H
H
F
OH


H
acetyl
acetyl
H
NH2


H
acetyl
acetyl
H
NH-






cyclopropyl


H
acetyl
acetyl
H
OH


acetyl
acetyl
acetyl
H
NH2


acetyl
acetyl
acetyl
H
NH-






cyclopropyl


acetyl
acetyl
acetyl
H
OH


monophosphate
acetyl
acetyl
H
NH2


monophosphate
acetyl
acetyl
H
NH-






cyclopropyl


monophosphate
acetyl
acetyl
H
OH


diphosphate
acetyl
acetyl
H
NH2


diphosphate
acetyl
acetyl
H
NH-






cyclopropyl


diphosphate
acetyl
acetyl
H
OH


triphosphate
acetyl
acetyl
H
NH2


triphosphate
acetyl
acetyl
H
NH-






cyclopropyl


triphosphate
acetyl
acetyl
H
OH









Alternatively, the following nucleosides of Formula VII are prepared, using the appropriate sugar and pyrimidine or purine bases.












(VII)








 







wherein:












R1
R2
R3
R6
X
Base





H
H
H
CH3
O
2,4-O-







Diacetyluracil


H
H
H
CH3
O
Hypoxanthine


H
H
H
CH3
O
2,4-O-







Diacetylthymine


H
H
H
CH3
O
Thymine


H
H
H
CH3
O
Cytosine


H
H
H
CH3
O
4-(N-mono-







acetyl)cytosine


H
H
H
CH3
O
4-(N,N-







diacetyl)cytosine


H
H
H
CH3
O
Uracil


H
H
H
CH3
O
5-Fluorouracil


H
H
H
CH3
S
2,4-O-







Diacetyluraci


H
H
H
CH3
S
Hypoxanthine


H
H
H
CH3
S
2,4-O-







Diacetylthymine


H
H
H
CH3
S
Thymine


H
H
H
CH3
S
Cytosine


H
H
H
CH3
S
4-(N-mono-







acetyl)cytosine


H
H
H
CH3
S
4-(N,N-







diacetyl)cytosine


H
H
H
CH3
S
Uracil


H
H
H
CH3
S
5-Fluorouracil


monophosphate
H
H
CH3
O
2,4-O-







Diacetyluracil


monophosphate
H
H
CH3
O
Hypoxanthine


monophosphate
H
H
CH3
O
2,4-O-







Diacetylthym


monophosphate
H
H
CH3
O
Thymine


monophosphate
H
H
CH3
O
Cytosine


monophosphate
H
H
CH3
O
4-(N-mono-







acetyl)cytosine


monophosphate
H
H
CH3
O
4-N,N-







diacetyl)cytosine


monophosphate
H
H
CH3
O
Uracil


monophosphate
H
H
CH3
O
5-Fluorouracil


monophosphate
H
H
CH3
S
2,4-O-







Diacetyluracil


monophosphate
H
H
CH3
S
Hypoxanthine


monophosphate
H
H
CH3
5
2,4-O-







Diacetylthym


monophosphate
H
H
CH3
S
Thymine


monophosphate
H
H
CH3
S
Cytosine


monophosphate
H
H
CH3
S
4-(N-mono-







acetyl)cytosine


monophosphate
H
H
CH3
S
4-(N,N-







diacetyl)cytosine


monophosphate
H
H
CH3
S
Uracil


monophosphate
H
H
CH3
S
5-Fluorouracil


diphosphate
H
H
CH3
O
2,4-O-







Diacetyluracil


diphosphate
H
H
CH3
O
Hypoxanthine


diphosphate
H
H
CH3
O
2,4-O-







Diacetylthymine


diphosphate
H
H
CH3
O
Thymine


diphosphate
H
H
CH3
O
Cytosine


diphosphate
H
H
CH3
O
4-(N-mono-







acetyl)cytosrne


diphosphate
H
H
CH3
O
4-(N,N-







diacetyl)cytosine


diphosphate
H
H
CH3
O
Uracil


diphosphate
H
H
CH3
O
5-Fluorouracil


diphosphate
H
H
CH3
S
2,4-O-







Diacetyluracil


diphosphate
H
H
CH3
S
Hypoxanthine


diphosphate
H
H
CH3
S
2,4-O-







Diacetylthym


diphosphate
H
H
CH3
S
Thymine


diphosphate
H
H
CH3
S
Cytosine


triphosphate
H
H
CH3
O
2,4-O-







Diacetyluracil


triphosphate
H
H
CH3
O
Hypoxanthine


triphosphate
H
H
CH3
O
2,4-O-







Diacetylthymine


triphosphate
H
H
CH3
O
Thymine


triphosphate
H
H
CH3
O
Cytosine


triphosphate
H
H
CH3
O
4-(N-mono-







acetyl)cytosine


triphosphate
H
H
CH3
O
4-(N,N-







diacetyl)cytosine


triphosphate
H
H
CH3
O
Uracil


triphosphate
H
H
CH3
O
5-Fluorouracil


triphosphate
H
H
CH3
S
2,4-O-







Diacetyluracil


triphosphate
H
H
CH3
S
Hypoxanthine


triphosphate
H
H
CH3
S
2,4-O-







Diacetylthymine


triphosphate
H
H
CH3
S
Thymine


triphosphate
H
H
CH3
S
Cytosine


monophosphate
monophosphate
monophosphate
CF3
O
2,4-O-







Diacetyluracil


monophosphate
monophosphate
monophosphate
CF3
O
Hypoxanthine


monophosphate
monophosphate
monophosphate
CF3
O
2,4-O-







Diacetylthymine


monophosphate
monophosphate
monophosphate
CF3
O
Thymine


monophosphate
monophosphate
monophosphate
CF3
O
Cytosine


monophosphate
monophosphate
monophosphate
CF3
O
4-(N-mono-







acetyl)cytosine


monophosphate
monophosphate
monophosphate
CF3
O
4-(N,N-







diacetyl)cytosine


monophosphate
monophosphate
monophosphate
CF3
O
Uracil


monophosphate
monophosphate
monophosphate
CF3
O
5-Fluorouracil


monophosphate
monophosphate
monophosphate
CF3
S
2,4-O-







Diacetyluracil


monophosphate
monophosphate
monophosphate
CF3
S
Hypoxanthine


monophosphate
monophosphate
monophosphate
CF3
S
2,4-O-







Diacetylthymine


monophosphate
monophosphate
monophosphate
CF3
S
Thymine


monophosphate
monophosphate
monophosphate
CF3
S
Cytosine


monophosphate
monophosphate
monophosphate
CF3
S
4-(N-mono-







acetyl)cytosine


monophosphate
monophosphate
monophosphate
CF3
S
4-(N,N-







diacetyl)cytosine


monophosphate
monophosphate
monophosphate
CF3
S
Uracil


monophosphate
monophosphate
monophosphate
CF3
S
5-Fluorouracil


acetyl
acetyl
acetyl
CF3
O
4-N,N-







diacetyl)cytosine


acetyl
acetyl
acetyl
CF3
S
4-(N,N-







diacetyl)cytosine


acetyl
acetyl
acetyl
2-bromo-
O
4-(N,N-





vinyl

diacetyl)cytosine


acetyl
acetyl
acetyl
2-bromo-
S
4-(N,N-





vinyl

diacetyl)cytosine


H
H
H
CH3
O
2-(N,N-diacetyl)-







guanine


H
H
H
CH3
O
6-O-acetyl







guanine


H
H
H
CH3
O
8-fluoroguanine


H
H
H
CH3
O
guanine


H
H
H
CH3
O
6-(N,N-diacetyl)-







adenine


H
H
H
CH3
O
2-fluoroadenine


H
H
H
CH3
O
8-fluoroadenine


H
H
H
CH3
O
2,8-difluoro-







adenine


H
H
H
CH3
O
adenine


H
H
H
CH3
S
2-(N,N-diacetyl)-







guanine


H
H
H
CH3
S
6-O-acetyl







guanine


H
H
H
CH3
S
8-fluoroguanine


H
H
H
CH3
S
guanine


H
H
H
CH3
S
6-(N,N-diacetyl)-







adenine


H
H
H
CH3
S
2-fluoroadenine


H
H
H
CH3
S
8-fluoroadenine


H
H
H
CH3
S
2,8-difluoro-







adenine


H
H
H
CH3
S
adenine


monophosphate
H
H
CH3
O
2-(N,N-diacetyl)-







guanine


monophosphate
H
H
CH3
O
6-O-acetyl







guanine


monophosphate
H
H
CH3
O
8-fluoroguanine


monophosphate
H
H
CH3
O
guanine


monophosphate
H
H
CH3
O
6-(N,N-diacetyl)-







adenine


monophosphate
H
H
CH3
O
2-fluoroadenine


monophosphate
H
H
CH3
O
8-fluoroadenine


monophosphate
H
H
CH3
O
2,8-difluoro-







adenine


monophosphate
H
H
CH3
O
adenine


monophosphate
H
H
CH3
S
2-(N,N-diacetyl)-







guanine


monophosphate
H
H
CH3
S
6-O-acetyl







guanine


monophosphate
H
H
CH3
S
8-fluoroguanine


monophosphate
H
H
CH3
S
guanine


monophosphate
H
H
CH3
S
6-(N,N-diacetyl)-







adenine


monophosphate
H
H
CH3
S
2-fluoroadenine


monophosphate
H
H
CH3
S
8-fluoroadenine


monophosphate
H
H
CH3
S
2,8-difluoro-







adenine


monophosphate
H
H
CH3
S
adenine


diphosphate
H
H
CH3
O
2-(N,N-diacetyl)-







guanine


diphosphate
H
H
CH3
O
6-O-acetyl







guanine


diphosphate
H
H
CH3
O
8-fluoroguanine


diphosphate
H
H
CH3
O
guanine


diphosphate
H
H
CH3
O
6-(N,N-diacetyl)-







adenine


diphosphate
H
H
CH3
O
2-fluoroadenine


diphosphate
H
H
CH3
O
8-fluoroadenine


diphosphate
H
H
CH3
O
2,8-difluoro-







adenine


diphosphate
H
H
CH3
O
adenine


diphosphate
H
H
CH3
S
2-(N,N-diacetyl)-







guanine


diphosphate
H
H
CH3
S
6-O-acetyl







guanine


diphosphate
H
H
CH3
S
8-fluoroguanine


diphosphate
H
H
CH3
S
guanine


diphosphate
H
H
CH3
S
6-(N,N-diacetyl)-







adenine


diphosphate
H
H
CH3
S
2-fluoroadenine


diphosphate
H
H
CH3
S
8-fluoroadenine


diphosphate
H
H
CH3
S
2,8-difluoro-







adenine


diphosphate
H
H
CH3
S
adenine


triphosphate
H
H
CH3
O
2-(N,N-diacetyl)-







guanine


triphosphate
H
H
CH3
O
6-O-acetyl







guanine


triphosphate
H
H
CR3
O
8-fluoroguanine


triphosphate
H
H
CH3
O
guanine


triphosphate
H
H
CR3
O
6-(N,N-diacetyl)-







adenine


triphosphate
H
H
CH3
O
2-fluoroadenine


triphosphate
H
H
CH3
O
8-fluoroadenine


triphosphate
H
H
CH3
O
2,8-difluoro-







adenine


triphosphate
H
H
CH3
O
2-(N,N-diacetyl)-







guanine


triphosphate
H
H
CH3
S
6-O-acetyl







guanine


triphosphate
H
H
CH3
S
8-fluoroguanine


triphosphate
H
H
CH3
S
guanine


triphosphate
H
H
CH3
S
6-(N,N-diacetyl)-







adenine


triphosphate
H
H
CH3
S
2-fluoroadenine


triphosphate
H
H
CH3
S
8-fluoroadenine


triphosphate
H
H
CH3
S
2,8-difluoro-







adenine


triphosphate
H
H
CH3
S
adenine


monophosphate
monophosphate
monophosphate
CF3
O
2-(N,N-diacetyl)-







guanine


monophosphate
monophosphate
monophosphate
CF3
O
6-O-acetyl







guanine


monophosphate
monophosphate
monophosphate
CF3
O
8-fluoroguanine


monophosphate
monophosphate
monophosphate
CF3
O
guanine


monophosphate
monophosphate
monophosphate
CF3
O
6-(N,N-diacetyl)-







adenine


monophosphate
monophosphate
monophosphate
CF3
O
2-fluoroadenine


monophosphate
monophosphate
monophosphate
CF3
O
8-fluoroadenine


monophosphate
monophosphate
monophosphate
CF3
O
2,8-difluoro-







adenine


monophosphate
monophosphate
monophosphate
CF3
O
ademne


monophosphate
monophosphate
monophosphate
CF3
S
2-(N,N-diacetyl)-







guanine


monophosphate
monophosphate
monophosphate
CF3
S
6-O-acetyl







guanine


monophosphate
monophosphate
monophosphate
CF3
S
8-fluoroguanine


monophosphate
monophosphate
monophosphate
CF3
S
guanine


monophosphate
monophosphate
monophosphate
CF3
S
6-(N,N-diacetyl)-







adenine


monophosphate
monophosphate
monophosphate
CF3
S
2-fluoroadenine


monophosphate
monophosphate
monophosphate
CF3
S
8-fluoroadenine


monophosphate
monophosphate
monophosphate
CF3
S
2,8-difluoro-







adenine


monophosphate
monophosphate
monophosphate
CF3
S
adenine


acetyl
acetyl
acetyl
CF3
O
guanine


acetyl
acetyl
acetyl
CF3
S
guanine


acetyl
acetyl
acetyl
2-bromo-
O
guanine





vinyl


acetyl
acetyl
acetyl
2-bromo-
S
guanine





vinyl









Alternatively, the following nucleosides of Formula VIII are prepared, using the appropriate sugar and pyrimidine or purine bases.












(VIII)








 







wherein











R1
R2
R6
X
Base





H
H
CH3
O
2,4-O-Diacetyluracil


H
H
CH3
O
Hypoxanthine


H
H
CH3
O
2,4-O-Diacethylthymine


H
H
CH3
O
Thymine


H
H
CH3
O
Cytosine


H
H
CH3
O
4-(N-mono-acetyl)cytosine


H
H
CH3
O
4-(N,N-diacetyl)cytosine


H
H
CH3
O
Uracil


H
H
CH3
O
5-Fluorouracil


H
H
CH3
S
2,4-O-Diacetyluracil


H
H
CH3
S
Hypoxanthine


H
H
CH3
S
2,4-O-Diacetylthymine


H
H
CH3
S
Thymine


H
H
CH3
S
Cytosine


H
H
CH3
S
4-(N-mono-acetyl)cytosine


H
H
CH3
S
4-(N,N-diacetyl)cytosine


H
H
CH3
S
Uracil


H
H
CH3
S
5-Fluorouracil


monophosphate
H
CF3
O
2,4-O-Diacetyluracil


monophosphate
H
CF3
O
Hypoxanthine


monophosphate
H
CF3
O
2,4-O-Diacetylthymine


monophosphate
H
CF3
O
Thymine


monophosphate
H
CF3
O
Cytosine


monophosphate
H
CF3
O
4-(N-mono-acetyl)cytosine


monophosphate
H
CF3
O
4-(N,N-diacetyl)cytosine


monophosphate
H
CF3
O
Uracil


monophosphate
H
CF3
O
5-Fluorouracil


monophosphate
H
CF3
S
2,4-O-Diacetyluracil


monophosphate
H
CF3
S
Hypoxanthine


monophosphate
H
CF3
S
2,4-O-Diacetylthymine


monophosphate
H
CF3
S
Thymine


monophosphate
H
CH3
S
Cytosine


monophosphate
H
CH3
S
4-(N-mono-acetyl)cytosine


monophosphate
H
CH3
S
4-(N,N-diacetyl)cytosine


monophosphate
H
CH3
S
Uracil


monophosphate
H
CH3
S
5-Fluorouracil


diphosphate
H
CH3
O
2,4-O-Diacetyluracil


diphosphate
H
CH3
O
Hypoxanthine


diphosphate
H
CH3
O
2,4-O-diacethylthymine


diphosphate
H
CH3
O
Thymine


diphosphate
H
CH3
O
Cytosine


diphosphate
H
CH3
O
4-(N-mono-acetyl)cytosine


diphosphate
H
CH3
O
4-(N,N-diacetyl)cytosine


diphosphate
H
CH3
O
Uracil


diphosphate
H
CH3
O
5-Fluorouracil


diphosphate
H
CH3
S
2,4-O-Diacetyluracil


diphosphate
H
CH3
S
Hypoxanthine


diphosphate
H
CH3
S
2,4-O-Diacetylthymine


diphosphate
H
CH3
S
Thymine


diphosphate
H
CH3
S
Cytosine


diphosphate
H
CH3
S
4-(N-mono-acetyl)cytosine


diphosphate
H
CH3
S
4-(N,N-diacetyl)cytosine


diphosphate
H
CH3
S
Uracil


diphosphate
H
CH3
S
5-Fluorouracil


triphosphate
H
CH3
O
2,4-O-Diacetyluracil


triphosphate
H
CH3
O
Hypoxanthine


triphosphate
H
CH3
O
2,4-O-diacethylthymine


triphosphate
H
CH3
O
Thymine


triphosphate
H
CH3
O
Cytosine


triphosphate
H
CH3
O
4-(N-mono-acetyl)cytosine


triphosphate
H
CH3
O
4-(N,N-diacetyl)cytosine


triphosphate
H
CH3
O
Uracil


triphosphate
H
CH3
O
5-Fluorouracil


triphosphate
H
CH3
S
2,4-O-Diacetyluracil


triphosphate
H
CH3
S
Hypoxanthine


triphosphate
H
CH3
S
2,4-O-Diacetylthymine


triphosphate
H
CH3
S
Thymine


triphosphate
H
CH3
S
Cytosine


triphosphate
H
CH3
S
4-(N-mono-acetyl)cytosine


triphosphate
H
CH3
S
4-(N,N-diacetyl)cytosine


triphosphate
H
CH3
S
Uracil


triphosphate
H
CH3
S
5-Fluorouracil


monophosphate
monophosphate
CF3
O
2,4-O-Diacetyluracil


monophosphate
monophosphate
CF3
O
Hypoxanthine


monophosphate
monophosphate
CF3
O
2,4-O-Diacetylthyinine


monophosphate
monophosphate
CF3
O
Thymine


monophosphate
monophosphate
CF3
O
Cytosine


monophosphate
monophosphate
CF3
O
4-(N-mono-acetyl)cytosine


monophosphate
monophosphate
CF3
O
4-(N,N-diacetyl)cytosine


monophosphate
monophosphate
CF3
O
Uracil


monophosphate
monophosphate
CF3
O
5-Fluorouracil


monophosphate
monophosphate
CF3
S
2,4-O-Diacetyluracil


monophosphate
monophosphate
CF3
S
Hypoxanthine


monophosphate
monophosphate
CF3
S
2,4-O-Diacetylthymine


monophosphate
monophosphate
CF3
S
Thymine


monophosphate
monophosphate
CF3
S
Cytosine


monophosphate
monophosphate
CF3
S
4-(N-mono-acetyl)cytosine


monophosphate
monophosphate
CF3
S
4-(N,N-diacetyl)cytosine


monophosphate
monophosphate
CF3
S
Uracil


monophosphate
monophosphate
CF3
S
5-Fluorouracil


acetyl
acetyl
CF3
O
4-(N,N-diacetyl)cytosine


acetyl
acetyl
CF3
S
4-(N,N-diacetyl)cytosine


acetyl
acetyl
2-bromo-
O
4-(N,N-diacetyl)cytosine




vinyl


acetyl
acetyl
2-bromo-
S
4-(N,N-diacetyl)cytosine




vinyl


H
H
CH3
O
2-(N,N-diacetyl)-guanine


H
H
CH3
O
6-O-acetyl guanine


H
H
CH3
O
8-fluoroguanine


H
H
CH3
O
guanine


H
H
CH3
O
6-(N,N-diacetyl)-adenine


H
H
CH3
O
2-fluoroadenine


H
H
CH3
O
8-fluoroadenine


H
H
CH3
O
2,8-difluoro-adenine


H
H
CH3
O
adenine


H
H
CH3
S
2-(N,N-diacetyl)-guanine


H
H
CH3
S
6-O-acetyl guanine


H
H
CH3
S
8-fluoroguanine


H
H
CH3
S
guanine


H
H
CH3
S
6-(N,N-diacetyl)-adenine


H
H
CH3
S
2-fluoroadenine


H
H
CH3
S
8-fluoroadenine


H
H
CH3
S
2,8-difluoro-adenine


H
H
CH3
S
adenine


monophosphate
H
CH3
O
2-(N,N-diacetyl)-guanine


monophosphate
H
CH3
O
6-O-acetyl guanine


monophosphate
H
CH3
O
8-fluoroguanine


monophosphate
H
CH3
O
guanine


monophosphate
H
CH3
O
6-(N,N-diacetyl)-adenine


monophosphate
H
CH3
O
2-fluoroadenine


monophosphate
H
CH3
O
8-fluoroadenine


monophosphate
H
CH3
O
2,8-difluoro-adenine


monophosphate
H
CH3
O
adenine


monophosphate
H
CH3
S
2-(N,N-diacetyl)-guanine


monophosphate
H
CH3
S
6-O-acetyl guanine


monophosphate
H
CH3
S
8-fluoroguanine


monophosphate
H
CH3
S
guanine


monophosphate
H
CH3
S
6-(N,N-diacetyl)-adenine


monophosphate
H
CH3
S
2-fluoroadenine


monophosphate
H
CH3
S
8-fluoroadenine


monophosphate
H
CH3
S
2,8-difluoro-adenine


monophosphate
H
CH3
S
adenine


diphosphate
H
CH3
O
2-(N,N-diacetyl)-guanine


diphosphate
H
CH3
O
6-O-acetyl guanine


diphosphate
H
CH3
O
8-fluoroguanine


diphosphate
H
CH3
O
guanine


diphosphate
H
CH3
O
6-(N,N-diacetyl)-adenine


diphosphate
H
CH3
O
2-fluoroadenine


diphosphate
H
CH3
O
8-fluoroadenine


diphosphate
H
CH3
O
2,8-difluoro-adenine


diphosphate
H
CH3
O
adenine


diphosphate
H
CH3
S
2-(N,N-diacetyl)-guanine


diphosphate
H
CH3
S
6-O-acetyl guanine


diphosphate
H
CH3
S
8-fluoroguanine


diphosphate
H
CH3
S
guanine


diphosphate
H
CH3
S
6-(N,N-diacetyl)-adenine


diphosphate
H
CH3
S
2-fluoroadenine


diphosphate
H
CH3
S
8-fluoroadenine


diphosphate
H
CH3
S
2,8-difluoro-adenine


diphosphate
H
CH3
S
adenine


triphosphate
H
CH3
O
2-(N,N-diacetyl)-guanine


triphosphate
H
CH3
O
6-O-acetyl guanine


triphosphate
H
CH3
O
8-fluoroguanine


triphosphate
H
CH3
O
guanine


triphosphate
H
CH3
O
6-(N,N-diacetyl)-adenine


triphosphate
H
CH3
O
2-fluoroadenine


triphosphate
H
CH3
O
8-fluoroadenine


triphosphate
H
CH3
O
2,8-difluoro-adenine


triphosphate
H
CH3
O
adenine


triphosphate
H
CH3
S
2-(N,N-diacetyl)-guanine


triphosphate
H
CH3
S
6-O-acetyl guanine


triphosphate
H
CH3
S
8-fluoroguanine


triphosphate
H
CH3
S
guanine


triphosphate
H
CH3
S
6-(N,N-diacetyl)-adenine


triphosphate
H
CH3
S
2-fluoroadenine


triphosphate
H
CH3
S
8-fluoroadenine


triphosphate
H
CH3
S
2,8-difluoro-adenine


triphosphate
H
CH3
S
adenine


monophosphate
monophosphate
CF3
O
2-(N,N-diacetyl)-guanine


monophosphate
monophosphate
CF3
O
6-O-acetyl guanine


monophosphate
monophosphate
CF3
O
8-fluoroguanine


monophosphate
monophosphate
CF3
O
guanine


monophosphate
monophosphate
CF3
O
6-(N,N-diacetyl)-adenine


monophosphate
monophosphate
CF3
O
2-fluoroadenine


monophosphate
monophosphate
CF3
O
8-fluoroadenine


monophosphate
monophosphate
CF3
O
2,8-difluoro-adenine


monophosphate
monophosphate
CF3
O
adenine


monophosphate
monophosphate
CF3
S
2-(N,N-diacetyl)-guanine


monophosphate
monophosphate
CF3
S
6-O-acetyl guanine


monophosphate
monophosphate
CF3
S
8-fluoroguanine


monophosphate
monophosphate
CF3
S
guanine


monophosphate
monophosphate
CF3
S
6-(N,N-diacetyl)-adenine


monophosphate
monophosphate
CF3
S
2-fluoroadenine


monophosphate
monophosphate
CF3
S
8-fluoroadenine


monophosphate
monophosphate
CF3
S
2, 8-difluoro-adenine


monophosphate
monophosphate
CF3
S
adenine


acetyl
acetyl
CF3
O
guanine


acetyl
acetyl
CF3
S
guanine


acetyl
acetyl
2-bromo-
O
guanine




vinyl


acetyl
acetyl
2-bromo-
S
guanine




vinyl









Alternatively, the following nucleosides of Formula IX are prepared, using the appropriate sugar and pyrimidine or purine bases.












(IX)








 







wherein:










R1
R6
X
Base





H
CH3
O
2,4-O-Diacetyluracil


H
CH3
O
Hypoxanthine


H
CH3
O
2,4-O-Diacetylthymine


H
CH3
O
Thymine


H
CH3
O
Cytosine


H
CH3
O
4-(N-mono-acetyl)cytosine


H
CH3
O
4-(N,N-diacetyl)cytosine


H
CH3
O
Uracil


H
CH3
O
5-Fluorouracil


H
CH3
S
2,4-O-Diacetyluracil


H
CH3
S
Hypoxanthine


H
CH3
S
2,4-O-Diacetylthymine


H
CH3
S
Thymine


H
CH3
S
Cytosine


H
CH3
S
4-(N-mono-acetyl)cytosine


H
CH3
S
4-(N,N-diacetyl)cytosine


H
CH3
S
Uracil


H
CH3
S
5-Fluorouracil


monophosphate
CH3
O
2,4-O-Diacetyluracil


monophosphate
CH3
O
Hypoxanthine


monophosphate
CH3
O
2,4-O-Diacetylthymine


monophosphate
CH3
O
Thymine


monophosphate
CH3
O
Cytosine


monophosphate
CH3
O
4-(N-mono-acetyl)cytosine


monophosphate
CH3
O
4-(N,N-diacetyl)cytosine


monophosphate
CH3
O
Uracil


monophosphate
CH3
O
5-Fluorouracil


monophosphate
CH3
S
2,4-O-Diacetyluracil


monophosphate
CH3
S
Hypoxanthine


monophosphate
CH3
S
2,4-O-Diacetylthymine


monophosphate
CH3
S
Thymine


monophosphate
CH3
S
Cytosine


monophosphate
CH3
S
4-(N-mono-acetyl)cytosine


monophosphate
CH3
S
4-(N,N-diacetyl)cytos


monophosphate
CH3
S
Uracil


monophosphate
CH3
S
5-Fluorouracil


diphosphate
CH3
O
2,4-O-Diacetyluracil


diphosphate
CH3
O
Hypoxanthine


diphosphate
CH3
O
2,4-O-Diacetylthymine


diphosphate
CH3
O
Thymine


diphosphate
CH3
O
Cytosine


diphosphate
CH3
O
4-(N-mono-acetyl)cytosine


diphosphate
CH3
O
4-(N,N-diacetyl)cytosine


diphosphate
CH3
O
Uracil


diphosphate
CH3
O
5-Fluorouracil


diphosphate
CH3
S
2,4-O-Diacetyluracil


diphosphate
CH3
S
Hypoxanthine


diphosphate
CH3
S
2,4-O-Diacetylthymine


diphosphate
CH3
S
Thymine


diphosphate
CH3
S
Cytosine


triphosphate
CH3
O
2;4-O-Diacetyluracil


triphosphate
CH3
O
Hypoxanthine


triphosphate
CH3
O
2,4-O-Diacetylthymine


triphosphate
CH3
O
Thymine


triphosphate
CH3
O
Cytosine


triphosphate
CH3
O
4-(N-mono-acetyl)cytosine


triphosphate
CH3
O
4-(N,N-diacetyl)cytosine


triphosphate
CH3
O
Uracil


triphosphate
CH3
O
5-Fluorouracil


triphosphate
CH3
S
2,4-O-Diacetyluracil


triphosphate
CH3
S
Thymine


triphospahate
CH3
S
2,4-O-Diacetylthymine


triphospahate
CH3
S
Thymine


triphospahate
CH3
S
Cytosine


monophosphate
CF3
O
2,4-O-Diacetyluracil


monophosphate
CF3
O
ITypoxanthine


monophosphate
CF3
O
2,4-O-Diacetylthymine


monophosphate
CF3
O
Thymine


monophosphate
CF3
O
Cytosine


monophosphate
CF3
O
4-(N-mono-acetyl)cytosine


monophosphate
CF3
O
4-(N,N-diacetyl)cytos


monophosphate
CF3
O
Uracil


monophosphate
CF3
O
5-Fluorouracil


monophosphate
CF3
S
2,4-O-Diacetyluracil


monophosphate
CF3
S
Hypoxanthine


monophosphate
CF3
S
2,4-O-Diacetylthymine


monophosphate
CF3
S
Thymine


monophosphate
CF3
S
Cytosine


monophosphate
CF3
S
4-(N-mono-acetyl)cytosine


monophosphate
CF3
S
4-(N,N-diacetyl)cytosine


monophosphate
CF3
S
Uracil


monophosphate
CF3
S
5-Fluorouracil


acetyl
CF3
O
4-(N,N-diacetyl)cytosine


acetyl
CF3
S
4-(N,N-diacetyl)cytosine


acetyl
2-bromo-vinyl
O
4-(N,N-diacetyl)cytosine


acetyl
2-bromo-vinyl
S
4-(N,N-diacetyl)cytosine









Alternatively, the following nucleosides of Formula XVI are prepared, using the appropriate sugar and pyrimidine or purine bases.












(XVI)








 







wherein:














R1
R6
R7
R8
X
Base
R10
R9





H
CH3
H
H
O
2,4-O-Diacetyluracil
OH
Me


H
CH3
H
H
O
Hypoxanthine
OH
Me


H
CH3
H
H
O
2,4-O-Diacetylthymine
OH
Me


H
CH3
H
H
O
Thymine
OH
Me


H
CH3
H
H
O
Cytosine
OH
Me


H
CH3
H
H
O
4-(N-mono-acetyl)cytosine
OH
Me


H
CH3
H
H
O
4-(N,N-diacetyl)cytosine
OH
Me


H
CH3
H
H
O
Uracil
OH
Me


H
CH3
H
H
O
5-Fluorouracil
OH
Me


H
CH3
H
H
S
2,4-O-Diacetyluracil
OH
Me


H
CH3
H
H
S
Hypoxanthine
OH
Me


H
CH3
H
H
S
2,4-O-Diacetylthymine
OH
Me


H
CH3
H
H
S
Thymine
OH
Me


H
CH3
H
H
S
Cytosine
OH
Me


H
CH3
H
H
S
4-(N-mono-acetyl)cytosine
OH
Me


H
CH3
H
H
S
4-(N,N-diacetyl)cytosine
OH
Me


H
CH3
H
H
S
Uracil
OH
Me


H
CH3
H
H
S
5-Fluorouracil
OH
Me


monophosphate
CH3
H
H
O
2,4-O-Diacetyluracil
OH
Me


monophosphate
CH3
H
H
O
Hypoxanthine
OH
Me


monophosphate
CH3
H
H
O
2,4-O-Diacetylthymine
OH
Me


monophosphate
CH3
H
H
O
Thymine
OH
Me


monophosphate
CH3
H
H
O
Cytosine
OH
Me


monophosphate
CH3
H
H
O
4-(N-mono-acetyl)cytosine
OH
Me


monophosphate
CH3
H
H
O
4-(N,N-diacetyl)cytosine
OH
Me


monophosphate
CH3
H
H
O
Uracil
OH
Me


monophosphate
CH3
H
H
O
5-Fluorouracil
OH
Me


monophosphate
CH3
H
H
S
2,4-O-Diacetyluracil
OH
Me


monophosphate
CH3
H
H
S
Hypoxanthine
OH
Me


monophosphate
CH3
H
H
S
2,4-O-Diacetylthymine
OH
Me


monophosphate
CH3
H
H
S
Thymine
OH
Me


monophosphate
CH3
H
H
S
Cytosine
OH
Me


monophosphate
CH3
H
H
S
4-(N-mono-acetyl)cytosine
OH
Me


monophosphate
CH3
H
H
S
4-(N,N-diacetyl)cytosine
OH
Me


monophosphate
CH3
H
H
S
Uracil
OH
Me


monophosphate
CH3
H
H
S
5-Fluorouracil
OH
Me


diphosphate
CH3
H
H
O
2,4-O-Diacetyluracil
OH
Me


diphosphate
CH3
H
H
O
Hypoxanthine
OH
Me


diphosphate
CH3
H
H
O
2,4-O-Diacetylthymine
OH
Me


diphosphate
CH3
H
H
O
Thymine
OH
Me


diphosphate
CH3
H
H
O
Cytosine
OH
Me


diphosphate
CH3
H
H
O
4-(N-mono-acetyl)cytosine
OH
Me


diphosphate
CH3
H
H
O
4-(N,N-diacetyl)cytosine
OH
Me


diphosphate
CH3
H
H
O
Uracil
OH
Me


diphosphate
CH3
H
H
O
5-Fluorouracil
OH
Me


diphosphate
CH3
H
H
S
2,4-O-Diacetyluracil
OH
Me


diphosphate
CH3
H
H
S
Hypoxanthine
OH
Me


diphosphate
CH3
H
H
S
2,4-O-Diacetylthymine
OH
Me


diphosphate
CH3
H
H
S
Thymine
OH
Me


diphosphate
CH3
H
H
S
Cytosine
OH
Me


triphosphate
CH3
H
H
O
2,4-O-Diacetyluracil
OH
Me


triphosphate
CH3
H
H
O
Hypoxanthine
OH
Me


triphosphate
CH3
H
H
O
2,4-O-Diacetylthymine
OH
Me


triphosphate
CH3
H
H
O
Thymine
OH
Me


triphosphate
CH3
H
H
O
Cytosine
OH
Me


triphosphate
CH3
H
H
O
4-(N-mono-acetyl)cytosine
OH
Me


triphosphate
CH3
H
H
O
4-(N,N-diacetyl)cytosine
OH
Me


triphosphate
CH3
H
H
O
Uracil
OH
Me


triphosphate
CH3
H
H
O
5-Fluorouracil
OH
Me


triphosphate
CH3
H
H
S
2,4-O-Diacetyluracil
OH
Me


triphosphate
CH3
H
H
S
Hypoxanthine
OH
Me


triphosphate
CH3
H
H
S
2,4-O-Diacetylthymine
OH
Me


triphosphate
CH3
H
H
S
Thymine
OH
Me


triphosphate
CH3
H
H
S
Cytosine
OH
Me


monophosphate
CF3
H
H
O
2,4-O-Diacetyluracil
OH
Me


monophosphate
CF3
H
H
O
Hypoxanthine
OH
Me


monophosphate
CF3
H
H
O
2,4-O-Diacetylthymine
OH
Me


monophosphate
CF3
H
H
O
Thymine
OH
Me


monophosphate
CF3
H
H
O
Cytosine
OH
Me


monophosphate
CF3
H
H
O
4-(N-mono-acetyl)cytosine
OH
Me


monophosphate
CF3
H
H
O
4-(N,N-diacetyl)cytosine
OH
Me


monophosphate
CF3
H
H
O
Uracil
OH
Me


monophosphate
CF3
H
H
O
5-Fluorouracil
OH
Me


monophosphate
CF3
H
H
S
2,4-O-Diacetyluracil
OH
Me


monophosphate
CF3
H
H
S
Hypoxanthine
OH
Me


monophosphate
CF3
H
H
S
2,4-O-Diacetylthymine
OH
Me


monophosphate
CF3
H
H
S
Thymine
OH
Me


monophosphate
CF3
H
H
S
Cytosine
OH
Me


monophosphate
CF3
H
H
S
4-(N-mono-acetyl)cytosine
OH
Me


monophosphate
CF3
H
H
S
4-(N,N-diacetyl)cytosine
OH
Me


monophosphate
CF3
H
H
S
Uracil
OH
Me


monophosphate
CF3
H
H
S
5-Fluorouracil
OH
Me


acetyl
CH3
H
H
O
4-(N,N-diacetyl)cytosine
H
Br


acetyl
CH3
H
H
S
4-(N,N-diacetyl)cytosine
H
Br


acetyl
CH3
OH
H
O
4-(N,N-diacetyl)cytosine
H
Br


acetyl
CH3
OH
H
S
4-(N,N-diacetyl)cytosine
H
Br









Example 2
Preparation of 2′-C-methylriboadenine
The title compound was prepared according to a published procedure (R. E. Harry-O'kuru, J. M. Smith, and M. S. Wolfe, “A short, flexible route toward 2′-C-branched ribonucleosides”, J. Org. Chem. 1997, 62, 1754–1759) (Scheme 8).




    
    
        (a) Dess-Martin periodinane; (b) MeMgBr/TiCl4; (c) BzCl, DMAP, Et3N; (d) bis(trimethylsilyl)acetamide, N6-benzoyl adenine, TMSOTf; (e) NH3/MeOH
    
    


In a similar manner, but using the appropriate sugar and pyrimidine or purine bases, the following nucleosides of Formula II are prepared.












(II)








 







wherein;












R1
R2
R3
X1
X2
Y





H
H
H
H
H
H


H
H
H
H
H
NH2


H
H
H
H
H
NH-cyclopropyl


H
H
H
H
H
NH-methyl


H
H
H
H
H
NH-ethyl


H
H
H
H
H
NH-acetyl


H
H
H
H
H
OH


H
H
H
H
H
OMe


H
H
H
H
H
OEt


H
H
H
H
H
O-acetyl


H
H
H
H
H
SH


H
H
H
H
H
SMe


H
H
H
H
H
SEt


H
H
H
H
H
S-cyclopropyl


H
H
H
H
H
F


H
H
H
H
H
Cl


H
H
H
H
H
Br


H
H
H
H
H
I


monophosphate
H
H
H
H
NH2


monophosphate
H
H
H
H
NH-acetyl


monophosphate
H
H
H
H
NH-cyclopropyl


monophosphate
H
H
H
H
NH-methyl


monophosphate
H
H
H
H
NH-ethyl


monophosphate
H
H
H
H
OH


monophosphate
H
H
H
H
O-acetyl


monophosphate
H
H
H
H
OMe


monophosphate
H
H
H
H
OEt


monophosphate
H
H
H
H
O-cyclopropyl


monophosphate
H
H
H
H
SH


monophosphate
H
H
H
H
SMe


monophosphate
H
H
H
H
SEt


monophosphate
H
H
H
H
S-cyclopropyl


monophosphate
H
H
H
H
F


monophosphate
H
H
H
H
Cl


monophosphate
H
H
H
H
Br


monophosphate
H
H
H
H
I


diphosphate
H
H
H
H
NH2


diphosphate
H
H
H
H
NH-acetyl


diphosphate
H
H
H
H
NH-cyclopropyl


diphosphate
H
H
H
H
NH-methyl


diphosphate
H
H
H
H
NH-ethyl


diphosphate
H
H
H
H
OH


diphosphate
H
H
H
H
O-acetyl


diphosphate
H
H
H
H
OMe


diphosphate
H
H
H
H
OEt


diphosphate
H
H
H
H
O-cyclopropyl


diphosphate
H
H
H
H
SH


diphosphate
H
H
H
H
SMe


diphosphate
H
H
H
H
SEt


diphosphate
H
H
H
H
S-cyclopropyl


diphosphate
H
H
H
H
F


diphosphate
H
H
H
H
Cl


diphosphate
H
H
H
H
Br


diphosphate
H
H
H
H
I


triphosphate
H
H
H
H
NH2


triphosphate
H
H
H
H
NH-acetyl


triphosphate
H
H
H
H
NH-cyclopropyl


triphosphate
H
H
H
H
NIH-methyl


triphosphate
H
H
H
H
NH-ethyl


triphosphate
H
H
H
H
OH


triphosphate
H
H
H
H
OMe


triphosphate
H
H
H
H
OEt


triphosphate
H
H
H
H
O-cyclopropyl


triphosphate
H
H
H
H
O-acetyl


triphosphate
H
H
H
H
SH


triphosphate
H
H
H
H
SMe


triphosphate
H
H
H
H
SEt


triphosphate
H
H
H
H
S-cyclopropyl


triphosphate
H
H
H
H
F


triphosphate
H
H
H
H
Cl


triphosphate
H
H
H
H
Br


triphosphate
H
H
H
H
I


monophosphate
monophosphate
monophosphate
H
H
NH2


monophosphate
monophosphate
monophosphate
H
H
NH-cyclopropyl


monophosphate
monophosphate
monophosphate
H
H
OH


monophosphate
monophosphate
monophosphate
H
H
F


monophosphate
monophosphate
monophosphate
H
H
Cl


diphosphate
diphosphate
diphosphate
H
H
NH2


diphosphate
diphosphate
diphosphate
H
H
NH-cyclopropyl


diphosphate
diphosphate
diphosphate
H
H
OH


diphosphate
diphosphate
diphosphate
H
H
F


diphosphate
diphosphate
diphosphate
H
H
Cl


triphosphate
triphosphate
triphosphate
H
H
NH2


triphosphate
triphosphate
triphosphate
H
H
NH-cyclopropyl


triphosphate
triphosphate
triphosphate
H
H
OH


triphosphate
trphosphate
triphosphate
H
H
F


triphosphate
triphosphate
triphosphate
H
H
Cl


H
H
H
F
H
NH2


H
H
H
F
H
NH-cyclopropyl


H
H
H
F
H
OH


H
H
H
F
H
F


H
H
H
F
H
Cl


H
H
H
Cl
H
NH2


H
H
H
Cl
H
NH-cyclopropyl


H
H
H
Cl
H
OH


H
H
H
Cl
H
F


H
H
H
Cl
H
Cl


H
H
H
Br
H
NH2


H
H
H
Br
H
NH-cyclopropyl


H
H
H
Br
H
OH


H
H
H
Br
H
F


H
H
H
Br
H
Cl


H
H
H
NH2
H
NH2


H
H
H
NH2
H
NH-cyclopropyl


H
H
H
NH2
H
OH


H
H
H
NH2
H
F


H
H
H
NH2
H
Cl


H
H
H
SH
H
NH2


H
H
H
SH
H
NH-cyclopropyl


H
H
H
SH
H
OH


H
H
H
SH
H
F


H
H
H
SH
H
Cl


acetyl
H
H
H
H
NH2


acetyl
H
H
H
H
NH-cyclopropyl


acetyl
H
H
H
H
OH


acetyl
H
H
H
H
F


acetyl
H
H
H
H
Cl


acetyl
H
H
F
H
NH2


acetyl
H
H
F
H
NH-cyclopropyl


acetyl
H
H
F
H
OH


acetyl
H
H
F
H
F


acetyl
H
H
F
H
Cl


H
acetyl
acetyl
H
H
NH2


H
acetyl
acetyl
H
H
NH-cyclopropyl


H
acetyl
acetyl
H
H
OH


H
acetyl
acetyl
H
H
F


H
acetyl
acetyl
H
H
Cl


acetyl
acetyl
acetyl
H
H
NH2


acetyl
acetyl
acetyl
H
H
NH-cyclopropyl


acetyl
acetyl
acetyl
H
H
OH


acetyl
acetyl
acetyl
H
H
F


acetyl
acetyl
acetyl
H
H
Cl


monophosphate
acetyl
acetyl
H
H
NH2


monophosphate
acetyl
acetyl
H
H
NH-cyclopropyl


monophosphate
acetyl
acetyl
H
H
OH


monophosphate
acetyl
acetyl
H
H
F


monophosphate
acetyl
acetyl
H
H
Cl


diphosphate
acetyl
acetyl
H
H
NH2


diphosphate
acetyl
acetyl
H
H
NH-cyclopropyl


diphosphate
acetyl
acetyl
H
H
OH


diphosphate
acetyl
acetyl
H
H
F


diphosphate
acetyl
acetyl
H
H
Cl


triphosphate
acetyl
acetyl
H
H
NH2


triphosphate
acetyl
acetyl
H
H
NH-cyclopropyl


triphosphate
acetyl
acetyl
H
H
OH


triphosphate
acetyl
acetyl
H
H
F


triphosphate
acetyl
acetyl
H
H
Cl


H
H
H
H
NH2
H


H
H
H
H
NH2
NH2


H
H
H
H
NH2
NH-cyclopropyl


H
H
H
H
NH2
NH-methyl


H
H
H
H
NH2
NH-ethyl


H
H
H
H
NH2
NH-acetyl


H
H
H
H
NH2
OH


H
H
H
H
NH2
OMe


H
H
H
H
NH2
OEt


H
H
H
H
NH2
O-cyclopropyl


H
H
H
H
NH2
O-acetyl


H
H
H
H
NH2
SH


H
H
H
H
NH2
SMe


H
H
H
H
NH2
SEt


H
H
H
H
NH2
S-cyclopropyl


H
H
H
H
NH2
F


H
H
H
H
NH2
Cl


H
H
H
H
NH2
Br


H
H
H
H
NH2
I


monophosphate
H
H
H
NH2
NH2


monophosphate
H
H
H
NH2
NH-acetyl


monophosphate
H
H
H
NH2
NH-cyclopropyl


monophosphate
H
H
H
NH2
NH-methyl


monophosphate
H
H
H
NH2
NH-ethyl


monophosphate
H
H
H
NH2
OH


monophosphate
H
H
H
NH2
O-acetyl


monophosphate
H
H
H
NH2
OMe


monophosphate
H
H
H
NH2
OEt


monophosphate
H
H
H
NH2
O-cyclopropyl


monophosphate
H
H
H
NH2
SH


monophosphate
H
H
H
NH2
SMe


monophosphate
H
H
H
NH2
SEt


monophosphate
H
H
H
NH2
S-cyclopropyl


monophosphate
H
H
H
NH2
F


monophosphate
H
H
H
NH2
Cl


monophosphate
H
H
H
NH2
Br


monophosphate
H
H
H
NH2
I


diphosphate
H
H
H
NH2
NH2


diphosphate
H
H
H
NH2
NH-acetyl


diphosphate
H
H
H
NH2
NH-cyclopropyl


diphosphate
H
H
H
NH2
NH-methyl


diphosphate
H
H
H
NH2
NH-ethyl


diphosphate
H
H
H
NH2
OH


diphosphate
H
H
H
NH2
O-acetyl


diphosphate
H
H
H
NH2
OMe


diphosphate
H
H
H
NH2
OEt


diphosphate
H
H
H
NH2
O-cyclopropyl


diphosphate
H
H
H
NH2
SH


diphosphate
H
H
H
NH2
SMe


diphosphate
H
H
H
NH2
SEt


diphosphate
H
H
H
NH2
S-cyclopropyl


diphosphate
H
H
H
NH2
F


diphosphate
H
H
H
NH2
Cl


diphosphate
H
H
H
NH2
Br


diphosphate
H
H
H
NH2
I


triphosphate
H
H
H
NH2
NH2


triphosphate
H
H
H
NH2
NH-acetyl


triphosphate
H
H
H
NH2
NH-cyclopropyl


triphosphate
H
H
H
NH2
NH-methyl


triphosphate
H
H
H
NH2
NH-ethyl.


triphosphate
H
H
H
NH2
OH


triphosphate
H
H
H
NH2
OMe


triphosphate
H
H
H
NH2
OEt


triphosphate
H
H
H
NH2
O-cyclopropyl


triphosphate
H
H
H
NH2
O-acetyl


triphosphate
H
H
H
NH2
SH


triphosphate
H
H
H
NH2
SMe


triphosphate
H
H
H
NH2
SEt


triphosphate
H
H
H
NH2
S-cyclopropyl


triphosphate
H
H
H
NH2
F


triphosphate
H
H
H
NH2
Cl


triphosphate
H
H
H
NH2
Br


triphosphate
H
H
H
NH2
I


monophosphate
monophosphate
monophosphate
H
NH2
NH2


monophosphate
monophosphate
monophosphate
H
NH2
NH-cyclopropyl


monophosphate
monophosphate
monophosphate
H
NH2
OH


monophosphate
monophosphate
monophosphate
H
NH2
F


monophosphate
monophosphate
monophosphate
H
NH2
Cl


diphosphate
diphosphate
diphosphate
H
NH2
NH2


diphosphate
diphosphate
diphosphate
H
NH2
NH-cyclopropyl


diphosphate
diphosphate
diphosphate
H
NH2
OH


diphosphate
diphosphate
diphosphate
H
NH2
F


diphosphate
diphosphate
diphosphate
H
NH2
Cl


triphosphate
triphosphate
triphosphate
H
NH2
NH2


triphosphate
triphosphate
triphosphate
H
NH2
NH-cyclopropyl


triphosphate
triphosphate
triphosphate
H
NH2
OH


triphosphate
triphosphate
triphosphate
H
NH2
F


triphosphate
triphosphate
triphosphate
H
NH2
Cl


H
H
H
F
NH2
NH2


H
H
H
F
NH2
NH-cyclopropyl


H
H
H
F
NH2
OH


H
H
H
F
NH2
F


H
H
H
F
NH2
Cl


H
H
H
Cl
NH2
NH2


H
H
H
Cl
NH2
NH-cyclopropyl


H
H
H
Cl
NH2
OH


H
H
H
Cl
NH2
F


H
H
H
Cl
NH2
Cl


H
H
H
Br
NH2
NH2


H
H
H
Br
NH2
NH-cyclopropyl


H
H
H
Br
NH2
OH


H
H
H
Br
NH2
F


H
H
H
Br
NH2
Cl


H
H
H
NH2
NH2
NH2


H
H
H
NH2
NH2
NH-cyclopropyl


H
H
H
NH2
NH2
OH


H
H
H
NH2
NH2
F


H
H
H
NH2
NH2
Cl


H
H
H
SH
NH2
NH2


H
H
H
SH
NH2
NH-cyclopropyl


H
H
H
SH
NH2
OH


H
H
H
SH
NH2
F


H
H
H
SH
NH2
Cl


acetyl
H
H
H
NH2
NH2


acetyl
H
H
H
NH2
NH-cyclopropyl


acetyl
H
H
H
NH2
OH


acetyl
H
H
H
NH2
F


acetyl
H
H
H
NH2
Cl


acetyl
H
H
F
NH2
NH2


acetyl
H
H
F
NH2
NH-cyclopropyl


acetyl
H
H
F
NH2
OH


acetyl
H
H
F
NH2
F


acetyl
H
H
F
NH2
Cl


H
acetyl
acetyl
H
NH2
NH2


H
acetyl
acetyl
H
NH2
NH-cyclopropyl


H
acetyl
acetyl
H
NH2
OH


H
acetyl
acetyl
H
NH2
F


H
acetyl
acetyl
H
NH2
Cl


acetyl
acetyl
acetyl
H
NH2
NH2


acetyl
acetyl
acetyl
H
NH2
NIH-cyclopropyl


acetyl
acetyl
acetyl
H
NH2
OH


acetyl
acetyl
acetyl
H
NH2
F


acetyl
acetyl
acetyl
H
NH2
Cl


monophosphate
acetyl
acetyl
H
NH2
NH2


monophosphate
acetyl
acetyl
H
NH2
NH-cyclopropyl


monophosphate
acetyl
acetyl
H
NH2
OH


monophosphate
acetyl
acetyl
H
NH2
F


monophosphate
acetyl
acetyl
H
NH2
Cl


diphosphate
acetyl
acetyl
H
NH2
NH2


diphosphate
acetyl
acetyl
H
NH2
NH-cyclopropyl


diphosphate
acetyl
acetyl
H
NH2
OH


diphosphate
acetyl
acetyl
H
NH2
F


diphosphate
acetyl
acetyl
H
NH2
Cl


triphosphate
acetyl
acetyl
H
NH2
NH2


triphosphate
acetyl
acetyl
H
NH2
NH-cyclopropyl


triphosphate
acetyl
acetyl
H
NH2
OH


triphosphate
acetyl
acetyl
H
NH2
F


triphosphate
acetyl
acetyl
H
NH2
Cl


H
H
H
H
Cl
H


H
H
H
H
Cl
H


H
H
H
H
Cl
NH2


H
H
H
H
Cl
NH-cyclopropyl


H
H
H
H
Cl
NH-methyl


H
H
H
H
Cl
NH-ethyl


H
H
H
H
Cl
NH-acetyl


H
H
H
H
Cl
OH


H
H
H
H
Cl
OMe


H
H
H
H
Cl
OEt


H
H
H
H
Cl
O-cyclopropyl


H
H
H
H
Cl
O-acetyl


H
H
H
H
Cl
SH


H
H
H
H
Cl
SMe


H
H
H
H
Cl
SEt


H
H
H
H
Cl
S-cyclopropyl


monophosphate
H
H
H
Cl
NH2


monophosphate
H
H
H
Cl
NH-acetyl


monophosphate
H
H
H
Cl
NH-cyclopropyl


monophosphate
H
H
H
Cl
NH-methyl


monophosphate
H
H
H
Cl
NH-ethyl


monophosphate
H
H
H
Cl
OH


monophosphate
H
H
H
Cl
O-acetyl


monophosphate
H
H
H
Cl
OMe


monophosphate
H
H
H
Cl
OEt


monophosphate
H
H
H
Cl
O-cyclopropyl


monophosphate
H
H
H
Cl
SH


monophosphate
H
H
H
Cl
SMe


monophosphate
H
H
H
Cl
SEt


monophosphate
H
H
H
Cl
S-cyclopropyl


diphosphate
H
H
H
Cl
NH2


diphosphate
H
H
H
Cl
NH-acetyl


diphosphate
H
H
H
Cl
NH-cyclopropyl


diphosphate
H
H
H
Cl
NH-methyl


diphosphate
H
H
H
Cl
NH-ethyl


diphosphate
H
H
H
Cl
OH


diphosphate
H
H
H
Cl
O-acetyl


diphosphate
H
H
H
Cl
OMe


diphosphate
H
H
H
Cl
OEt


diphosphate
H
H
H
Cl
O-cyclopropyl


diphosphate
H
H
H
Cl
SH


diphosphate
H
H
H
Cl
SMe


diphosphate
H
H
H
Cl
SEt


diphosphate
H
H
H
Cl
S-cyclopropyl


triphosphate
H
H
H
Cl
NH2


triphosphate
H
H
H
Cl
NH-acetyl


triphosphate
H
H
H
Cl
NH-cyclopropyl


triphosphate
H
H
H
Cl
NH-methyl


triphosphate
H
H
H
Cl
NH-ethyl


triphosphate
H
H
H
Cl
OH


triphosphate
H
H
H
Cl
OMe


triphosphate
H
H
H
Cl
OEt


triphosphate
H
H
H
Cl
O-cyclopropyl


triphosphate
H
H
H
Cl
O-acetyl


triphosphate
H
H
H
Cl
SH


triphosphate
H
H
H
Cl
SMe


triphosphate
H
H
H
Cl
SEt


triphosphate
H
H
H
Cl
S-cyclopropyl


monophosphate
monophosphate
monophosphate
H
Cl
NH2


monophosphate
monophosphate
monophosphate
H
Cl
NH-cyclopropyl


monophosphate
monophosphate
monophosphate
H
Cl
OH


diphosphate
diphosphate
diphosphate
H
Cl
NH2


diphosphate
diphosphate
diphosphate
H
Cl
NH-cyclopropyl


diphosphate
diphosphate
diphosphate
H
Cl
OH


triphosphate
triphosphate
triphosphate
H
Cl
NH2


triphosphate
triphosphate
triphosphate
H
Cl
NH-cyclopropyl


triphosphate
triphosphate
triphosphate
H
Cl
OH


H
H
H
F
Cl
NH2


H
H
H
F
Cl
NH-cyclopropyl


H
H
H
F
Cl
OH


H
H
H
Cl
Cl
NH2


H
H
H
Cl
Cl
NH-cyclopropyl.


H
H
H
Cl
Cl
OH


H
H
H
Br
Cl
NH2


H
H
H
Br
Cl
NH-cyclopropyl


H
H
H
Br
Cl
OH


H
H
H
NH2
Cl
NH2


H
H
H
NH2
Cl
NH-cyclopropyl


H
H
H
NH2
Cl
OH


H
H
H
SH
Cl
NH2


H
H
H
SH
Cl
NH-cyclopropyl


H
H
H
SH
Cl
OH


acetyl
H
H
H
Cl
NH2


acetyl
H
H
H
Cl
NH-cyclopropyl


acetyl
H
H
H
Cl
OH


acetyl
H
H
F
Cl
NH2


acetyl
H
H
F
Cl
NH-cyclopropyl


acetyl
H
H
F
Cl
OH


H
acetyl
acetyl
H
Cl
NH2


H
acetyl
acetyl
H
Cl
NH-cyclopropyl


H
acetyl
acetyl
H
Cl
OH


acetyl
acetyl
acetyl
H
Cl
NH2


acetyl
acetyl
acetyl
H
Cl
NH-cyclopropyl


acetyl
acetyl
acetyl
H
Cl
OH


monophosphate
acetyl
acetyl
H
Cl
NH2


monophosphate
acetyl
acetyl
H
Cl
NH-cyclopropyl


monophosphate
acetyl
acetyl
H
Cl
OH


diphosphate
acetyl
acetyl
H
Cl
NH2


diphosphate
acetyl
acetyl
H
Cl
NH-cyclopropyl


diphosphate
acetyl
acetyl
H
Cl
OH


triphosphate
acetyl
acetyl
H
Cl
NH2


triphosphate
acetyl
acetyl
H
Cl
NH-cyclopropyl


triphosphate
acetyl
acetyl
H
Cl
OH


H
H
H
H
Cl
NH2


H
H
H
H
Cl
NH-cyclopropyl


H
H
H
H
Cl
OH


H
H
H
H
Br
NH2


H
H
H
H
Br
NH-cyclopropyl


H
H
H
H
Br
OH









Alternatively, the following nucleosides of Formula V are prepared, using the appropriate sugar and pyrimidine or purine bases.












(V)








 







wherein:











R1
R2
R3
X1
Y





H
H
H
H
H


H
H
H
H
NH2


H
H
H
H
NH-cyclo-






propyl


H
H
H
H
NH-methyl


H
H
H
H
NH-ethyl


H
H
H
H
NH-acetyl


H
H
H
H
OH


H
H
H
H
OMe


H
H
H
H
OEt


H
H
H
H
O-cyclopropyl


H
H
H
H
O-acetyl


H
H
H
H
SH


H
H
H
H
SMe


H
H
H
H
SEt


H
H
H
H
5-cyclopropyl


monophosphate
H
H
H
NH2


monophosphate
H
H
H
NH-acetyl


monophosphate
H
H
H
NH-cyclo-






propyl


monophosphate
H
H
H
NH-methyl


monophosphate
H
H
H
NH-ethyl


monophosphate
H
H
H
OH


monophosphate
H
H
H
O-acetyl


monophosphate
H
H
H
OMe


monophosphate
H
H
H
OEt


monophosphate
H
H
H
O-cyclopropyl


monophosphate
H
H
H
SH


monophosphate
H
H
H
SMe


monophosphate
H
H
H
SEt


monophosphate
H
H
H
5-cyclopropyl


diphosphate
H
H
H
NH2


diphosphate
H
H
H
NH-acetyl


diphosphate
H
H
H
NH-cyclo-






propyl


diphosphate
H
H
H
NH-methyl


diphosphate
H
H
H
NH-ethyl


diphosphate
H
H
H
OH


diphosphate
H
H
H
O-acetyl


diphosphate
H
H
H
OMe


diphosphate
H
H
H
OEt


diphosphate
H
H
H
O-cyclopropyl


diphosphate
H
H
H
SH


diphosphate
H
H
H
SMe


diphosphate
H
H
H
SEt


diphosphate
H
H
H
S-cyclopropyl


triphosphate
H
H
H
NH2


triphosphate
H
H
H
NH-acetyl


triphosphate
H
H
H
NH-cyclo-






propyl


triphosphate
H
H
H
NH-methyl


triphosphate
H
H
H
NH-ethyl


triphosphate
H
H
H
OH


triphosphate
H
H
H
OMe


triphosphate
H
H
H
OEt


triphosphate
H
H
H
O-cyclopropyl


triphosphate
H
H
H
O-acetyl


triphosphate
H
H
H
SH


triphosphate
H
H
H
SMe


triphosphate
H
H
H
SEt


triphosphate
H
H
H
8-cyclopropyl


monophosphate
monophosphate
monophosphate
H
NH2


monophosphate
monophosphate
monophosphate
H
NH-cyclo-






propyl


monophosphate
monophosphate
monophosphate
H
OH


diphosphate
diphosphate
diphosphate
H
NH2


diphosphate
diphosphate
diphosphate
H
NH-cyclo-






propyl


diphosphate
diphosphate
diphosphate
H
OH


triphosphate
triphosphate
triphosphate
H
NH2


triphosphate
triphosphate
triphosphate
H
NH-cyclo-






propyl


triphosphate
triphosphate
triphosphate
H
OH


H
H
H
F
NH2


H
H
H
F
NH-cyclo-






propyl


H
H
H
F
OH


H
H
H
Cl
NH2


H
H
H
Cl
NH-cyclo-






propyl


H
H
H
Cl
OH


H
H
H
Br
NH2


H
H
H
Br
NH-cyclo-






propyl


H
H
H
Br
OH


H
H
H
NH2
NH2


H
H
H
NH2
NH-cyclo-






propyl


H
H
H
NH2
OH


H
H
H
SH
NH2


H
H
H
SH
NH-cyclo-






propyl


H
H
H
SH
OH


acetyl
H
H
H
NH2


acetyl
H
H
H
NH-cyclo-






propyl


acetyl
H
H
H
OH


acetyl
H
H
F
NH2


acetyl
H
H
F
NH-cyclo-






propyl


acetyl
H
H
F
OH


H
acetyl
acetyl
H
NH2


H
acetyl
acetyl
H
NH-cyclo-






propyl


H
acetyl
acetyl
H
OH


acetyl
acetyl
acetyl
H
NH2


acetyl
acetyl
acetyl
H
NH-cyclo-






propyl


acetyl
acetyl
acetyl
H
OH


monophosphate
acetyl
acetyl
H
NH2


monophosphate
acetyl
acetyl
H
NH-cyclo-






propyl


monophosphate
acetyl
acetyl
H
OH


diphosphate
acetyl
acetyl
H
NH2


diphosphate
acetyl
acetyl
H
NH-cyclo-






propyl


diphosphate
acetyl
acetyl
H
OH


triphosphate
acetyl
acetyl
H
NH2


triphosphate
acetyl
acetyl
H
NH-cyclo-






propyl


triphosphate
acetyl
acetyl
H
OH









Alternatively, the following nucleosides of Formula X are prepared, using the appropriate sugar and pyrimidine or purine bases.












(X)








 












R1
R2
R3
R6
X
Base





H
H
H
CH3
O
2,4-O-







Diacetyluracil


H
H
H
CH3
O
Hypoxanthine


H
H
H
CH3
O
2,4-O-







Diacetylthymine


H
H
H
CH3
O
Thymine


H
H
H
CH3
O
Cytosine


H
H
H
CH3
O
4-(N-mono-







acetyl)cytosine


H
H
H
CH3
O
4-(N,N-







diacetyl)cytosine


H
H
H
CH3
O
Uracil


H
H
H
CH3
O
5-Fluorouracil


H
H
H
CH3
S
2,4-O-







Diacetyluraci


H
H
H
CH3
S
Hypoxanthine


H
H
H
CH3
S
2,4-O-







Diacetylthymine


H
H
H
CH3
S
Thymine


H
H
H
CH3
S
Cytosine


H
H
H
CH3
S
4-(N-mono-







acetyl)cytosine


H
H
H
CH3
S
4-(N,N-







diacetyl)cytosine


H
H
H
CH3
S
Uracil


H
H
H
CH3
S
5-Fluorouracil


monophosphate
H
H
CH3
O
2,4-O-







Diacetyluracil


monophosphate
H
H
CH3
O
Hypoxanthine


monophosphate
H
H
CH3
O
2,4-O-







Diacetylthym


monophosphate
H
H
CH3
O
Thymine


monophosphate
H
H
CH3
O
Cytosine


monophosphate
H
H
CH3
O
4-(N-mono-







acetyl)cytosine


monophosphate
H
H
CH3
O
4-(N,N-







diacetyl)cytosine


monophosphate
H
H
CH3
O
Uracil


monophosphate
H
H
CH3
O
5-Fluorouracil


monophosphate
H
H
CH3
S
2,4-O-







Diacetyluracil


monophosphate
H
H
CH3
S
Hypoxanthine


monophosphate
H
H
CH3
S
2,4-O-







Diacetylthym


monophosphate
H
H
CH3
S
Thymine


monophosphate
H
H
CH3
S
Cytosine


monophosphate
H
H
CH3
S
4-(N-mono-







acetyl)cytosine


monophosphate
H
H
CH3
S
4-(N,N-







diacetyl)cytosine


monophosphate
H
H
CH3
S
Uracil


monophosphate
H
H
CH3
S
5-Fluorouracil


diphosphate
H
H
CH3
O
2,4-O-







Diacetyluracil


diphosphate
H
H
CH3
O
Hypoxanthine


diphosphate
H
H
CH3
O
2,4-O-







Diacetylthymine


diphosphate
H
H
CH3
O
Thymine


diphosphate
H
H
CH3
O
Cytosine


diphosphate
H
H
CH3
O
4-(N-mono-







acetyl)cytosine


diphosphate
H
H
CH3
O
4-(N,N-







diacetyl)cytosine


diphosphate
H
H
CH3
O
Uracil


diphosphate
H
H
CH3
O
5-Fluorouracil


diphosphate
H
H
CH3
S
2,4-O-







Diacetyluracil


diphosphate
H
H
CH3
S
Hypoxanthine


diphosphate
H
H
CH3
S
2,4-O-







Diacetylthym


diphosphate
H
H
CH3
S
Thymine


diphosphate
H
H
CH3
S
Cytosine


triphosphate
H
H
CH3
O
2,4-O-







Diacetyluracil


triphosphate
H
H
CH3
O
Hypoxanthine


triphosphate
H
H
CH3
O
2,4-O-







Diacetylthymine


triphosphate
H
H
CH3
O
Thymine


triphosphate
H
H
CH3
O
Cytosine


triphosphate
H
H
CH3
O
4-(N-mono-







acetyl)cytosine


triphosphate
H
H
CH3
O
4-(N,N-







diacetyl)cytosine


triphosphate
H
H
CH3
O
Uracil


triphosphate
H
H
CH3
O
5-Fluorouracil


triphosphate
H
H
CH3
S
2,4-O-







Diacetyluracil


triphosphate
H
H
CH3
S
Hypoxanthine


triphosphate
H
H
CH3
S
2,4-O-







Diacetylthymine


triphosphate
H
H
CH3
S
Thymine


triphosphate
H
H
CH3
S
Cytosine


monophosphate
monophosphate
monophosphate
CF3
O
2,4-O-







Diacetyluracil


monophosphate
monophosphate
monophosphate
CF3
O
Hypoxanthine


monophosphate
monophosphate
monophosphate
CF3
O
2,4-O-







Diacetylthymine


monophosphate
monophosphate
monophosphate
CF3
O
Thymine


monophosphate
monophosphate
monophosphate
CF3
O
Cytosine


monophosphate
monophosphate
monophosphate
CF3
O
4-(N-mono-







acetyl)cytosine


monophosphate
monophosphate
monophosphate
CF3
O
4-(N,N-







diacetyl)cytosine


monophosphate
monophosphate
monophosphate
CF3
O
Uracil


monophosphate
monophosphate
monophosphate
CF3
O
5-Fluorouracil


monophosphate
monophosphate
monophosphate
CF3
S
2,4-O-







Diacetyluracil


monophosphate
monophosphate
monophosphate
CF3
S
Hypoxanthine


monophosphate
monophosphate
monophosphate
CF3
S
2,4-O-







Diacetylthymine


monophosphate
monophosphate
monophosphate
CF3
S
Thymine


monophosphate
monophosphate
monophosphate
CF3
S
Cytosine


monophosphate
monophosphate
monophosphate
CF3
S
4-(N-mono-







acetyl)cytosine


monophosphate
monophosphate
monophosphate
CF3
S
4-(N,N-







diacetyl)cytosine


monophosphate
monophosphate
monophosphate
CF3
S
Uracil


monophosphate
monophosphate
monophosphate
CF3
S
5-Fluorouracil


acetyl
acetyl
acetyl
CF3
O
4-(N,N-







diacetyl)cytosine


acetyl
acetyl
acetyl
CF3
S
4-(N,N-







diacetyl)cytosine


acetyl
acetyl
acetyl
2-bromo-O
S
4-(N,N-





vinyl

diacetyl)cytosine


acetyl
acetyl
acetyl
2-bromo-
S
4-(N,N-





vinyl

diacetyl)cytosine


H
H
H
CH3
O
2-(N,N-diacetyl)-







guanine


H
H
H
CH3
O
6-O-acetyl







guanine


H
H
H
CH3
O
8-fluoroguanine


H
H
H
CH3
O
guanine


H
H
H
CH3
O
6-(N,N-diacetyl)-







adenine


H
H
H
CH3
O
2-fluoroadenine


H
H
H
CH3
O
8-fluoroadenine


H
H
H
CH3
O
2,8-difluoro-







adenine


H
H
H
CH3
O
adenine


H
H
H
CH3
S
2-(N,N-diacetyl)-







guanine


H
H
H
CH3
S
6-O-acetyl







guanine


H
H
H
CH3
S
8-fluoroguanine


H
H
H
CH3
S
guanine


H
H
H
CH3
S
6-(N,N-diacetyl)-







adenine


H
H
H
CH3
S
2-fluoroadenine


H
H
H
CH3
S
8-fluoroadenine


H
H
H
CH3
S
2,8-difluoro-







adenine


H
H
H
CH3
S
adenine


monophosphate
H
H
CH3
O
2-{N,N-diacetyl)-







guanine


monophosphate
H
H
CH3
O
6-O-acetyl







guanine


monophosphate
H
H
CH3
O
8-fluoroguanine


monophosphate
H
H
CH3
O
guanine


monophosphate
H
H
CH3
O
6-(N,N-diacetyl)-







adenine


monophosphate
H
H
CH3
O
2-fluoroadenine


monophosphate
H
H
CH3
O
8-fluoroadenine


monophosphate
H
H
CH3
O
2,8-difluoro-







adenine


monophosphate
H
H
CH3
O
adenine


monophosphate
H
H
CH3
S
2-(N,N-diacetyl)-







guanine


monophosphate
H
H
CH3
S
6-O-acetyl







guanine


monophosphate
H
H
CH3
S
8-fluoroguanine


monophosphate
H
H
CH3
S
guanine


monophosphate
H
H
CH3
S
6-(N,N-diacetyl)-







adenine


monophosphate
H
H
CH3
S
2-fluoroadenine


monophosphate
H
H
CH3
S
8-fluoroadenine


monophosphate
H
H
CH3
S
2,8-difluoro-







adenine


monophosphate
H
H
CH3
S
adenine


diphosphate
H
H
CH3
O
2-(N,N-diacetyl)-







guanine


diphosphate
H
H
CH3
O
6-O-acetyl







guanine


diphosphate
H
H
CH3
O
8-fluoroguanine


diphosphate
H
H
CH3
O
guanine


diphosphate
H
H
CH3
O
6-(N,N-diacetyl)-







adenine


diphosphate
H
H
CH3
O
2-fluoroadenine


diphosphate
H
H
CH3
O
8-fluoroadenine


diphosphate
H
H
CH3
O
2,8-difluoro-







adenine


diphosphate
H
H
CH3
O
adenine


diphosphate
H
H
CH3
S
2-(N,N-diacetyl)-







guanine


diphosphate
H
H
CH3
S
6-O-acetyl







guanine


diphosphate
H
H
CH3
S
8-fluoroguanine


diphosphate
H
H
CH3
S
guanine


diphosphate
H
H
CH3
S
6-(N,N-diacetyl)-







adenine


diphosphate
H
H
CH3
S
2-fluoroadenine


diphosphate
H
H
CH3
S
8-fluoroadenine


diphosphate
H
H
CH3
S
2,8-difluoro-







adenine


diphosphate
H
H
CH3
S
adenine


triphosphate
H
H
CH3
O
2-(N,N-diacetyl)-







guanine


triphosphate
H
H
CH3
O
6-O-acetyl







guanine


triphosphate
H
H
CH3
O
8-fluoroguanine


triphosphate
H
H
CH3
O
guanine


triphosphate
H
H
CH3
O
6-(N,N-diacetyl)-







adenine


triphosphate
H
H
CH3
O
2-fluoroadenine


triphosphate
H
H
CH3
O
8-fluoroadenine


triphosphate
H
H
CH3
O
2,8-difluoro-







adenine


triphosphate
H
H
CH3
O
2-(N,N-diacetyl)-







guanine


triphosphate
H
H
CH3
S
6-O-acetyl







guanine


triphosphate
H
H
CH3
S
8-fluoroguanine


tiiphosphate
H
H
CH3
S
guanine


triphosphate
H
H
CH3
S
6-(N,N-diacetyl)-







adenine


triphosphate
H
H
CH3
S
2-fluoroadenine


triphosphate
H
H
CH3
S
8-fluoroadenine


triphosphate
H
H
CH3
S
2,8-difluoro-







adenine


triphosphate
H
H
CH3
S
adenine


monophosphate
monophosphate
monophosphate
CF3
O
2-(N,N-diacetyl)-







guanine


monophosphate
monophosphate
monophosphate
CF3
O
6-O-acetyl







guanine


monophosphate
monophosphate
monophosphate
CF3
O
8-fluoroguanine


monophosphate
monophosphate
monophosphate
CF3
O
guanine


monophosphate
monophosphate
monophosphate
CF3
O
6-(N,N-diacetyl)-







adenine


monophosphate
monophosphate
monophosphate
CF3
O
2-fluoroadenine


monophosphate
monophosphate
monophosphate
CF3
O
8-fluoroadenine


monophosphate
monophosphate
monophosphate
CF3
O
2,8-difluoro-







adenine


monophosphate
monophosphate
monophosphate
CF3
O
adenine


monophosphate
monophosphate
monophosphate
CF3
S
2-(N,N-diacetyl)-







guanine


monophosphate
monophosphate
monophosphate
CF3
S
6-O-acetyl







guanine


monophosphate
monophosphate
monophosphate
CF3
S
8-fluoroguanine


monophosphate
monophosphate
monophosphate
CF3
S
guanine


monophosphate
monophosphate
monophosphate
CF3
S
6-(N,N-diacetyl)-







adenine


monophosphate
monophosphate
monophosphate
CF3
S
2-fluoroadenine


monophosphate
monophosphate
monophosphate
CF3
S
8-fluoroadenine


monophosphate
monophosphate
monophosphate
CF3
S
2,8-difluoro-







adenine


monophosphate
monophosphate
monophosphate
CF3
S
adenine


acetyl
acetyl
acetyl
CF3
O
guanine


acetyl
acetyl
acetyl
CF3
S
guanine


acetyl
acetyl
acetyl
2-bromo-
O
guanine





vinyl


acetyl
acetyl
acetyl
2-bromo-
S
guanine





vinyl









Alternatively, the following nucleosides of Formula XI are prepared, using the appropriate sugar and pyrimidine or purine bases.












(XI)








 







wherein:












R1
R2
R7
R6
X
Base





H
H
H
CH3
O
2,4-O-Diacetyluracil


H
H
H
CH3
O
Hypoxanthine


H
H
H
CH3
O
2,4-O-Diacetylthymine


H
H
H
CH3
O
Thymine


H
H
H
CH3
O
Cytosine


H
H
H
CH3
O
4-(N-mono-







acetyl)cytosine


H
H
H
CH3
O
4-(N,N-diacetyl)cytosine


H
H
H
CH3
O
Uracil


H
H
H
CH3
O
5-Fluorouracil


H
H
H
CH3
S
2,4-O-Diacetyluracil


H
H
H
CH3
S
Hypoxanthine


H
H
H
CH3
S
2,4-O-Diacetylthymine


H
H
H
CH3
S
Thymine


H
H
H
CH3
S
Cytosine


H
H
H
CH3
S
4-(N-mono-acetyl)cytosin


H
H
H
CH3
S
4-(N,N-diacetyl)cytosine


H
H
H
CH3
S
Uracil


H
H
H
CH3
S
5-Fluorouracil





CH3


monophosphate
H
H
CH3
O
2,4-O-Diacetyluracil


monophosphate
H
H
CH3
O
Hypoxanthine


monophosphate
H
H
CH3
O
2,4-O-Diacetylthymine


monophosphate
H
H
CH3
O
Thymine


monophosphate
H
H
CH3
O
Cytosine


monophosphate
H
H
CH3
O
4-(N-mono-







acetyl)cytosine


monophosphate
H
H
CH3
O
4-(N,N-diacetyl)cytosine


monophosphate
H
H
CH3
O
Uracil


monophosphate
H
H
CH3
O
5-Fluorouracil


monophosphate
H
H
CH3
S
2,4-O-Diacetyluracil


monophosphate
H
H
CH3
S
Hypoxanthine


monophosphate
H
H
CH3
S
2,4-O-Diacetylthymine


monophosphate
H
H
CH3
S
Thymine


monophosphate
H
H
CH3
S
Cytosine


monophosphate
H
H
CH3
S
4-(N-mono-







acetyl)cytosine


monophosphate
H
H
CH3
S
4-(N,N-diacetyl)cytosine


monophosphate
H
H
CH3
S
Uracil


monophosphate
H
H
CH3
S
5-Fluorouracil


diphosphate
H
H
CH3
O
2,4-O-Diacetylurac


diphosphate
H
H
CH3
O
Hypoxanthine


diphosphate
H
H
CH3
O
2,4-O-Diacetylthymine


diphosphate
H
H
CH3
O
Thymine


diphosphate
H
H
CH3
O
Cytosine


diphosphate
H
H
CH3
O
4-(N-mono-







acetyl)cytosine


diphosphate
H
H
CH3
O
4-(N,N-diacetyl)cytosine


diphosphate
H
H
CH3
O
Uracil


diphosphate
H
H
CH3
O
5-Fluorouracil


diphosphate
H
H
CH3
S
2,4-O-Diacetyluracil


diphosphate
H
H
CH3
S
Hypoxanthine


diphosphate
H
H
CH3
S
2,4-O-Diacetylthym


diphosphate
H
H
CH3
S
Thymine


diphosphate
H
H
CH3
S
Cytosine


triphosphate
H
H
CH3
O
2,4-O-Diacetyluracil


triphosphate
H
H
CH3
O
Hypoxanthine


triphosphate
H
H
CH3
O
2,4-O-Diacetylthymine


triphosphate
H
H
CH3
O
Thymine


triphosphate
H
H
CH3
O
Cytosine


triphosphate
H
H
CH3
O
4-(N-mono-







acetyl)cytosine


triphosphate
H
H
CH3
O
4-(N,N-diacetyl)cytos


triphosphate
H
H
CH3
O
Uracil


triphosphate
H
H
CH3
O
5-Fluorouracil


triphosphate
H
H
CH3
S
2,4-O-Diacetyluracil


triphosphate
H
H
CH3
S
Hypoxanthine


triphosphate
H
H
CH3
S
2,4-O-Diacetylthym


triphosphate
H
H
CH3
S
Thymine


triphosphate
H
H
CH3
S
Cytosine


monophosphate
monophosphate
Br
CF3
O
2,4-O-Diacetyluracil


monophosphate
monophosphate
Br
CF3
O
Hypoxanthine


monophosphate
monophosphate
Br
CF3
O
2,4-O-Diacetylthymine


monophosphate
monophosphate
Br
CF3
O
Thymine


monophosphate
monophosphate
Br
CF3
O
Cytosine


monophosphate
monophosphate
Br
CF3
O
4-(N-mono-







acetyl)cytosine


monophosphate
monophosphate
Br
CF3
O
4-(N,N-diacetyl)cytosine


monophosphate
monophosphate
Br
CF3
O
Uracil


monophosphate
monophosphate
Br
CF3
O
5-Fluorouracil


monophosphate
monophosphate
Br
CF3
S
2,4-O-Diacetyluracil


monophosphate
monophosphate
Br
CF3
S
Hypoxanthine


monophosphate
monophosphate
Br
CF3
S
2,4-O-Diacetylthymine


monophosphate
monophosphate
Br
CF3
S
Thymine


monophosphate
monophosphate
Br
CF3
S
Cytosine


monophosphate
monophosphate
Br
CF3
S
4-(N-mono-







acetyl)cytosine


monophosphate
monophosphate
Br
CF3
S
4-(N,N-diacetyl)cytos


monophosphate
monophosphate
Br
CF3
S
Uracil


monophosphate
monophosphate
Br
CF3
S
5-Fluorouracil


acetyl
acetyl
NO2
CF3
O
4-(N,N-diacetyl)cytosine


acetyl
acetyl
NO2
CF3
S
4-(N,N-diacetyl)cytosine


acetyl
acetyl
NO2
CF3
O
4-(N,N-diacetyl)cytosine


acetyl
acetyl
NO2
2-bromo-
S
4-(N,N-diacetyl)cytosine





vinyl









Alternatively, the following nucleosides of Formula XII are prepared, using the appropriate sugar and pyrimidine or purine bases.












(XII)








 







wherein:










R1
R6
X
Base





H
CH3
O
2,4-O-Diacetyluracil


H
CH3
O
Hypoxanthine


H
CH3
O
2,4-O-Diacetylthymine


H
CH3
O
Thymine


H
CH3
O
Cytosine


H
CH3
O
4-(N-mono-acetyl)cytosine


H
CH3
O
4-(N,N-diacetyl)cytosine


H
CH3
O
Uracil


H
CH3
O
5-Fluorouracil


H
CH3
S
2,4-O-Diacetyluracil


H
CH3
S
Hypoxanthine


H
CH3
S
2,4-O-Diacetylthymine


H
CH3
S
Thymine


H
CH3
S
Cytosine


H
CH3
S
4-(N-mono-acetyl)cytosine


H
CH3
S
4-(N,N-diacetyl)cytosine


H
CH3
S
Uracil


H
CH3
S
5-Fluorouracil


monophosphate
CH3
O
2,4-O-Diacetyluracil


monophosphate
CH3
O
Hypoxanthine


monophosphate
CH3
O
2,4-O-Diacetylthymine


monophosphate
CH3
O
Thymine


monophosphate
CH3
O
Cytosine


monophosphate
CH3
O
4-(N-mono-acetyl)cytosine


monophosphate
CH3
O
4-(N,N-diacetyl)cytosine


monophosphate
CH3
O
Uracil


monophosphate
CH3
O
5-Fluorouracil


monophosphate
CH3
S
2,4-O-Diacetyluracil


monophosphate
CH3
S
Hypoxanthine


monophosphate
CH3
S
2,4-O-Diacetylthymine


monophosphate
CH3
S
Thymine


monophosphate
CH3
S
Cytosine


monophosphate
CH3
S
4-(N-mono-acetyl)cytosine


monophosphate
CH3
S
4-(N,N-diacetyl)cytosine


monophosphate
CH3
S
Uracil


monophosphate
CH3
S
5-Fluorouracil


diphosphate
CH3
O
2,4-O-Diacetyluracil


diphosphate
CH3
O
Hypoxanthine


diphosphate
CH3
O
2,4-O-Diacetylthymine


diphosphate
CH3
O
Thymine


diphosphate
CH3
O
Cytosine


diphosphate
CH3
O
4-(N-mono-acetyl)cytosine


diphosphate
CH3
O
4-(N,N-diacetyl)cytosine


diphosphate
CH3
O
Uracil


diphosphate
CH3
O
5-Fluorouracil


diphosphate
CH3
S
2,4-O-Diacetyluracil


diphosphate
CH3
S
Hypoxanthine


diphosphate
CH3
S
2,4-O-Diacetylthymine


diphosphate
CH3
S
Thymine


diphosphate
CH3
S
Cytosine


triphosphate
CH3
O
2,4-O-Diacetyluracil


triphosphate
CH3
O
Hypoxanthine


triphosphate
CH3
O
2,4-O-Diacetylthymine


triphosphate
CH3
O
Thymine


triphosphate
CH3
O
Cytosine


triphosphate
CH3
O
4-(N-mono-acetyl)cytosine


triphosphate
CH3
O
4-(N,N-diacetyl)cytosine


triphosphate
CH3
O
Uracil


triphosphate
CH3
O
5-Fluorouracil


triphosphate
CH3
S
2,4-O-Diacetyluracil


triphosphate
CH3
S
Hypoxanthine


triphosphate
CH3
S
2,4-O-Diacetylthymine


triphosphate
CH3
S
Thymine


triphosphate
CH3
S
Cytosine


monophosphate
CF3
O
2,4-O-Diacetyluracil


monophosphate
CF3
O
Hypoxanthine


monophosphate
CF3
O
2,4-O-Diacetylthymine


monophosphate
CF3
O
Thymine


monophosphate
CF3
O
Cytosine


monophosphate
CF3
O
4-(N-mono-acetyl)cytosine


monophosphate
CF3
O
4-(N,N-diacetyl)cytosine


monophosphate
CF3
O
Uracil


monophosphate
CF3
O
5-Fluorouracil


monophosphate
CF3
S
2,4-O-Diacetyluracil


monophosphate
CF3
S
Hypoxanthine


monophosphate
CF3
S
2,4-O-Diacetylthymine


monophosphate
CF3
S
Thymine


monophosphate
CF3
S
Cytosine


monophosphate
CF3
S
4-(N-mono-acetyl)cytosine


monophosphate
CF3
S
4-(N,N-diacetyl)cytosine


monophosphate
CF3
S
Uracil


monophosphate
CF3
S
5-Fluorouracil


acetyl
CF3
O
4-(N,N-diacetyl)cytosine


acetyl
CF3
S
4-(N,N-diacetyl)cytosine


acetyl
2-bromo-vinyl
O
4-(N,N-diacetyl)cytosine


acetyl
2-bromo-vinyl
S
4-(N,N-diacetyl)cytosine









Alternatively, the following nucleosides of Formula XVII are prepared, using the appropriate sugar and pyrimidine or purine bases.












(XVII)








 













R1
R6
R7
X
Base
R9
R10





H
CH3
H
O
2,4-O-Diacetyluracil
NHAc
Me


H
CH3
H
O
Hypoxanthine
NH2
Me


H
CH3
H
O
2,4-O-Diacetylthymine
NHAc
Me


H
CH3
H
O
Thymine
NH2
Me


H
CH3
H
O
Cytosine
NH2
Me


H
CH3
H
O
4-(N-mono-acetyl)cytosine
NHAc
Me


H
CH3
H
O
4-(N,N-diacetyl)cytosine
NHAc
Me


H
CH3
H
O
Uracil
NH2
Me


H
CH3
H
O
5-Fluorouracil
NH2
Me


H
CH3
H
S
2,4-O-Diacetyluracil
NHAc
Me


H
CH3
H
S
Hypoxanthine
NH2
Me


H
CH3
H
S
2,4-O-Diacetylthymine
NHAc
Me


H
CH3
H
S
Thymine
NH2
Me


H
CH3
H
S
Cytosine
NH2
Me


H
CH3
H
S
4-(N-mono-acetyl)cytosine
NHAc
Me


H
CH3
H
S
4-(N,N-diacetyl)cytosine
NHAc
Me


H
CH3
H
S
Uracil
NH2
Me


H
CH3
H
S
5-Fluorouracil
NH2
Me


monophosphate
CH3
H
O
2,4-O-Diacetyluracil
NHAc
Me


monophosphate
CH3
H
O
Hypoxanthine
NH2
Me


monophosphate
CH3
H
O
2,4-O-Diacetylthymine
NHAc
Me


monophosphate
CH3
H
O
Thymine
NH2
Me


monophosphate
CH3
H
O
Cytosine
NH2
Me


monophosphate
CH3
H
O
4-(N-mono-acetyl)cytosine
NHAC
Me


monophosphate
CH3
H
O
4-(N,N-diacetyl)cytosine
NHAc
Me


monophosphate
CH3
H
O
Uracil
NH2
Me


monophosphate
CH3
H
O
5-Fluorouracil
NH2
Me


monophosphate
CH3
H
S
2,4-O-Diacetyluracil
NHAc
Me


monophosphate
CH3
H
S
Hypoxanthine
NH2
Me


monophosphate
CH3
H
S
2,4-O-Diacetylthymine
NHAc
Me


monophosphate
CH3
H
S
Thymine
NH2
Me


monophosphate
CH3
H
S
Cytosine
NH2
Me


monophosphate
CH3
H
S
4-(N-mono-acetyl)cytosine
NHAc
Me


monophosphate
CH3
H
S
4-(N,N-diacetyl)cytosine
NHAc
Me


monophosphate
CH3
H
S
Uracil
NH2
Me


monophosphate
CH3
H
S
5-Fluorouracil
NH2
Me


diphosphate
CH3
H
O
2,4-O-Diacetyluracil
NHAc
Me


diphosphate
CH3
H
O
Hypoxanthine
NH2
Me


diphosphate
CH3
H
O
2,4-O-Diacetylthymine
NH2
Me


diphosphate
CH3
H
O
Thymine
NH2
Me


diphosphate
CH3
H
O
Cytosine
NH2
Me


diphosphate
CH3
H
O
4-(N-mono-acetyl)cytosine
NHAc
Me


diphosphate
CH3
H
O
4-(N,N-diacetyl)cytos
NHAc
Me


diphosphate
CH3
H
O
Uracil
NH2
Me


diphosphate
CH3
H
O
5-Fluorouracil
NH2
Me


diphosphate
CH3
H
S
2,4-O-DiacetyluracilNH2
Me


diphosphate
CH3
H
S
Hypoxanthine
NH2
Me


diphosphate
CH3
H
S
2,4-O-Diacetylthymine
NHAc
Me


diphosphate
CH3
H
S
Thymine
NH2
Me


diphosphate
CH3
H
S
Cytosine
NH2
Me


triphosphate
CH3
H
O
2,4-O-Diacetyluracil
NHAc
Me


triphosphate
CH3
H
O
Hypoxanthine
NHAc
Me


triphosphate
CH3
H
O
2,4-O-Diacetylthymine
NHAc
Me


triphosphate
CH3
H
O
Thymine
NH2
Me


triphosphate
CH3
H
O
Cytosine
NH2
Me


triphosphate
CH3
H
O
4-(N-mono-acetyl)cytosine
NHAc
Me


triphosphate
CH3
H
O
4-(N,N-diacetyl)cytosine
NH2
Me


triphosphate
CH3
H
O
Uracil
NH2
Me


triphosphate
CH3
H
O
5-Fluorouracil
NH2
Me


triphosphate
CH3
H
S
2,4-O-Diacetyluracil
NH2
Me


triphosphate
CH3
H
S
Hypoxanthine
NH2
Me


triphosphate
CH3
H
S
2,4-O-Diacetylthyinine
NH2
Me


triphosphate
CH3
H
S
Thymine
NH2
Me


triphosphate
CH3
H
S
Cytosine
NH2
Me


monophosphate
CF3
H
O
2,4-O-Diacetyluracil
NH2
Me


monophosphate
CF3
H
O
Hypoxanthine
NH2
Me


monophosphate
CF3
H
O
2,4-O-Diacetylthyinine
NH2
Me


monophosphate
CF3
H
O
Thymine
NH2
Me


monophosphate
CF3
H
O
Cytosine
NH2
Me


monophosphate
CF3
H
O
4-(N-mono-acetyl)cytosine
NH2
Me


monophosphate
CF3
H
O
4-(N,N-diacetyl)cytosine
NH2
Me


monophosphate
CF3
H
O
Uracil
NH2
Me


monophosphate
CF3
H
O
5-Fluorouracil
NH2
Me


monophosphate
CF3
H
S
2,4-O-Diacetyluracil
NH2
Me


monophosphate
CF3
H
S
Hypoxanthine
NH2
Me


monophosphate
CF3
H
S
2,4-O-Diacetylthymine
NH2
Me


monophosphate
CF3
H
S
Thymine
NH2
Me


monophosphate
CF3
H
S
Cytosine
NH2
Me


monophosphate
CF3
H
S
4-(N-mono-acetyl)cytosine
NH2
Me


monophosphate
CF3
H
S
4-(N,N-diacetyl)cytosine
NH2
Me


monophosphate
CF3
H
S
Uracil
NH2
Me


monophosphate
CF3
H
S
5-Fluorouracil
NH2
Me


acetyl
CH3
H
O
4-(N,N-diacetyl)cytosine
H
Br


acetyl
CH3
H
S
4-(N,N-diacetyl)cytosine
H
Br


acetyl
CH3
OH
O
4-(N,N-diacetyl)cytosine
H
Br


acetyl
CH3
OH
S
4-(N,N-diacetyl)cytosine
H
Br









Example 3
Preparation of 3′-C-methylriboadenine
The title compound can be prepared according to a published procedure (R. F. Nutt, M. J. Dickinson, F. W. Holly, and E. Walton, “Branched-chain sugar nucleosides. III. 3′-C-methyladenine”, J. Org. Chem. 1968, 33, 1789–1795) (Scheme 9).




(a) RuO2/NaIO4; (b) MeMgI/TiCl4; (c) HCl/MeOH/H2O; (d) BzCl/pyridine; (e) AcBr, HBr/AcOH; (f) chloromercuri-6-benzamidopurine; (g) NH3/MeOH.

In a similar manner, but using the appropriate sugar and pyrimidine or purine bases, the following nucleosides of Formula III are prepared.












(III)








 







wherein:












R1
R2
R3
X1
X2
Y





H
H
H
H
H
H


H
H
H
H
H
NH2


H
H
H
H
H
NH-cyclopropyl


H
H
H
H
H
NH-methyl


H
H
H
H
H
NH-ethyl


H
H
H
H
H
NH-acetyl


H
H
H
H
H
OH


H
H
H
H
H
OMe


H
H
H
H
H
OEt


H
H
H
H
H
O-cyclopropyl


H
H
H
H
H
O-acetyl


H
H
H
H
H
SH


H
H
H
H
H
SMe


H
H
H
H
H
SEt


H
H
H
H
H
5-cyclopropyl


H
H
H
H
H
F


H
H
H
H
H
Cl


H
H
H
H
H
Br


H
H
H
H
H
I


monophosphate
H
H
H
H
NH2


monophosphate
H
H
H
H
NH-acetyl


monophosphate
H
H
H
H
NH-cyclopropyl


monophosphate
H
H
H
H
NH-methyl


monophosphate
H
H
H
H
NH-ethyl


monophosphate
H
H
H
H
OH


monophosphate
H
H
H
H
O-acetyl


monophosphate
H
H
H
H
OMe


monophosphate
H
H
H
H
OEt


monophosphate
H
H
H
H
O-cyclopropyl


monophosphate
H
H
H
H
SH


monophosphate
H
H
H
H
SMe


monophosphate
H
H
H
H
SEt


monophosphate
H
H
H
H
S-cyclopropyl


monophosphate
H
H
H
H
F


monophosphate
H
H
H
H
Cl


monophosphate
H
H
H
H
Br


monophosphate
H
H
H
H
I


diphosphate
H
H
H
H
NH2


diphosphate
H
H
H
H
NH-acetyl


diphosphate
H
H
H
H
NH-cyclopropyl


diphosphate
H
H
H
H
NH-methyl


diphosphate
H
H
H
H
NH-ethyl


diphosphate
H
H
H
H
OH


diphosphate
H
H
H
H
O-acetyl


diphosphate
H
H
H
H
OMe


diphosphate
H
H
H
H
OEt


diphosphate
H
H
H
H
O-cyclopropyl


diphosphate
H
H
H
H
SH


diphosphate
H
H
H
H
SMe


diphosphate
H
H
H
H
SEt


diphosphate
H
H
H
H
S-cyclopropyl


diphosphate
H
H
H
H
F


diphosphate
H
H
H
H
Cl


diphosphate
H
H
H
H
Br


diphosphate
H
H
H
H
I


triphosphate
H
H
H
H
NH2


triphosphate
H
H
H
H
NH-acetyl


triphosphate
H
H
H
H
NH-cyclopropyl


triphosphate
H
H
H
H
NH-methyl


triphosphate
H
H
H
H
NH-ethyl


triphosphate
H
H
H
H
OH


triphosphate
H
H
H
H
OMe


triphosphate
H
H
H
H
OEt


triphosphate
H
H
H
H
O-cyclopropyl


triphosphate
H
H
H
H
O-acetyl


triphosphate
H
H
H
H
SH


triphosphate
H
H
H
H
SMe


triphosphate
H
H
H
H
SEt


triphosphate
H
H
H
H
5-cyclopropyl


triphosphate
H
H
H
H
F


triphosphate
H
H
H
H
Cl


triphosphate
H
H
H
H
Br


triphosphate
H
H
H
H
I


monophosphate
monophosphate
monophosphate
H
H
NH2


monophosphate
monophosphate
monophosphate
H
H
NH-cyclopropyl


monophosphate
monophosphate
monophosphate
H
H
OH


monophosphate
monophosphate
monophosphate
H
H
F


monophosphate
monophosphate
monophosphate
H
H
Cl


diphosphate
diphosphate
diphosphate
H
H
NH2


diphosphate
diphosphate
diphosphate
H
H
NH-cyclopropyl


diphosphate
diphosphate
diphosphate
H
H
OH


diphosphate
diphosphate
diphosphate
H
H
F


diphosphate
diphosphate
diphosphate
H
H
Cl


triphosphate
triphosphate
triphosphate
H
H
NH2


triphosphate
triphosphate
triphosphate
H
H
NH-cyclopropyl


triphosphate
triphosphate
triphosphate
H
H
OH


triphosphate
triphosphate
triphosphate
H
H
F


triphosphate
triphosphate
triphosphate
H
H
Cl


H
H
H
F
H
NH2


H
H
H
F
H
NH-cyclopropyl


H
H
H
F
H
OH


H
H
H
F
H
F


H
H
H
F
H
Cl


H
H
H
Cl
H
NH2


H
H
H
Cl
H
NH-cyclopropyl


H
H
H
Cl
H
OH


H
H
H
Cl
H
F


H
H
H
Cl
H
Cl


H
H
H
Br
H
NH2


H
H
H
Br
H
NH-cyclopropyl


H
H
H
Br
H
OH


H
H
H
Br
H
F


H
H
H
Br
H
Cl


H
H
H
NH2
H
NH2


H
H
H
NH2
H
NH-cyclopropyl


H
H
H
NH2
H
OH


H
H
H
NH2
H
F


H
H
H
NH2
H
Cl


H
H
H
SH
H
NH2


H
H
H
SH
H
NH-cyclopropyl


H
H
H
SH
H
OH


H
H
H
SH
H
F


H
H
H
SH
H
Cl


acetyl
H
H
H
H
NH2


acetyl
H
H
H
H
NH-cyclopropyl


acetyl
H
H
H
H
OH


acetyl
H
H
H
H
F


acetyl
H
H
H
H
Cl


acetyl
H
H
F
H
NH2


acetyl
H
H
F
H
NH-cyclopropyl


acetyl
H
H
F
H
OH


acetyl
H
H
F
H
F


acetyl
H
H
F
H
Cl


H
acetyl
acetyl
H
H
NH2


H
acetyl
acetyl
H
H
NH-cyclopropyl


H
acetyl
acetyl
H
H
OH


H
acetyl
acetyl
H
H
F


H
acetyl
acetyl
H
H
Cl


acetyl
acetyl
acetyl
H
H
NH2


acetyl
acetyl
acetyl
H
H
NH-cyclopropyl


acetyl
acetyl
acetyl
H
H
OH


acetyl
acetyl
acetyl
H
H
F


acetyl
acetyl
acetyl
H
H
Cl


monophosphate
acetyl
acetyl
H
H
NH2


monophosphate
acetyl
acetyl
H
H
NH-cyclopropyl


monophosphate
acetyl
acetyl
H
H
OH


monophosphate
acetyl
acetyl
H
H
F


monophosphate
acetyl
acetyl
H
H
Cl


diphosphate
acetyl
acetyl
H
H
NH2


diphosphate
acetyl
acetyl
H
H
NH-cyclopropyl


diphosphate
acetyl
acetyl
H
H
OH


diphosphate
acetyl
acetyl
H
H
F


diphosphate
acetyl
acetyl
H
H
Cl


triphosphate
acetyl
acetyl
H
H
NH2


triphosphate
acetyl
acetyl
H
H
NH-cyclopropyl


triphosphate
acetyl
acetyl
H
H
OH


triphosphate
acetyl
acetyl
H
H
F


triphosphate
acetyl
acetyl
H
H
Cl


H
H
H
H
NH2
H


H
H
H
H
NH2
NH2


H
H
H
H
NH2
NH-cyclopropyl


H
H
H
H
NH2
NH-methyl


H
H
H
H
NH2
NH-ethyl


H
H
H
H
NH2
NH-acetyl


H
H
H
H
NH2
OH


H
H
H
H
NH2
OMe


H
H
H
H
NH2
OEt


H
H
H
H
NH2
O-cyclopropyl


H
H
H
H
NH2
O-acetyl


H
H
H
H
NH2
SH


H
H
H
H
NH2
SMe


H
H
H
H
NH2
SEt


H
H
H
H
NH2
S-cyclopropyl


H
H
H
H
NH2
F


H
H
H
H
NH2
Cl


H
H
H
H
NH2
Br


H
H
H
H
NH2
I


monophosphate
H
H
H
NH2
NH2


monophosphate
H
H
H
NH2
NH-acetyl


monophosphate
H
H
H
NH2
NH-cyclopropyl


monophosphate
H
H
H
NH2
NH-methyl


monophosphate
H
H
H
NH2
NH-ethyl


monophosphate
H
H
H
NH2
OH


monophosphate
H
H
H
NH2
O-acetyl


monophosphate
H
H
H
NH2
OMe


monophosphate
H
H
H
NH2
OEt


monophosphate
H
H
H
NH2
O-cyclopropyl


monophosphate
H
H
H
NH2
SH


monophosphate
H
H
H
NH2
SMe


monophosphate
H
H
H
NH2
SEt


monophosphate
H
H
H
NH2
S-cyclopropyl


monophosphate
H
H
H
NH2
F


monophosphate
H
H
H
NH2
Cl


monophosphate
H
H
H
NH2
Br


monophosphate
H
H
H
NH2
I


diphosphate
H
H
H
NH2
NH2


diphosphate
H
H
H
NH2
NH-acetyl


diphosphate
H
H
H
NH2
NH-cyclopropyl


diphosphate
H
H
H
NH2
NH-methyl


diphosphate
H
H
H
NH2
NH-ethyl


diphosphate
H
H
H
NH2
OH


diphosphate
H
H
H
NH2
O-acetyl


diphosphate
H
H
H
NH2
OMe


diphosphate
H
H
H
NH2
OEt


diphosphate
H
H
H
NH2
O-cyclopropyl


diphosphate
H
H
H
NH2
SH


diphosphate
H
H
H
NH2
SMe


diphosphate
H
H
H
NH2
SEt


diphosphate
H
H
H
NH2
5-cyclopropyl


diphosphate
H
H
H
NH2
F


diphosphate
H
H
H
NH2
Cl


diphosphate
H
H
H
NH2
Br


diphosphate
H
H
H
NH2
I


triphosphate
H
H
H
NH2
NH2


triphosphate
H
H
H
NH2
NH-acetyl


triphosphate
H
H
H
NH2
NH-cyclopropyl


triphosphate
H
H
H
NH2
NH-methyl


triphosphate
H
H
H
NH2
NH-ethyl


triphosphate
H
H
H
NH2
OH


triphosphate
H
H
H
NH2
OMe


triphosphate
H
H
H
NH2
OEt


triphosphate
H
H
H
NH2
O-cyclopropyl


triphosphate
H
H
H
NH2
O-acetyl


triphosphate
H
H
H
NH2
SH


triphosphate
H
H
H
NH2
SMe


triphosphate
H
H
H
NH2
SEt


triphosphate
H
H
H
NH2
S-cyclopropyl


triphosphate
H
H
H
NH2
F


triphosphate
H
H
H
NH2
Cl


triphosphate
H
H
H
NH2
Br


triphosphate
H
H
H
NH2
I


monophosphate
monophosphate
monophosphate
H
NH2
NH2


monophosphate
monophosphate
monophosphate
H
NH2
NH-cyclopropyl


monophosphate
monophosphate
monophosphate
H
NH2
OH


monophosphate
monophosphate
monophosphate
H
NH2
F


monophosphate
monophosphate
monophosphate
H
NH2
Cl


diphosphate
diphosphate
diphosphate
H
NH2
NH2


diphosphate
diphosphate
diphosphate
H
NH2
NH-cyclopropyl


diphosphate
diphosphate
diphosphate
H
NH2
OH


diphosphate
diphosphate
diphosphate
H
NH2
F


diphosphate
diphosphate
diphosphate
H
NH2
Cl


triphosphate
triphosphate
triphosphate
H
NH2
NH2


triphosphate
triphosphate
triphosphate
H
NH2
NH-cyclopropyl


triphosphate
triphosphate
triphosphate
H
NH2
OH


triphosphate
triphosphate
triphosphate
H
NH2
F


triphosphate
triphosphate
triphosphate
H
NH2
Cl


H
H
H
F
NH2
NH2


H
H
H
F
NH2
NH-cyclopropyl


H
H
H
F
NH2
OH


H
H
H
F
NH2
F


H
H
H
F
NH2
Cl


H
H
H
Cl
NH2
NH2


H
H
H
Cl
NH2
NH-cyclopropyl


H
H
H
Cl
NH2
OH


H
H
H
Cl
NH2
F


H
H
H
Cl
NH2
Cl


H
H
H
Br
NH2
NH2


H
H
H
Br
NH2
NH-cyclopropyl


H
H
H
Br
NH2
OH


H
H
H
Br
NH2
F


H
H
H
Br
NH2
Cl


H
H
H
NH2
NH2
NH2


H
H
H
NH2
NH2
NH-cyclopropyl


H
H
H
NH2
NH2
OH


H
H
H
NH2
NH2
F


H
H
H
NH2
NH2
Cl


H
H
H
SH
NH2
NH2


H
H
H
SH
NH2
NH-cyclopropyl


H
H
H
SH
NH2
OH


H
H
H
SH
NH2
F


H
H
H
SH
NH2
Cl


acetyl
H
H
H
NH2
NH2


acetyl
H
H
H
NH2
NH-cyclopropyl


acetyl
H
H
H
NH2
OH


acetyl
H
H
H
NH2
F


acetyl
H
H
H
NH2
Cl


acetyl
H
H
F
NH2
NH2


acetyl
H
H
F
NH2
NH-cyclopropyl


acetyl
H
H
F
NH2
OH


acetyl
H
H
F
NH2
F


acetyl
H
H
F
NH2
Cl


H
acetyl
acetyl
H
NH2
NH2


H
acetyl
acetyl
H
NH2
NH-cyclopropyl


H
acetyl
acetyl
H
NH2
OH


H
acetyl
acetyl
H
NH2
F


H
acetyl
acetyl
H
NH2
Cl


acetyl
acetyl
acetyl
H
NH2
NH2


acetyl
acetyl
acetyl
H
NH2
NH-cyclopropyl


acetyl
acetyl
acetyl
H
NH2
OH


acetyl
acetyl
acetyl
H
NH2
F


acetyl
acetyl
acetyl
H
NH2
Cl


monophosphate
acetyl
acetyl
H
NH2
NH2


monophosphate
acetyl
acetyl
H
NH2
NH-cyclopropyl


monophosphate
acetyl
acetyl
H
NH2
OH


monophosphate
acetyl
acetyl
H
NH2
F


monophosphate
acetyl
acetyl
H
NH2
Cl


dephosphate
acetyl
acetyl
H
NH2
NH2


dephosphate
acetyl
acetyl
H
NH2
NH-cyclopropyl


dephosphate
acetyl
acetyl
H
NH2
OH


dephosphate
acetyl
acetyl
H
NH2
F


dephosphate
acetyl
acetyl
H
NH2
Cl


triphosphate
acetyl
acetyl
H
NH2
NH2


triphosphate
acetyl
acetyl
H
NH2
NH-cyclopropyl


triphosphate
acetyl
acetyl
H
NH2
OH


triphosphate
acetyl
acetyl
H
NH2
F


triphosphate
acetyl
acetyl
H
NH2
Cl


H
H
H
H
Cl
H


H
H
H
H
Cl
H


H
H
H
H
Cl
NH2


H
H
H
H
Cl
NH-cyclopropyl


H
H
H
H
Cl
NH-methyl


H
H
H
H
Cl
NH-ethyl


H
H
H
H
Cl
NH-acetyl


H
H
H
H
Cl
OH


H
H
H
H
Cl
OMe


H
H
H
H
Cl
OEt


H
H
H
H
Cl
O-cyclopropyl


H
H
H
H
Cl
O-acetyl


H
H
H
H
Cl
SH


H
H
H
H
Cl
SMe


H
H
H
H
Cl
SEt


H
H
H
H
Cl
5-cyclopropyl


monophosphate
H
H
H
Cl
NH2


monophosphate
H
H
H
Cl
NH-acetyl


monophosphate
H
H
H
Cl
NH-cyclopropyl


monophosphate
H
H
H
Cl
NH-methyl


monophosphate
H
H
H
Cl
NH-ethyl


monophosphate
H
H
H
Cl
OH


monophosphate
H
H
H
Cl
O-acetyl


monophosphate
H
H
H
Cl
OMe


monophosphate
H
H
H
Cl
OEt


monophosphate
H
H
H
Cl
O-cyclopropyl


monophosphate
H
H
H
Cl
SH


monophosphate
H
H
H
Cl
SMe


monophosphate
H
H
H
Cl
SEt


monophosphate
H
H
H
Cl
S-cyclopropyl


diphosphate
H
H
H
Cl
NH2


diphosphate
H
H
H
Cl
NH-acetyl


diphosphate
H
H
H
Cl
NH-cyclopropyl


diphosphate
H
H
H
Cl
NH-methyl


diphosphate
H
H
H
Cl
NH-ethyl


diphosphate
H
H
H
Cl
OH


diphosphate
H
H
H
Cl
O-acetyl


diphosphate
H
H
H
Cl
OMe


diphosphate
H
H
H
Cl
OEt


diphosphate
H
H
H
Cl
O-cyclopropyl


diphosphate
H
H
H
Cl
SH


diphosphate
H
H
H
Cl
SMe


diphosphate
H
H
H
Cl
SEt


diphosphate
H
H
H
Cl
5-cyclopropyl


triphosphate
H
H
H
Cl
NH2


triphosphate
H
H
H
Cl
NH-acetyl


triphosphate
H
H
H
Cl
NH-cyclopropyl


triphosphate
H
H
H
Cl
NH-methyl


triphosphate
H
H
H
Cl
NH-ethyl


triphosphate
H
H
H
Cl
OH


triphosphate
H
H
H
Cl
OMe


triphosphate
H
H
H
Cl
OEt


triphosphate
H
H
H
Cl
O-cyclopropyl


triphosphate
H
H
H
Cl
O-acetyl


triphosphate
H
H
H
Cl
SH


triphosphate
H
H
H
Cl
SMe


triphosphate
H
H
H
Cl
SEt


triphosphate
H
H
H
Cl
S-cyclopropyl


monophosphate
monophosphate
monophosphate
H
Cl
NH2


monophosphate
monophosphate
monophosphate
H
Cl
NH-cyclopropyl


monophosphate
monophosphate
monophosphate
H
Cl
OH


diphosphate
diphosphate
diphosphate
H
Cl
NH2


diphosphate
diphosphate
diphosphate
H
Cl
NH-cyclopropyl


diphosphate
diphosphate
diphosphate
H
Cl
OH


triphosphate
triphosphate
triphosphate
H
Cl
NH2


triphosphate
triphosphate
triphosphate
H
Cl
NH-cyclopropyl


triphosphate
triphosphate
triphosphate
H
Cl
OH


H
H
H
F
Cl
NH2


H
H
H
F
Cl
NH-cyclopropyl


H
H
H
F
Cl
OH


H
H
H
Cl
Cl
NH2


H
H
H
Cl
Cl
NH-cyclopropyl


H
H
H
Cl
Cl
OH


H
H
H
Br
Cl
NH2


H
H
H
Br
Cl
NH-cyclopropyl


H
H
H
Br
Cl
OH


H
H
H
NH2
Cl
NH2


H
H
H
NH2
Cl
NH-cyclopropyl


H
H
H
NH2
Cl
OH


H
H
H
SH
Cl
NH2


H
H
H
SH
Cl
NH-cyclopropyl


H
H
H
SH
Cl
OH


acetyl
H
H
H
Cl
NH2


acetyl
H
H
H
Cl
NH-cyclopropyl


acetyl
H
H
H
Cl
OH


acetyl
H
H
F
Cl
NH2


acetyl
H
H
F
Cl
NH-cyclopropyl


acetyl
H
H
F
Cl
OH


H
acetyl
acetyl
H
Cl
NH2


H
acetyl
acetyl
H
Cl
NH-cyclopropyl


H
acetyl
acetyl
H
Cl
OH


acetyl
acetyl
acetyl
H
Cl
NH2


acetyl
acetyl
acetyl
H
Cl
NH-cyclopropyl


acetyl
acetyl
acetyl
H
Cl
OH


monophosphate
acetyl
acetyl
H
Cl
NH2


monophosphate
acetyl
acetyl
H
Cl
NH-cyclopropyl


monophosphate
acetyl
acetyl
H
Cl
OH


diphosphate
acetyl
acetyl
H
Cl
NH2


diphosphate
acetyl
acetyl
H
Cl
NH-cyclopropyl


diphosphate
acetyl
acetyl
H
Cl
OH


triphosphate
acetyl
acetyl
H
Cl
NH2


triphosphate
acetyl
acetyl
H
Cl
NH-cyclopropyl


triphosphate
acetyl
acetyl
H
Cl
OH


H
H
H
H
Cl
NH2


H
H
H
H
Cl
NH-cyclopropyl


H
H
H
H
Cl
OH


H
H
H
H
Br
NH2


H
H
H
H
Br
NH-cyclopropyl


H
H
H
H
Br
OH









Alternatively, the following nucleosides of Formula VI are prepared, using the appropriate sugar and pyrimidine or purine bases.












(VI)













wherein:











R1
R2
R3
X1
Y





H
H
H
H
H


H
H
H
H
NH2


H
H
H
H
NH-cyclopropyl


H
H
H
H
NH-methyl


H
H
H
H
NH-ethyl


H
H
H
H
NH-acetyl


H
H
H
H
OH


H
H
H
H
OMe


H
H
H
H
OEt


H
H
H
H
O-cyclopropyl


H
H
H
H
O-acetyl


H
H
H
H
SH


H
H
H
H
SMe


H
H
H
H
SEt


H
H
H
H
S-cyclopropyl


mono-
H
H
H
NH2


phosphate


mono-
H
H
H
NH-acetyl


phosphate


mono-
H
H
H
NH-cyclopropyl


phosphate


mono-
H
H
H
NH-methyl


phosphate


mono-
H
H
H
NH-ethyl


phosphate


mono-
H
H
H
OH


phosphate


mono-
H
H
H
O-acetyl


phosphate


mono-
H
H
H
OMe


phosphate


mono-
H
H
H
OEt


phosphate


mono-
H
H
H
O-cyclopropyl


phosphate


mono-
H
H
H
SH


phosphate


mono-
H
H
H
SMe


phosphate


mono-
H
H
H
SEt


phosphate


mono-
H
H
H
S-cyclopropyl


phosphate


diphosphate
H
H
H
NH2


diphosphate
H
H
H
NH-acetyl


diphosphate
H
H
H
NH-cyclopropyl


diphosphate
H
H
H
NH-methyl


diphosphate
H
H
H
NH-ethyl


diphosphate
H
H
H
OH


diphosphate
H
H
H
O-acetyl


diphosphate
H
H
H
OMe


diphosphate
H
H
H
OEt


diphosphate
H
H
H
O-cyclopropyl


diphosphate
H
H
H
SH


diphosphate
H
H
H
SMe


diphosphate
H
H
H
SEt


diphosphate
H
H
H
S-cyclopropyl


triphosphate
H
H
H
NH2


triphosphate
H
H
H
NH-acetyl


triphosphate
H
H
H
NH-cyclopropyl


triphosphate
H
H
H
NH-methyl


triphosphate
H
H
H
NH-ethyl


triphosphate
H
H
H
OH


triphosphate
H
H
H
OMe


triphosphate
H
H
H
OEt


triphosphate
H
H
H
O-cyclopropyl


triphosphate
H
H
H
O-acetyl


triphosphate
H
H
H
SH


triphosphate
H
H
H
SMe


triphosphate
H
H
H
SEt


triphosphate
H
H
H
S-cyclopropyl


mono-
monophosphate
monophosphate
H
NH2


phosphate


mono-
monophosphate
monophosphate
H
NH-cyclopropyl


phosphate


mono-
monophosphate
monophosphate
H
OH


phosphate


diphosphate
diphosphate
diphosphate
H
NH2


diphosphate
diphosphate
diphosphate
H
NH-cyclopropyl


diphosphate
diphosphate
diphosphate
H
OH


triphosphate
triphosphate
triphosphate
H
NH2


triphosphate
triphosphate
triphosphate
H
NH-cyclopropyl


triphosphate
triphosphate
triphosphate
H
OH


H
H
H
F
NH2


H
H
H
F
NH-cyclopropyl


H
H
H
F
OH


H
H
H
Cl
NH2


H
H
H
Cl
NH-cyclopropyl


H
H
H
Cl
OH


H
H
H
Br
NH2


H
H
H
Br
NH-cyclopropyl


H
H
H
Br
OH


H
H
H
NH2
NH2


H
H
H
NH2
NH-cyclopropyl


H
H
H
NH2
OH


H
H
H
SH
NH2


H
H
H
SH
NH-cyclopropyl


H
H
H
SH
OH


acetyl
H
H
H
NH2


acetyl
H
H
H
NH-cyclopropyl


acetyl
H
H
H
OH


acetyl
H
H
F
NH2


acetyl
H
H
F
NH-cyclopropyl


acetyl
H
H
F
OH


H
acetyl
acetyl
H
NH2


H
acetyl
acetyl
H
NH-cyclopropyl


H
acetyl
acetyl
H
OH


acetyl
acetyl
acetyl
H
NH2


acetyl
acetyl
acetyl
H
NH-cyclopropyl


acetyl
acetyl
acetyl
H
OH


mono-
acetyl
acetyl
H
NH2


phosphate


mono-
acetyl
acetyl
H
NH-cyclopropyl


phosphate


mono-
acetyl
acetyl
H
OH


phosphate


diphosphate
acetyl
acetyl
H
NH2


diphosphate
acetyl
acetyl
H
NH-cyclopropyl


diphosphate
acetyl
acetyl
H
OH


triphosphate
acetyl
acetyl
H
NH2


triphosphate
acetyl
acetyl
H
NH-cyclopropyl


triphosphate
acetyl
acetyl
H
OH









Alternatively, the following nucleosides of Formula XIII are prepared, using the appropriate sugar and pyrimidine or purine bases.












(XIII)













wherein:












R1
R2
R3
R6
X
Base





H
H
H
CH3
O
2,4-O-Diacetyluracil


H
H
H
CH3
O
Hypoxanthine


H
H
H
CH3
O
2,4-O-Diacetylthymine


H
H
H
CH3
O
Thymine


H
H
H
CH3
O
Cytosine


H
H
H
CH3
O
4-(N-mono-acetyl)cytosine


H
H
H
CH3
O
4-(N,N-diacetyl)cytosine


H
H
H
CH3
O
Uracil


H
H
H
CH3
O
5-Fluorouracil


H
H
H
CH3
S
2,4-O-Diacetyluraci


H
H
H
CH3
S
Hypoxanthine


H
H
H
CH3
S
2,4-O-Diacetylthymine


H
H
H
CH3
S
Thymine


H
H
H
CH3
S
Cytosine


H
H
H
CH3
S
4-(N-mono-acetyl)cytosine


H
H
H
CH3
S
4-(N,N-diacetyl)cytosine


H
H
H
CH3
S
Uracil


H
H
H
CH3
S
5-Fluorouracil


monophosphate
H
H
CH3
O
2,4-O-Diacetyluracil


monophosphate
H
H
CH3
O
Hypoxanthine


monophosphate
H
H
CH3
O
2,4-O-Diacetylthym


monophosphate
H
H
CH3
O
Thymine


monophosphate
H
H
CH3
O
Cytosine


monophosphate
H
H
CH3
O
4-(N-mono-acetyl)cytosine


monophosphate
H
H
CH3
O
4-(N,N-diacetyl)cytosine


monophosphate
H
H
CH3
O
Uracil


monophosphate
H
H
CH3
O
5-Fluorouracil


monophosphate
H
H
CH3
S
2,4-O-Diacetyluracil


monophosphate
H
H
CH3
S
Hypoxanthine


monophosphate
H
H
CH3
S
2,4-O-Diacetylthym


monophosphate
H
H
CH3
S
Thymine


monophosphate
H
H
CH3
S
Cytosine


monophosphate
H
H
CH3
S
4-(N-mono-acetyl)cytosine


monophosphate
H
H
CH3
S
4-(N,N-diacetyl)cytosine


monophosphate
H
H
CH3
S
Uracil


monophosphate
H
H
CH3
S
5-Fluorouracil


diphosphate
H
H
CH3
O
2,4-O-Diacetyluracil


diphosphate
H
H
CH3
O
Hypoxanthine


diphosphate
H
H
CH3
O
2,4-O-Diacetylthymine


diphosphate
H
H
CH3
O
Thymine


diphosphate
H
H
CH3
O
Cytosine


diphosphate
H
H
CH3
O
4-(N-mono-acetyl)cytosine


diphosphate
H
H
CH3
O
4-(N,N-diacetyl)cytosine


diphosphate
H
H
CH3
O
Uracil


diphosphate
H
H
CH3
O
5-Fluorouracil


diphosphate
H
H
CH3
S
2,4-O-Diacetyluracil


diphosphate
H
H
CH3
S
Hypoxanthine


diphosphate
H
H
CH3
S
2,4-O-Diacetylthym


diphosphate
H
H
CH3
S
Thymine


diphosphate
H
H
CH3
S
Cytosine


triphosphate
H
H
CH3
O
2,4-O-Diacetyluracil


triphosphate
H
H
CH3
O
Hypoxanthine


triphosphate
H
H
CH3
O
2,4-O-Diacetylthymine


triphosphate
H
H
CH3
O
Thymine


triphosphate
H
H
CH3
O
Cytosine


triphosphate
H
H
CH3
O
4-(N-mono-acetyl)cytosine


triphosphate
H
H
CH3
O
4-(N,N-diacetyl)cytosine


triphosphate
H
H
CH3
O
Uracil


triphosphate
H
H
CH3
O
5-Fluorouracil


triphosphate
H
H
CH3
S
2,4-O-Diacetyluracil


triphosphate
H
H
CH3
S
Hypoxanthine


triphosphate
H
H
CH3
S
2,4-O-Diacetylthymine


triphosphate
H
H
CH3
S
Thymine


triphosphate
H
H
CH3
S
Cytosine


monophosphate
monophosphate
monophosphate
CF3
O
2,4-O-Diacetyluracil


monophosphate
monophosphate
monophosphate
CF3
O
Hypoxanthine


monophosphate
monophosphate
monophosphate
CF3
O
2,4-O-Diacetylthymine


monophosphate
monophosphate
monophosphate
CF3
O
Thymine


monophosphate
monophosphate
monophosphate
CF3
O
Cytosine


monophosphate
monophosphate
monophosphate
CF3
O
4-(N-mono-acetyl)cytosine


monophosphate
monophosphate
monophosphate
CF3
O
4-(N,N-diacetyl)cytosine


monophosphate
monophosphate
monophosphate
CF3
O
Uracil


monophosphate
monophosphate
monophosphate
CF3
O
5-Fluorouracil


monophosphate
monophosphate
monophosphate
CF3
S
2,4-O-Diacetyluracil


monophosphate
monophosphate
monophosphate
CF3
S
Hypoxanthine


monophosphate
monophosphate
monophosphate
CF3
S
2,4-O-Diacetylthymine


monophosphate
monophosphate
monophosphate
CF3
S
Thymine


monophosphate
monophosphate
monophosphate
CF3
S
Cytosine


monophosphate
monophosphate
monophosphate
CF3
S
4-(N-mono-acetyl)cytosine


monophosphate
monophosphate
monophosphate
CF3
S
4-(N,N-diacetyl)cytosine


monophosphate
monophosphate
monophosphate
CF3
S
Uracil


monophosphate
monophosphate
monophosphate
CF3
S
5-Fluorouracil


acetyl
acetyl
acetyl
CF3
O
4-(N,N-diacetyl)cytosine


acetyl
acetyl
acetyl
CF3
S
4-(N,N-diacetyl)cytosine


acetyl
acetyl
acetyl
2-bromo-vinyl
O
4-(N,N-diacetyl)cytosine


acetyl
acetyl
acetyl
2-bromo-vinyl
S
4-(N,N-diacetyl)cytosine


H
H
H
CH3
O
2-(N,N-diacetyl)-guanine


H
H
H
CH3
O
6-O-acetyl guanine


H
H
H
CH3
O
8-fluoroguanine


H
H
H
CH3
O
guanine


H
H
H
CH3
O
6-(N,N-diacetyl)-adenine


H
H
H
CH3
O
2-fluoroadenine


H
H
H
CH3
O
8-fluoroadenine


H
H
H
CH3
O
2,8-difluoro-adenine


H
H
H
CH3
O
adenine


H
H
H
CH3
S
2-(N,N-diacetyl)-guanine


H
H
H
CH3
S
6-O-acetyl guanine


H
H
H
CH3
S
8-fluoroguanine


H
H
H
CH3
S
guanine


H
H
H
CH3
S
6-(N,N-diacetyl)-adenine


H
H
H
CH3
S
2-fluoroadenine


H
H
H
CH3
S
8-fluoroadenine


H
H
H
CH3
S
2,8-difluoro-adenine


H
H
H
CH3
S
adenine


monophosphate
H
H
CH3
O
2-(N,N-diacetyl)-guanine


monophosphate
H
H
CH3
O
6-O-acetyl guanine


monophosphate
H
H
CH3
O
8-fluoroguanine


monophosphate
H
H
CH3
O
guanine


monophsophate
H
H
CH3
O
6-(N,N-diacetyl)-adenine


monophosphate
H
H
CH3
O
2-fluoroadenine


monophosphate
H
H
CH3
O
8-fluoroadenine


monophosphate
H
H
CH3
O
2,8-difluoro-adenine


monophosphate
H
H
CH3
O
adenine


monophosphate
H
H
CH3
S
2-(N,N-diacetyl)-guanine


monophosphate
H
H
CH3
S
6-O-acetyl guanine


monophosphate
H
H
CH3
S
8-fluoroguanine


monophosphate
H
H
CH3
S
guanine


monophosphate
H
H
CH3
S
6-(N,N-diacetyl)-adenine


monophosphate
H
H
CH3
S
2-fluoroadenine


monophosphate
H
H
CH3
S
8-fluoroadenine


monophosphate
H
H
CH3
S
2,8-difluoro-adenine


monophosphate
H
H
CH3
S
adenine


diphosphate
H
H
CH3
O
2-(N,N-diacetyl)-guanine


diphosphate
H
H
CH3
O
6-O-acetyl guanine


diphosphate
H
H
CH3
O
8-fluoroguanine


diphosphate
H
H
CH3
O
guanine


diphosphate
H
H
CH3
O
6-(N,N-diacetyl)-adenine


diphosphate
H
H
CH3
O
2-fluoroadenine


diphosphate
H
H
CH3
O
8-fluoroadenine


diphosphate
H
H
CH3
O
2,8-difluoro-adenine


diphosphate
H
H
CH3
O
adenine


diphosphate
H
H
CH3
S
2-(N,N-diacetyl)-guanine


diphosphate
H
H
CH3
S
6-O-acetyl guanine


diphosphate
H
H
CH3
S
8-fluoroguanine


diphosphate
H
H
CH3
S
guanine


diphosphate
H
H
CH3
S
6-(N,N-diacetyl)-adenine


diphosphate
H
H
CH3
S
2-fluoroadenine


diphosphate
H
H
CH3
S
8-fluoroadenine


diphosphate
H
H
CH3
S
2,8-difluoro-adenine


diphosphate
H
H
CH3
S
adenine


triphosphate
H
H
CH3
O
2-(N,N-diacetyl)-guanine


triphosphate
H
H
CH3
O
6-O-acetyl guanine


triphosphate
H
H
CH3
O
8-fluoroguanine


triphosphate
H
H
CH3
O
guanine


triphosphate
H
H
CH3
O
6-(N,N-diacetyl)-adenine


triphosphate
H
H
CH3
O
2-fluoroadenine


triphosphate
H
H
CH3
O
8-fluoroadenine


triphosphate
H
H
CH3
O
2,8-difluoro-adenine


triphosphate
H
H
CH3
O
2-(N,N-diacetyl)-guanine


triphosphate
H
H
CH3
S
6-O-acetyl guanine


triphosphate
H
H
CH3
S
8-fluoroguanine


triphosphate
H
H
CH3
S
guanine


triphosphate
H
H
CH3
S
6-(N,N-diacetyl)-adenine


triphosphate
H
H
CH3
S
2-fluoroadenine


triphosphate
H
H
CH3
S
8-fluoroadenine


triphosphate
H
H
CH3
S
2,8-difluoro-adenine


triphosphate
H
H
CH3
S
adenine


monophosphate
monophosphate
monophosphate
CF3
O
2-(N,N-diacetyl)-guanine


monophosphate
monophosphate
monophosphate
CF3
O
6-O-acetyl guanine


monophosphate
monophosphate
monophosphate
CF3
O
8-fluoroguanine


monophosphate
monophosphate
monophosphate
CF3
O
guanine


monophosphate
monophosphate
monophosphate
CF3
O
6-(N,N-diacetyl)-adenine


monophosphate
monophosphate
monophosphate
CF3
O
2-fluoroadenine


monophosphate
monophosphate
monophosphate
CF3
O
8-fluoroadenine


monophosphate
monophosphate
monophosphate
CF3
O
2,8-difluoro-adenine


monophosphate
monophosphate
monophosphate
CF3
O
adenine


monophosphate
monophosphate
monophosphate
CF3
S
2-(N,N-diacetyl)-guanine


monophosphate
monophosphate
monophosphate
CF3
S
6-O-acetyl guanine


monophosphate
monophosphate
monophosphate
CF3
S
8-fluoroguanine


monophosphate
monophosphate
monophosphate
CF3
S
guanine


monophosphate
monophosphate
monophosphate
CF3
S
6-(N,N-diacetyl)-adenine


monophosphate
monophosphate
monophosphate
CF3
S
2-fluoroadenine


monophosphate
monophosphate
monophosphate
CF3
S
8-fluoroadenine


monophosphate
monophosphate
monophosphate
CF3
S
2,8-difluoro-adenine


monophosphate
monophosphate
monophosphate
CF3
S
adenine


acetyl
acetyl
acetyl
CF3
O
guanine


acetyl
acetyl
acetyl
CF3
S
guanine


acetyl
acetyl
acetyl
2-bromo-vinyl
O
guanine


acetyl
acetyl
acetyl
2-bromo-vinyl
S
guanine









Alternatively, the following nucleosides of Formula XIV are prepared, using the appropriate sugar and pyrimidine or purine bases.












(XIV)













wherein:











R1
R2
R6
X
Base





H
H
CH3
O
2,4-O-Diacetyluracil


H
H
CH3
O
Hypoxanthine


H
H
CH3
O
2,4-O-Diacetylthymine


H
H
CH3
O
Thymine


H
H
CH3
O
Cytosine


H
H
CH3
O
4-(N-mono-acetyl)cytosine


H
H
CH3
O
4-(N,N-diacetyl)cytosine


H
H
CH3
O
Uracil


H
H
CH3
O
5-Fluorouracil


H
H
CH3
S
2,4-O-Diacetyluracil


H
H
CH3
S
Hypoxanthine


H
H
CH3
S
2,4-O-Diacetylthymine


H
H
CH3
S
Thymine


H
H
CH3
S
Cytosine


H
H
CH3
S
4-(N-mono-acetyl)cytosin


H
H
CH3
S
4-(N,N-diacetyl)cytosine


H
H
CH3
S
Uracil


H
H
CH3
S
5-Fluorouracil


mono-
H
CH3
O
2,4-O-Diacetyluracil


phosphate


mono-
H
CH3
O
Hypoxanthine


phosphate


mono-
H
CH3
O
2,4-O-Diacetylthym


phosphate


mono-
H
CH3
O
Thymine


phosphate


mono-
H
CH3
O
Cytosine


phosphate


mono-
H
CH3
O
4-(N-mono-acetyl)cytosine


phosphate


mono-
H
CH3
O
4-(N,N-diacetyl)cytos


phosphate


mono-
H
CH3
O
Uracil


phosphate


mono-
H
CH3
O
5-Fluorouracil


phosphate


mono-
H
CH3
S
2,4-O-Diacetyluracil


phosphate


mono-
H
CH3
S
Hypoxanthine


phosphate


mono-
H
CH3
S
2,4-O-Diacetylthym


phosphate


mono-
H
CH3
S
Thymine


phosphate


mono-
H
CH3
S
Cytosine


phosphate


mono-
H
CH3
S
4-(N-mono-acetyl)cytosine


phosphate


mono-
H
CH3
S
4-(N,N-diacetyl)cytosine


phosphate


mono-
H
CH3
S
Uracil


phosphate


mono-
H
CH3
S
5-Fluorouracil


phosphate


diphosphate
H
CH3
O
2,4-O-Diacetyluracil


diphosphate
H
CH3
O
Hypoxanthine


diphosphate
H
CH3
O
2,4-O-Diacetylthymine


diphosphate
H
CH3
O
Thymine


diphosphate
H
CH3
O
Cytosine


diphosphate
H
CH3
O
4-(N-mono-acetyl)cytosine


diphosphate
H
CH3
O
4-(N,N-diacetyl)cytosine


diphosphate
H
CH3
O
Uracil


diphosphate
H
CH3
O
5-Fluorouracil


diphosphate
H
CH3
S
2,4-O-Diacetyluracil


diphosphate
H
CH3
S
Hypoxanthine


diphosphate
H
CH3
S
2,4-0-Diacetylthymine


diphosphate
H
CH3
S
Thymine


diphosphate
H
CH3
S
Cytosine


triphosphate
H
CH3
O
2,4-O-Diacetyluracil


triphosphate
H
CH3
O
Hypoxanthine


triphosphate
H
CH3
O
2,4-O-Diacetylthymine


triphosphate
H
CH3
O
Thymine


triphosphate
H
CH3
O
Cytosine


triphosphate
H
CH3
O
4-(N-mono-acetyl)cytosine


triphosphate
H
CH3
O
4-(N,N-diacetyl)cytosine


triphosphate
H
CH3
O
Uracil


triphosphate
H
CH3
O
5-Fluorouracil


triphosphate
H
CH3
S
2,4-O-Diacetyluracil


triphosphate
H
CH3
S
Hypoxanthine


triphosphate
H
CH3
S
2,4-O-Diacetylthymine


triphosphate
H
CH3
S
Thymine


triphosphate
H
CH3
S
Cytosine


mono-
mono-
CF3
O
2,4-O-Diacetyluracil


phosphate
phosphate


mono-
mono-
CF3
O
Hypoxanthine


phosphate
phosphate


mono-
mono-
CF3
O
2,4-O-Diacetylthymine


phosphate
phosphate


mono-
mono-
CF3
O
Thymine


phosphate
phosphate


mono-
mono-
CF3
O
Cytosine


phosphate
phosphate


mono-
mono-
CF3
O
4-(N-mono-acetyl)cytosine


phosphate
phosphate


mono-
mono-
CF3
O
4-(N,N-diacetyl)cytosine


phosphate
phosphate


mono-
mono-
CF3
O
Uracil


phosphate
phosphate


mono-
mono-
CF3
O
5-Fluorouracil


phosphate
phosphate


mono-
mono-
CF3
S
2,4-O-Diacetyluracil


phosphate
phosphate


mono-
mono-
CF3
S
Hypoxanthine


phosphate
phosphate


mono-
mono-
CF3
S
2,4-O-Diacetylthymine


phosphate
phosphate


mono-
mono-
CF3
S
Thymine


phosphate
phosphate


mono-
mono-
CF3
S
Cytosine


phosphate
phosphate


mono-
mono-
CF3
S
4-(N-mono-acetyl)cytosine


phosphate
phosphate


mono-
mono-
CF3
S
4-(N,N-diacetyl)cytosine


phosphate
phosphate


mono-
mono-
CF3
S
Uracil


phosphate
phosphate


mono-
mono-
CF3
S
5-Fluorouracil


phosphate
phosphate


acetyl
acetyl
CF3
O
4-(N,N-diacetyl)cytosine


acetyl
acetyl
CF3
S
4-(N,N-diacetyl)cytosine


acetyl
acetyl
2-bromo-
O
4-(N,N-diacetyl)cytosine




vinyl


acetyl
acetyl
2-bromo-
S
4-(N,N-diacetyl)cytosine




vinyl









Alternatively, the following nucleosides of Formula XV are prepared, using the appropriate sugar and pyrimidine or purine bases.












(XV)













wherein:










R1
R6
X
Base





H
CH3
O
2,4-O-Diacetyluracil


H
CH3
O
Hypoxanthine


H
CH3
O
2,4-O-Diacetylthymine


H
CH3
O
Thymine


H
CH3
O
Cytosine


H
CH3
O
4-(N-mono-acetyl)cytosine


H
CH3
O
4-(N,N-diacetyl)cytosine


H
CH3
O
Uracil


H
CH3
O
5-Fluorouracil


H
CH3
S
2,4-O-Diacetyluracil


H
CH3
S
Hypoxanthine


H
CH3
S
2,4-O-Diacetylthymine


H
CH3
S
Thymine


H
CH3
S
Cytosine


H
CH3
S
4-(N-mono-acetyl)cytosine


H
CH3
S
4-(N,N-diacetyl)cytosine


H
CH3
S
Uracil


H
CH3
S
5-Fluorouracil


monophosphate
CH3
O
2,4-O-Diacetyluracil


monophosphate
CH3
O
Hypoxanthine


monophosphate
CH3
O
2,4-O-Diacetylthymine


monophosphate
CH3
O
Thymine


monophosphate
CH3
O
Cytosine


monophosphate
CH3
O
4-(N-mono-acetyl)cytosine


monophosphate
CH3
O
4-(N,N-diacetyl)cytosine


monophosphate
CH3
O
Uracil


monophosphate
CH3
O
5-Fluorouracil


monophosphate
CH3
S
2,4-O-Diacetyluracil


monophosphate
CH3
S
Hypoxanthine


monophosphate
CH3
S
2,4-O-Diacetylthymine


monophosphate
CH3
S
Thymine


monophosphate
CH3
S
Cytosine


monophosphate
CH3
S
4-(N-mono-acetyl)cytosine


monophosphate
CH3
S
4-(N,N-diacetyl)cytosine


monophosphate
CH3
S
Uracil


monophosphate
CH3
S
5-Fluorouracil


diphosphate
CH3
O
2,4-O-Diacetyluracil


diphosphate
CH3
O
Hypoxanthine


diphosphate
CH3
O
2,4-O-Diacetylthymine


diphosphate
CH3
O
Thymine


diphosphate
CH3
O
Cytosine


diphosphate
CH3
O
4-(N-mono-acetyl)cytosine


diphosphate
CH3
O
4-(N,N-diacetyl)cytosine


diphosphate
CH3
O
Uracil


diphosphate
CH3
O
5-Fluorouracil


diphosphate
CH3
S
2,4-O-Diacetyluracil


diphosphate
CH3
S
Hypoxanthine


diphosphate
CH3
S
2,4-O-Diacetylthymine


diphosphate
CH3
S
Thymine


diphosphate
CH3
S
Cytosine


triphosphate
CH3
O
2,4-O-Diacetyluracil


triphosphate
CH3
O
Hypoxanthine


triphosphate
CH3
O
2,4-O-Diacetylthymine


triphosphate
CH3
O
Thymine


triphosphate
CH3
O
Cytosine


triphosphate
CH3
O
4-(N-mono-acetyl)cytosine


triphosphate
CH3
O
4-(N,N-diacetyl)cytosine


triphosphate
CH3
O
Uracil


triphosphate
CH3
O
5-Fluorouracil


triphosphate
CH3
S
2,4-O-Diacetyluracil


triphosphate
CH3
S
Hypoxanthine


triphosphate
CH3
S
2,4-O-Diacetylthymine


triphosphate
CH3
S
Thymine


triphosphate
CH3
S
Cytosine


monophosphate
CF3
O
2,4-O-Diacetyluracil


monophosphate
CF3
O
Hypoxanthine


monophosphate
CF3
O
2,4-O-Diacetylthymine


monophosphate
CF3
O
Thymine


monophosphate
CF3
O
Cytosine


monophosphate
CF3
O
4-(N-mono-acetyl)cytosine


monophosphate
CF3
O
4-(N,N-diacetyl)cytosine


monophosphate
CF3
O
Uracil


monophosphate
CF3
O
5-Fluorouracil


monophosphate
CF3
S
2,4-O-Diacetyluracil


monophosphate
CF3
S
Hypoxanthine


monophosphate
CF3
S
2,4-O-Diacetylthymine


monophosphate
CF3
S
Thymine


monophosphate
CF3
S
Cytosine


monophosphate
CF3
S
4-(N-mono-acetyl)cytosine


monophosphate
CF3
S
4-(N,N-diacetyl)cytosine


monophosphate
CF3
S
Uracil


monophosphate
CF3
S
5-Fluorouracil


acetyl
CF3
O
4-(N,N-diacetyl)cytosine


acetyl
CF3
S
4-(N,N-diacetyl)cytosine


acetyl
2-bromo-vinyl
O
4-(N,N-diacetyl)cytosine


acetyl
2-bromo-vinyl
S
4-(N,N-diacetyl)cytosine









Alternatively, the following nucleosides of Formula XVIII are prepared, using the appropriate sugar and pyrimidine or purine bases.












(XVIII)













wherein:













R1
R6
R7
X
Base
R8
R9





H
CH3
OH
O
2,4-O-Diacetyluracil
H
Me


H
CH3
OH
O
Hypoxanthine
H
Me


H
CH3
OH
O
2,4-O-Diacetylthymine
H
Me


H
CH3
OH
O
Thymine
H
Me


H
CH3
OH
O
Cytosine
H
Me


H
CH3
OH
O
4-(N-mono-acetyl)cytosine
H
Me


H
CH3
OH
O
4-(N,N-diacetyl)cytosine
H
Me


H
CH3
OH
O
Uracil
H
Me


H
CH3
OH
O
5-Fluorouracil
H
Me


H
CH3
OH
S
2,4-O-Diacetyluracil
H
Me


H
CH3
OH
S
Hypoxanthine
H
Me


H
CH3
OH
S
2,4-0-Diacetylthymine
H
Me


H
CH3
OH
S
Thymine
H
Me


H
CH3
OH
S
Cytosine
H
Me


H
CH3
OH
S
4-(N-mono-acetyl)cytosine
H
Me


H
CH3
OH
S
4-(N,N-diacetyl)cytosine
H
Me


H
CH3
OH
S
Uracil
H
Me


H
CH3
OH
S
5-Fluorouracil
H
Me


monophosphate
CH3
OH
O
2,4-O-Diacetyluracil
H
Me


monophosphate
CH3
OH
O
Hypoxanthine
H
Me


monophosphate
CH3
OH
O
2,4-O-Diacetylthymine
H
Me


monophosphate
CH3
OH
O
Thymine
H
Me


monophosphate
CH3
OH
O
Cytosine
H
Me


monophosphate
CH3
OH
O
4-(N-mono-acetyl)cytosine
H
Me


monophosphate
CH3
OH
O
4-(N,N-diacetyl)cytosine
H
Me


monophosphate
CH3
OH
O
Uracil
H
Me


monophosphate
CH3
OH
O
5-Fluorouracil
H
Me


monophosphate
CH3
OH
S
2,4-O-Diacetyluracil
H
Me


monophosphate
CH3
OH
S
Hypoxanthine
H
Me


monophosphate
CH3
OH
S
2,4-O-Diacetylthymine
H
Me


monophosphate
CH3
OH
S
Thymine
H
Me


monophosphate
CH3
OH
S
Cytosine
H
Me


monophosphate
CH3
OH
S
4-(N-mono-acetyl)cytosine
H
Me


monophosphate
CH3
OH
S
4-(N,N-diacetyl)cytosine
H
Me


monophosphate
CH3
OH
S
Uracil
H
Me


monophosphate
CH3
OH
S
5-Fluorouracil
H
Me


diphosphate
CH3
OH
O
2,4-O-Diacetyluracil
H
Me


diphosphate
CH3
OH
O
Hypoxanthine
H
Me


diphosphate
CH3
OH
O
2,4-O-Diacetylthymine
H
Me


diphosphate
CH3
OH
O
Thymine
H
Me


diphosphate
CH3
OH
O
Cytosine
H
Me


diphosphate
CH3
OH
O
4-(N-mono-acetyl)cytosine
H
Me


diphosphate
CH3
OH
O
4-(N,N-diacetyl)cytosine
H
Me


diphosphate
CH3
OH
O
Uracil
H
Me


diphosphate
CH3
OH
O
5-Fluorouracil
H
Me


diphosphate
CH3
OH
S
2,4-O-Diacetyluracil
H
Me


diphosphate
CH3
OH
S
Hypoxanthine
H
Me


diphosphate
CH3
OH
S
2,4-O-Diacetylthymine
H
Me


diphosphate
CH3
OH
S
Thymine
H
Me


diphosphate
CH3
OH
S
Cytosine
H
Me


triphosphate
CH3
OH
O
2,4-O-Diacetyluracil
H
Me


triphosphate
CH3
OH
O
Hypoxanthine
H
Me


triphosphate
CH3
OH
O
2,4-O-Diacetylthymine
H
Me


triphosphate
CH3
OH
O
Thymine
H
Me


triphosphate
CH3
OH
O
Cytosine
H
Me


triphosphate
CH3
OH
O
4-(N-mono-acetyl)cytosine
H
Me


triphosphate
CH3
OH
O
4-(N,N-diacetyl)cytosine
H
Me


triphosphate
CH3
OH
O
Uracil
H
Me


triphosphate
CH3
OH
O
5-Fluorouracil
H
Me


triphosphate
CH3
OH
S
2,4-O-Diacetyluracil
H
Me


triphosphate
CH3
OH
S
Hypoxanthine
H
Me


triphosphate
CH3
OH
S
2,4-O-Diacetylthymine
H
Me


triphosphate
CH3
OH
S
Thymine
H
Me


triphosphate
CH3
OH
S
Cytosine
H
Me


monophosphate
CF3
OH
O
2,4-O-Diacetyluracil
H
Me


monophosphate
CF3
OH
O
Hypoxanthine
H
Me


monophosphate
CF3
OH
O
2,4-O-Diacetylthymine
H
Me


monophosphate
CF3
OH
O
Thymine
H
Me


monophosphate
CF3
OH
O
Cytosine
H
Me


monophosphate
CF3
OH
O
4-(N-mono-acetyl)cytosine
H
Me


monophosphate
CF3
OH
O
4-(N,N-diacetyl)cytosine
H
Me


monophosphate
CF3
OH
O
Uracil
H
Me


monophosphate
CF3
OH
O
5-Fluorouracil
H
Me


monophosphate
CF3
OH
S
2,4-O-Diacetyluracil
H
Me


monophosphate
CF3
OH
S
Hypoxanthine
H
Me


monophosphate
CF3
OH
S
2,4-O-Diacetylthymine
H
Me


monophosphate
CF3
OH
S
Thymine
H
Me


monophosphate
CF3
OH
S
Cytosine
H
Me


monophosphate
CF3
OH
S
4-(N-mono-acetyl)cytosine
H
Me


monophosphate
CF3
OH
S
4-(N,N-diacetyl)cytosine
H
Me


monophosphate
CF3
OH
S
Uracil
H
Me


monophosphate
CF3
OH
S
5-Fluorouracil
H
Me


acetyl
CH3
OH
O
4-(N,N-diacetyl)cytosine
H
Br


acetyl
CH3
OH
S
4-(N,N-diacetyl)cytosine
H
Br









VII. Anti-Flavivirus or Pestivirus Activity

Compounds can exhibit anti-flavivirus or pestivirus activity by inhibiting flavivirus or pestivirus polymerase, by inhibiting other enzymes needed in the replication cycle, or by other pathways.
EXAMPLES
The test compounds were dissolved in DMSO at an initial concentration of 200 μM and then were serially diluted in culture medium.
Unless otherwise stated, baby hamster kidney (BHK-21) (ATCC CCL-10) and Bos Taurus (BT) (ATCC CRL 1390) cells were grown at 37° C. in a humidified CO2 (5%) atmosphere. BHK-21 cells were passaged in Eagle MEM additioned of 2 mM L-glutamine, 10% fetal bovine seruim (FBS, Gibco) and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate and 0.1 mM non-essential amino acids. BT cells were passaged in Dulbecco's modified Eagle's medium with 4 mM L-glutamine and 10% horse serum (HS, Gibco), adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose and 1.0 mM sodium pyruvate. The vaccine strain 17D (YFV-17D) (Stamaril®, Pasteur Merieux) and Bovine Viral Diarrhea virus (BVDV) (ATCC VR-534) were used to infect BHK and BT cells, respectively, in 75 cm2 bottles. After a 3 day incubation period at 37° C., extensive cytopathic effect was observed. Cultures were freeze-thawed three times, cell debris were removed by centrifugation and the supernatant was aliquoted and stored at −70° C. YFV-17D and BVDV were titrated in BHK-21 and BT cells, respectively, that were grown to confluency in 24-well plates.
Example 4
Phosphorylation Assay of Nucleoside to Active Triphosphate
To determine the cellular metabolism of the compounds, HepG2 cells were obtained from the American Type Culture Collection (Rockville, Md.), and were grown in 225 cm2 tissue culture flasks in minimal essential medium supplemented with non-essential amino acids, 1% penicillin-streptomycin. The medium was renewed every three days, and the cells were subcultured once a week. After detachment of the adherent monolayer with a 10 minute exposure to 30 mL of trypsin-EDTA and three consecutive washes with medium, confluent HepG2 cells were seeded at a density of 2.5×106 cells per well in a 6-well plate and exposed to 10 μM of [3H] labeled active compound (500 dpm/pmol) for the specified time periods. The cells were maintained at 37° C. under a 5% CO2 atmosphere. At the selected time points, the cells were washed three times with ice-cold phosphate-buffered saline (PBS). Intracellular active compound and its respective metabolites were extracted by incubating the cell pellet overnight at −20° C. with 60% methanol followed by extraction-with an additional 20 μL of cold methanol for one hour in an ice bath. The extracts were then combined, dried under gentle filtered air flow and stored at −20° C. until HPLC analysis. The preliminary results of the HPLC analysis are tabulated in Table 1.









TABLE 1









[pmol/million cells]












β-D-2′-CH3-
β-D-2′-CH3-
β-D-2′-CH3-
β-D-2′-CH3-


Time (h)
riboA-TP
riboU-TP
riboC-TP
riboG-TP














 2
33.1
0.40
2.24
ND


 4
67.7
1.21
3.99
ND


 8
147
1.57
9.76
2.85


24
427
6.39
34.9
0.91


30
456
7.18
36.2
3.22


48
288
9.42
56.4
6.26









Example 5
Bioavailability Assay in Cynomolgus Monkeys
Within 1 week prior to the study initiation, the cynomolgus monkey was surgically implanted with a chronic venous catheter and subcutaneous venous access port (VAP) to facilitate blood collection and underwent a physical examination including hematology and serum chemistry evaluations and the body weight was recorded. Each monkey (six total), received approximately 250 uCi of 3H activity with each dose of active compound, namely β-D-2′-CH3-riboG at a dose level of 10 mg/kg at a dose concentration of 5 mg/mL, either via an intravenous bolus (3 monkeys, IV), or via oral gavage (3 monkeys, PO). Each dosing syringe was weighed before dosing to gravimetrically determine the quantity of formulation administered. Urine samples were collected via pan catch at the designated intervals (approximately 18–0 hours pre-dose, 0–4, 4–8 and 8–12 hours post-dosage) and processed. Blood samples were collected as well (pre-dose, 0.25, 0.5, 1, 2, 3, 6, 8, 12 and 24 hours post-dosage) via the chronic venous catheter and VAP or from a peripheral vessel if the chronic venous catheter procedure should not be possible. The blood and urine samples were analyzed for the maximum concentration (Cmax), time when the maximum concentration was achieved (Tmax), area under the curve (AUC), half life of the dosage concentration (T1/2), clearance (CL), steady state volume and distribution (VSS) and bioavailability (F), which are tabulated in Tables 2 and 3, and graphically illustrated in FIGS. 2 and 3, respectively.







TABLE 2







Oral Bioavailability in Monkeys














AUC
Norm





Dose
(ng/
AUC (ng/
Mean Norm AUC
F



(mg)
mL × h)
mL × h/mg)
(ng/mL × h/mg)
(%)
















IV Monkey 1
46.44
13614
293.2




IV Monkey 2
24.53
6581
268.3


IV Monkey 3
20.72
6079
293.4
284.9


PO Monkey 1
29.04
758
26.1


PO Monkey 2
30.93
898
29.0


PO Monkey 3
30.04
1842
61.3
38.8
13.6
















TABLE 3







Experimental Pharmacokinetics of


β-D-2′-CH3-riboG in Cynomolgus Monkeys










IV
PO















Dose/Route (mg/kg)
10
10



Cmax (ng/mL)
6945.6 ± 1886.0
217.7 ± 132.1



Tmax (hr)
0.25 ± 0.00
2.00 ± 1.00



AUC (ng/mL × hr)
8758.0 ± 4212.9
1166.0 ± 589.6 



T1/2 (hr)
7.9 ± 5.4
10.3 ± 4.1 



CL (L/hr/kg)
1.28 ± 0.48



VSS (L/kg)
2.09 ± 0.54











F (%)
13.8











Example 6
Bone Marrow Toxicity Assay
Human bone marrow cells were collected from normal healthy volunteers and the mononuclear population was separated by Ficoll-Hypaque gradient centrifugation as described previously by Sommadossi J-P, Carlisle R. “Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro” Antimicrobial Agents and Chemotherapy 1987; 31:452–454; and Sommadossi J-P, Schinazi R F, Chu C K, Xie M-Y. “Comparison of cytotoxicity of the (−)- and (+)-enantiomer of 2′,3′-dideoxy-3′-thiacytidine in normal human bone marrow progenitor cells” Biochemical Pharmacology 1992; 44:1921–1925. The culture assays for CFU-GM and BFU-E were performed using a bilayer soft agar or methylcellulose method. Drugs were diluted in tissue culture medium and filtered. After 14 to 18 days at 37° C. in a humidified atmosphere of 5% CO2 in air, colonies of greater than 50 cells were counted using an inverted microscope. The results in Table 4 are presented as the percent inhibition of colony formation in the presence of drug compared to solvent control cultures.







TABLE 4







Human Bone Marrow Toxicity CFU-GM and BFU-E Clonogenic Assays










IC50 in μM












Treatment
CFU-GM
BFU-E







ribavirin
 ~5
 ~1



β-D-2′-CH3-riboA
>100
>100



β-D-2′-CH3-riboU
>100
>100



β-D-2′-CH3-riboC
 >10
 >10



β-D-2′-CH3-riboG
 >10
>100










Example 7
Mitochondria Toxicity Assay
HepG2 cells were cultured in 12-well plates as described above and exposed to various concentrations of drugs as taught by Pan-Zhou X-R, Cui L, Zhou X-J, Sommadossi J-P, Darley-Usmer V M. “Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells” Antimicrob Agents Chemother 2000; 44:496–503. Lactic acid levels in the culture medium after 4 day drug exposure was measured using a Boehringer lactic acid assay kit. Lactic acid levels were normalized by cell number as measured by hemocytometer count. The preliminary results from this assay are tabulated in Table 5.







TABLE 5







Mitochondrial Toxicity Study (L-lactic acid assay)











Conc. (μM)
lactate (mg/106 cell)
% of Control













Control

2.18



FIAU
10
3.73
170.4


β-D-2′-CH3-riboC
1
2.52
115.3



10
2.36
107.9



50
2.26
103.4



100
2.21
101.2



























Example 8
Cytotoxicity Assay
Cells were seeded at a rate of between 5×103 and 5×104/well into 96-well plates in growth medium overnight at 37° C. in a humidified CO2 (5%) atmosphere. New growth medium containing serial dilutions of the drugs was then added. After incubation for 4 days, cultures were fixed in 50% TCA and stained with sulforhodamineB. The optical density was read at 550 nm. The cytotoxic concentration was expressed as the concentration required to reduce the cell number by 50% (CC50). The data is tabulated in Table 6.







TABLE 6







MDBK versus Human Hepatoma









CC50, μM












Compound
MDBK
Huh7
HepG2







β-D-2′-CH3-riboA
 20
   40
50–60



β-D-2′-CH3-riboU
>250  
>250
>250



β-D-2′-CH3-riboC
100
>250
  150



β-D-2′-CH3-riboG
100
>250
>250



Ribavirin
 5
   25
  150










Example 9
Cell Protection Assay (CPA)
The assay was performed essentially as described by Baginski, S. G.; Pevear, D. C.; Seipel, M.; Sun, S. C. C.; Benetatos, C. A.; Chunduru, S. K.; Rice, C. M. and M. S. Collett “Mechanism of action of a pestivirus antiviral compound” PNAS USA 2000, 97(14), 7981–7986. MDBK cells (ATCC) were seeded onto 96-well culture plates (4,000 cells per well) 24 hours before use. After infection with BVDV (strain NADL, ATCC) at a multiplicity of infection (MOI) of 0.02 plaque forming units (PFU) per cell, serial dilutions of test compounds were added to both infected and uninfected cells in a final concentration of 0.5% DMSO in growth medium. Each dilution was tested in quadruplicate. Cell densities and virus inocula were adjusted to ensure continuous cell growth throughout the experiment and to achieve more than 90% virus-induced cell destruction in the untreated controls after four days post-infection. After four days, plates were fixed with 50% TCA and stained with sulforhodamine B. The optical density of the wells was read in a microplate reader at 550 nm. The 50% effective concentration (EC50) values were defined as the compound concentration that achieved 50% reduction of cytopathic effect of the virus. The results are tabulated in Table 7. FIGS. 4 and 5 provide a graphical illustration of the methodology used to arrive at the 50% effective concentration (EC50) values for β-D-2′-CH3-riboG and ribavirin. FIG. 6 compares the results of the CPA for β-D-2′-CH3-riboG, β-D-2′-CH3-riboC, β-D-2′-CH3-riboU, β-D-2′-CH3-riboA and ribavirin







TABLE 7







Cell Protection Assay










EC50, μM
CC50, μM















β-D-2′-CH3-riboA
2
 20



β-D-2′-CH3-riboU
20 
>250  



β-D-2′-CH3-riboC
2
100



β-D-2′-CH3-riboG
4
100



Ribavirin
>3  
 5










Example 10
Plaque Reduction Assay
For each compound the effective concentration was determined in duplicate 24-well plates by plaque reduction assays. Cell monolayers were infected with 100 PFU/well of virus. Then, serial dilutions of test compounds in MEM supplemented with 2% inactivated serum and 0.75% of methyl cellulose were added to the monolayers. Cultures were further incubated at 37° C. for 3 days, then fixed with 50% ethanol and 0.8% Crystal Violet, washed and air-dried. Then plaques were counted to determine the concentration to obtain 90% virus suppression and tabulated in Table 8. FIG. 7 is a graphical illustration of the results from the Plaque Reduction Assay. FIG. 8 is an image of BVDV plaque formation in the presence of increasing concentrations of β-D-2′-CH3-riboU.







TABLE 8







Viral Suppression via Plaque Reduction Assay









EC90, μM














β-D-2′-CH3-riboA
<3



β-D-2′-CH3-riboU
<81 



β-D-2′-CH3-riboC
<9



β-D-2′-CH3-riboG
<9










Example 11
Yield Reduction Assay
For each compound the concentration to obtain a 6-log reduction in viral load was determined in duplicate 24-well plates by yield reduction assays. The assay was performed as described by Baginski, S. G.; Pevear, D. C.; Seipel, M.; Sun, S. C. C.; Benetatos, C. A.; Chunduru, S. K.; Rice, C. M. and M. S. Collett “Mechanism of action of a pestivirus antiviral compound” PNAS USA 2000, 97(14), 7981–7986, with minor modifications. Briefly, MDBK cells were seeded onto 24-well plates (2×105 cells per well) 24 hours before infection with BVDV (NADL strain) at a multiplicity of infection (MOI) of 0.1 PFU per cell. Serial dilutions of test compounds were added to cells in a final concentration of 0.5% DMSO in growth medium. Each dilution was tested in triplicate. After three days, cell cultures (cell monolayers and supernatants) were lysed by three freeze-thaw cycles, and virus yield was quantified by plaque assay. Briefly, MDBK cells were seeded onto 6-well plates (5×105 cells per well) 24 h before use. Cells were inoculated with 0.2 mL of test lysates for 1 hour, washed and overlaid with 0.5% agarose in growth medium. After 3 days, cell monolayers were fixed with 3.5% formaldehyde and stained with 1% crystal violet (w/v in 50% ethanol) to visualize plaques. The plaques were counted to determine the concentration to obtain a 6-log reduction in viral load as tabulated in Table 9. FIG. 9 is a graphical illustration of the results from the Yield, Reduction Assay. FIG. 8 is an image of BVDV yield reduction in the presence of increasing concentrations of β-D-2′-CH3-riboC.







TABLE 9







Concentration to Obtain 6-log Reduction









Conc. for 6-log Reduction (μM)














β-D-2′-CH3-riboU
120 



β-D-2′-CH3-riboG
20



β-D-2′-CH3-riboC
20



β-D-2′-CH3-riboA
 9










Example 12
Comparative Cytotoxicity
Table 10 summarizes the cytoxicity of two compounds of this invention, β-D-1′-CH3-riboA and β-D-2′-CH3-riboA, in comparison to RBV (“ribavirin”), in various cell systems.







TABLE 10







Comparative Cytotoxicity* (CC50)












BD
BHK
VERO
MT-4

















β-D-1′-CH3-riboA
>100
200
>100
18  



β-D-2′-CH3-riboA
   75
 22
   22
6.6



RBV
ND
 50
   11
ND







*Compound concentration (μM) required to reduce the viability of cells by 50%.






The chemical structures for β-D1′-CH3-riboA and β-D-2′-CH3-riboA are as follows:




Table 11 summarizes the antiviral activity of β-D-1′-CH3-riboA and β-D-2′-CH3-riboA against several viruses within the flavivirus and pestivirus genuses.







TABLE 11







Comparative Antiviral Activity* (EC50)













BVDV
YFV
PICO
VSV
HIV-1
















β-D-1′-CH3-riboA
10
7.0
51
>100
>18


β-D-2′-CH3-riboA
0.1
0.2
5.0
>100
>6.6


RBV
ND
30
>30
ND
ND





*Compound concentration (μM) required to reduce the plaque number by 50%. The following virus-cell system were used: BVDC-BT, YFV-BHK, PICO (Cosxackie B1 and Polio Sabin)/VSV-Vero.






Table 12 summarizes the antiviral activity and toxicity of β-D-2′-methyl-riboG, β-D-2′-methyl-riboC and β-D-2′-methyl-riboU, against a couple of viruses within the flavivirus and pestivirus genuses.







TABLE 12







Comparative Antiviral Activity* (EC50)












BVDV

YFV













EC50*
CC50**
EC50*
CC50**

















β-D-2′-CH3-riboG
2
>100
1.2
   20



β-D-2′-CH3-riboC
3.7
>100
70
>100



β-D-2′-CH3-riboU
20
>100
33
>100







*Compound concentration (μM) required to reduce the plaque number by 50%. The following virus-cell system were used: BVDC-BT and YFV-BHK.



*Compound concentration (μM) required to reduce the viability of cells by 50%.






The chemical structures for β-D-2′-CH3-riboG, β-D-2′-CH3-riboC and β-D-2′-CH3-riboU are as follows:




Table 13 summarizes the anti-viral activity of several compounds of this invention against BVDV in three different assays.







TABLE 13







for BVDV












Cell
Plaque
Yield Reduction
Cytotoxicity













Protection
Reduction
EC90,
6 log10
Huh7 cells


Compound
(EC50, μM)
(EC90, μM)
μM
reduction (μM)
(EC50, μM)















β-D-2′-CH3-riboA
2
<3
<2
 9
50


β-D-2′-CH3-riboT
>250
ND
ND
ND
>250


β-D-2′-CH3-riboU
20
<81
24
120 
>250


β-D-2′-CH3-riboC
2
<9
<4
20
>250


β-D-2′-CH3-riboG
4
<9
3
20
>250


β-D-2′-CH3-riboI
45
ND
ND
ND
>250


Ribavirin
>3
>200
>20
toxic
20









This invention has been described with reference to its preferred embodiments. Variations and modifications of the invention, will be obvious to those skilled in the art from the foregoing detailed description of the invention.

## Claims

1. A method for the treatment of a flavivirus or pestivirus infection in a host, comprising administering to said host an anti-virally effective amount of a compound of Formula XVII:




or a pharmaceutically acceptable salt or ester thereof, wherein:
Base is a purine;
R1 and R2 are independently H; phosphate; a stabilized phosphate prodrug; acyl; alkyl; sulfonate ester; benzyl, wherein the phenyl group is optionally substituted with one or more substituents selected from hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, phosphonate, either unprotected or protected as necessary; a lipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo provides a compound wherein R1 and R2 are independently H or phosphate;
R6 is alkyl, azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —O(acyl), —O(alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, or —N(acyl)2;
R7 and R9 are independently OR2, hydroxy, alkyl, azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —O(acyl), —O(alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, or —N(acyl)2;
R10 is H, alkyl, chlorine, bromine or iodine;
X is O, S, SO2 or CH2.

2. The method of claim 1 for the treatment of a flavivirus or pestivirus infection in a host, wherein the base is selected from the group consisting of N6-alkylpurine, N6-acylpurine, N6-benzylpurine, N6-halopurine, N6-vinylpurine, N6-acetylenic purine, N6-acyl purine, N6-hydroxyalkyl purine, N6-thioalkyl purine, N2-alkylpurine, N2-alkyl-6-thiopurine, C5-hydroxyalkyl purine, N2-alkylpurine, N2-alkyl-6-thiopurine, adenine, guanine, hypoxanthine, 2,6-diaminopunne and 6-chloropurine.

3. The method of claim 1 for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an anti-virally effective amount of a compound of Formula X or XI:




or a pharmaceutically acceptable salt or ester thereof, wherein:
Base is a purine;
R1, R2 and R3 are independently H; phosphate or a stabilized phosphate prodrug; acyl; alkyl; sulfonate ester; or benzyl, wherein the phenyl group is optionally substituted; a lipid; an amino acid; a carbohydrate; a peptide; cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo provides a compound wherein R1, R2 and R3 are independently H or phosphate;
R6 is alkyl, azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), O(acyl), —O(alkyl), —O(alkenyl), chloro, bromo, fluoro, iodo, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, or —N(acyl)2;
R7 is, OR3, hydroxy, alkyl, azido, cyano, alkenyl, alkynyl, Br-vinyl, —C(O)O(alkyl), —O(acyl), —O(alkyl), —O(alkenyl), chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, or —N(acyl)2; and
X is O, S, SO2 or CH2.

4. The method of claim 1 for the treatment of a flavivirus or pestivirus infection in a host, wherein, in the compound of Formula XVII:
R10 is H, alkyl, chlorine, bromine or iodine;
R7 and R9 are independently OR2, alkyl, alkenyl, alkynyl, Br-vinyl, O-alkenyl, chlorine, bromine, iodine, NO2, NH2, —NH(lower alkyl), —NH(acyl), —N(lower alkyl)2, or —N(acyl)2;
R6 is alkyl, chlorine, bromine or iodine;
X is O, S, SO2or CH2.

5. The method of claim 1 wherein R1 hydrogen or phosphate.

6. The method of claim 1 wherein R2 is hydrogen, acyl or alkyl.

7. The method of claim 1 wherein R6 is alkyl.

8. The method of claim 1 wherein R7 and R9 are independently selected from OR2 or hydroxy.

9. The method of claim 1 wherein R7 is hydroxy.

10. The method of claim 1 wherein R9 is hydroxy.

11. The method of claim 1 wherein R7 and R9 are hydroxy.

12. The method of claim 1 wherein R10 is hydrogen.

13. The method of claim 1 wherein X is O.

14. The method of claim 1 wherein
R1 is hydrogen or phosphate;
R2 is hydrogen, acyl or alkyl;
R6 is alkyl;
R7 and R9 are independently OR2, or hydroxy;
R10 is hydrogen; and
X is O.

15. The method of claim 1, wherein the base is a purine selected from the group consisting of N6-alkylpurines, guanine, adenine, hypoxanthine, 2,6-diaminopurine, and 6-chloropurine.

16. The method of claim 1 for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an antivirally effective amount of a compound of the structure:




or a pharmaceutically acceptable salt or ester thereof.

17. The method of claim 1 for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an antivirally effective amount of a compound of the structure:




or a pharmaceutically acceptable salt or ester thereof, wherein R is hydrogen or alkyl.

18. The method of claim 17, wherein R is methyl, ethyl, propyl, isopropyl, or cyclopropyl.

19. The method of claim 18 wherein R is butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, or neopentyl.

20. The method of claim 1 for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an antivirally effective amount of a compound of the structure:




or a pharmaceutically acceptable salt or ester thereof.

21. The method of claim 1 for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an antivirally effective amount of a compound of the structure:




or a pharmaceutically acceptable salt or ester thereof.

22. The method of claim 1 for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an antivirally effective amount of a compound of the structure:




or a pharmaceutically acceptable salt or ester thereof.

23. The method of claim 1 for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an antivirally effective amount of a compound of the structure:




or a pharmaceutically acceptable salt or ester thereof.

24. The method of claim 1 for the treatment of a flavivirus or pestivirus infection in a host, comprising administering an antivirally effective amount of a compound of the structure:




or a pharmaceutically acceptable salt or ester thereof.

25. The method of claim 1 for the treatment of a flavivirus or pestivirus infection in a host, wherein the purine base is selected from the group consisting of




wherein R is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, cyclopentyl, isopentyl, or neopentyl.

26. The method of claim 1, wherein the method comprises administering the compound or a pharmaceutically acceptable salt or ester thereof in combination or alternation with a second anti-flavivirus or anti-pestivirus agent.

27. The method of claim 26, wherein the second anti-flavivirus or anti-pestivirus agent is selected from the group consisting of consisting of interferon, ribavirin, a protease inhibitor, a thiazolidine derivative, a polymerase inhibitor, and a helicase inhibitor.

28. The method of claim 27, wherein the second anti-flavivirus or anti-pestivirus agent is interferon.

29. The method of claim 27, wherein the second anti-flavivirus or anti-pestivirus agent is a protease inhibitor.

30. The method of claim 27, wherein the second anti-flavivirus or anti-pestivirus agent is ribavirin.

31. The method of claim 1, wherein the compound is in the form of a dosage unit.

32. The method of claim 31, wherein the dosage unit contains 50 to 1000 mg of said compound.

33. The method of claim 31, wherein said dosage unit is a tablet or capsule.

34. The method of claim 1, wherein the host is a human.

35. The method of claim 1, wherein the compound is in substantially pure form.

36. The method of claim 1, wherein the compound is at least 90% by weight of the β-D-isomer.

37. The method of claims 1, wherein the compound is at least 95% by weight of the β-D-isomer.

38. The method of claim 1, wherein the flavivirus or pestivirus is a Dengue virus.

39. The method of claim 1, wherein the flavivirus or pestivirus is a West Nile virus.

40. The method of claim 1, wherein the flavivirus or pestivirus is a yellow fever virus.

41. The method of claim 1, wherein the flavivirus or pestivirus is a bovine viral diarrhea virus (BVDV).

42. The method of claim 1, wherein the flavivirus or pestivirus is not a hepatitis C virus.